
<html lang="en"     class="pb-page"  data-request-id="648253dc-b8e3-43fc-9b04-e2b1c345893a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.6b01504;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-3;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis" /></meta><meta name="dc.Creator" content="Malliga R.  Iyer" /></meta><meta name="dc.Creator" content="Resat  Cinar" /></meta><meta name="dc.Creator" content="Alexis  Katz" /></meta><meta name="dc.Creator" content="Michael  Gao" /></meta><meta name="dc.Creator" content="Katalin  Erdelyi" /></meta><meta name="dc.Creator" content="Tony  Jourdan" /></meta><meta name="dc.Creator" content="Nathan J.  Coffey" /></meta><meta name="dc.Creator" content="Pal  Pacher" /></meta><meta name="dc.Creator" content="George  Kunos" /></meta><meta name="dc.Description" content="We report the design, synthesis, and structure–activity relationships of novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory ef..." /></meta><meta name="Description" content="We report the design, synthesis, and structure–activity relationships of novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory ef..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 27, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01504" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="This article not subject to U.S. Copyright.  Published 2017 by the American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01504" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01504" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01504" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01504" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0020.jpeg" /></meta><meta property="og:description" content="We report the design, synthesis, and structure–activity relationships of novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect on inducible nitric oxide synthase (iNOS). A series of 3,4-diarylpyrazolinecarboximidamides were synthesized and evaluated in CB1 receptor (CB1R) binding assays and iNOS activity assays. The novel compounds, designed to have limited brain penetrance, elicited potent in vitro CB1R antagonist activities and iNOS inhibitory activities. Some key compounds displayed high CB1R binding affinities. Compound 7 demonstrated potent in vivo pharmacological activities such as reduction of food intake mediated by the antagonism of the CB1Rs and antifibrotic effect in the animal models of fibrosis mediated by iNOS inhibition and CB1R antagonism." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01504"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01504">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01504&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01504&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01504&amp;href=/doi/10.1021/acs.jmedchem.6b01504" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1126-1141</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01496" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01540" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB<sub>1</sub>R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Malliga+R.++Iyer">Malliga R. Iyer</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol "><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-0116-4619" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Resat++Cinar">Resat Cinar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexis++Katz">Alexis Katz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Gao">Michael Gao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katalin++Erdelyi">Katalin Erdelyi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tony++Jourdan">Tony Jourdan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathan+J.++Coffey">Nathan J. Coffey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pal++Pacher">Pal Pacher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=George++Kunos">George Kunos</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Laboratory of Physiologic Studies, and <sup>‡</sup>Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span></div><div class="corresp-info"><strong>*</strong>M.R.I.: e-mail, <a href="/cdn-cgi/l/email-protection#0845696464616f692641716d7a48666160266f677e"><span class="__cf_email__" data-cfemail="1855797474717f793651617d6a58767170367f776e">[email protected]</span></a>; phone, 301-217-5207.</div><div class="corresp-info"><strong>*</strong>G.K.: e-mail, <a href="/cdn-cgi/l/email-protection#4007252f3227256e0b352e2f33002e29286e272f36"><span class="__cf_email__" data-cfemail="2b6c4e44594c4e05605e4544586b454243054c445d">[email protected]</span></a>; phone, 301-443-2069.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01504&amp;href=/doi/10.1021%2Facs.jmedchem.6b01504" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1126–1141</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 13, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 October 2016</li><li><span class="item_label"><b>Published</b> online</span>27 January 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 February 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01504" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01504</a></div><div class="article_header-article-copyright"><strong>Copyright © This article not subject to U.S. Copyright.  Published 2017 by the American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1126%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMalliga%2BR.%2BIyer%252C%2BResat%2BCinar%252C%2BAlexis%2BKatz%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D3%26contentID%3Dacs.jmedchem.6b01504%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%252C%2BNon-Brain-Penetrant%252C%2BHybrid%2BCannabinoid%2BCB1R%2BInverse%2BAgonist%252FInducible%2BNitric%2BOxide%2BSynthase%2B%2528iNOS%2529%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BLiver%2BFibrosis%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1141%26publicationDate%3DFebruary%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01504"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1902</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01504" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Malliga&quot;,&quot;last_name&quot;:&quot;R. Iyer&quot;},{&quot;first_name&quot;:&quot;Resat&quot;,&quot;last_name&quot;:&quot;Cinar&quot;},{&quot;first_name&quot;:&quot;Alexis&quot;,&quot;last_name&quot;:&quot;Katz&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Katalin&quot;,&quot;last_name&quot;:&quot;Erdelyi&quot;},{&quot;first_name&quot;:&quot;Tony&quot;,&quot;last_name&quot;:&quot;Jourdan&quot;},{&quot;first_name&quot;:&quot;Nathan&quot;,&quot;last_name&quot;:&quot;J. Coffey&quot;},{&quot;first_name&quot;:&quot;Pal&quot;,&quot;last_name&quot;:&quot;Pacher&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;Kunos&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;1126-1141&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01504&quot;},&quot;abstract&quot;:&quot;We report the design, synthesis, and structure–activity relationships of novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect on inducible nitric oxide synthase (iNOS). A series of 3,4-diarylpyrazolinecarboximidamides were synthesized and evaluated in CB1 receptor (CB1R) binding assays and iNOS activity assays. The novel compounds, designed to have limited brain penetrance, elicited potent in vitro CB1R antagonist activities and iNOS inhibitory activities. Some key compounds displayed high CB1R binding affinities. Compound 7 demonstrated potent in vivo pharmacological activities such as reduction of food intake mediated by the antagonism of the CB1Rs and antifibrotic effect in the animal models of fibrosis mediated by iNOS inhibition and CB1R antagonism.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01504&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01504" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01504&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01504" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01504&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01504" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01504&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01504&amp;href=/doi/10.1021/acs.jmedchem.6b01504" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01504" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01504" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01504%26sid%3Dliteratum%253Aachs%26pmid%3D28085283%26genre%3Darticle%26aulast%3DIyer%26date%3D2017%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%252C%2BNon-Brain-Penetrant%252C%2BHybrid%2BCannabinoid%2BCB1R%2BInverse%2BAgonist%252FInducible%2BNitric%2BOxide%2BSynthase%2B%2528iNOS%2529%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BLiver%2BFibrosis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D3%26spage%3D1126%26epage%3D1141%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/jmcmar.2017.60.issue-3/20170209/jmcmar.2017.60.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We report the design, synthesis, and structure–activity relationships of novel dual-target compounds with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB<sub>1</sub>R) and inhibitory effect on inducible nitric oxide synthase (iNOS). A series of 3,4-diarylpyrazolinecarboximidamides were synthesized and evaluated in CB<sub>1</sub> receptor (CB<sub>1</sub>R) binding assays and iNOS activity assays. The novel compounds, designed to have limited brain penetrance, elicited potent in vitro CB<sub>1</sub>R antagonist activities and iNOS inhibitory activities. Some key compounds displayed high CB<sub>1</sub>R binding affinities. Compound <b>7</b> demonstrated potent in vivo pharmacological activities such as reduction of food intake mediated by the antagonism of the CB<sub>1</sub>Rs and antifibrotic effect in the animal models of fibrosis mediated by iNOS inhibition and CB<sub>1</sub>R antagonism.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The endocannabinoid system (EC) includes two main G-protein-coupled receptors (CB<sub>1</sub>R and CB<sub>2</sub>R), endogenous ligands, and endocannabinoids (ECs) that bind to these receptors along with several enzymes responsible for the biosynthesis and the degradation of these ECs (e.g., fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL)).<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> The CB<sub>1</sub>R and CB<sub>2</sub>R belong to the family of G-protein-coupled receptors (GPCRs) acting through the inhibitory G-protein (G<sub>i</sub>/G<sub>o</sub>). The CB<sub>1</sub> receptor is mainly expressed in the central nervous system, where it is one of the most abundant receptors of GPCRs and is responsible for the psychoactive effects of marijuana and synthetic agonists.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The behavioral effects of exogenous cannabinoids like memory, cognition, and motor functions corroborate the central nervous system (CNS) presence of the CB<sub>1</sub>R.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> It is also expressed in a number of peripheral tissues like liver, testis, and ileum. The CB<sub>2</sub> receptor is mainly located in cells of the immune system and involved in the immunomodulatory effects induced by cannabinoids.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Recent evidence shows that these receptors may also exist in the CNS.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The modulation of the endocannabinoid system through the antagonism of CB<sub>1</sub>R has long been a viable therapeutic strategy. Indeed, this system has shown beneficial effects in several diseases like addiction,<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> GI disorders,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and cognitive and neuroinflammatory disorders.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">An overactive endocannabinoid/CB<sub>1</sub>R system has been implicated in obesity,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> its metabolic complications, and even fibrosis.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Fibrosis characterized by the buildup of excessive fibrous connective tissue in an organ during chronic inflammation or injury repair is a key pathological process often leading to organ dysfunction and failure (e.g., liver, lung, and kidney). In the liver, fibrosis can develop as a result of hepatitis C virus (HCV) infection, chronic alcoholism, or fatty liver disease and can progress to cirrhosis and hepatocellular carcinoma. Fibrosis, which can lead to progressive loss of tissue function and eventual organ failure, has been estimated to contribute to ∼45% of deaths in the developed world. Hence new therapeutics to attenuate fibrosis are urgently needed.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">In the past decade, CB<sub>1</sub>R inverse agonists (even neutral antagonists) have been the subject of much attention for their ability to treat obesity, diabetes, and other metabolic syndromes.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Despite their promising therapeutic effects, the CNS-mediated adverse effects of these brain-penetrant compounds like anxiety and development of suicidal tendencies precluded successful clinical use of the first-in-class CB<sub>1</sub> inverse agonist rimonabant (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Consequently, the development of similar CB<sub>1</sub> antagonists like ibipinabant, taranabant, and otenabant were halted at various stages.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Nevertheless, these molecules by way of detailed studies and the CB<sub>1</sub> receptor target itself have so many therapeutic benefits, which can be harnessed, that renewed focus has been established on a new class of CB<sub>1</sub>R antagonists/inverse agonists that are restricted in the peripheral space.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19-21)</a> Our group has been recently involved in the study of peripherally selective antagonists<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a> based on variations of ibipinabant scaffold.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> One approach has been to produce compounds that have polar surface areas (PSA) of >90 which can result in a low permeability into the CNS. This has led us to specific moieties that have use in inhibiting inducible nitric oxide synthase (iNOS) and that could be manipulated to yield beneficial effects against fibrotic cells and tissues. It is known that endocannabinoids acting via CB<sub>1</sub>Rs promote fibrosis, whereas CB<sub>1</sub>R antagonist/inverse agonist like rimonabant mitigates fibrosis in animal models with moderate to low efficacy.<a onclick="showRef(event, 'ref12 ref24 ref26'); return false;" href="javascript:void(0);" class="ref ref12 ref24 ref26">(12, 24, 26)</a> Inducible nitric oxide synthase (iNOS), an enzyme that catalyzes the generation of proinflammatory reactive nitrogen species, is induced in fibrotic tissue, and iNOS inhibitors, with various amidino warheads like <i>N</i>-(3-(aminomethyl)benzyl)acetamidine (1400W), have antifibrotic activity in animal models or fibrosis.<a onclick="showRef(event, 'ref24 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref24 ref27 ref28">(24, 27, 28)</a> Hence we reasoned that a hybrid compound inhibiting both CB<sub>1</sub>R and iNOS might have beneficial effects in mitigating fibrosis and its related complications. Peripheral restriction of hybrid CB<sub>1</sub>R/iNOS inhibitors is of paramount importance to minimize any neuropsychiatric side effects secondary to blockade of CB<sub>1</sub>R in the CNS. Peripheral restriction of these compounds also precludes their ability to reduce brain iNOS activity, which has been proposed to aggravate certain neuroinflammatory conditions.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. CB<sub>1</sub>R inverse agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">In this paper we report in detail our efforts toward the design, synthesis, and characterization of peripherally restricted dual inhibitors of CB<sub>1</sub>R and iNOS. The compound ibipinabant is a highly selective CB<sub>1</sub> receptor inverse agonist developed by Solvay, whose further development was halted due to related CNS adverse issues arising from brain permeability of the compound.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> This compound has a higher topological PSA than rimonabant but still falls short of the PSA range for CNS nonpermeable compound. Inclusion of an <span class="smallcaps smallerCapital">l</span>-valine amide side attachment as in (<i>S</i>)-2-((<i>S</i>)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamido)-3-methylbutanamide (JD5037)<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) instead of the methyl group rendered the molecule non-brain-permeable and improved the pharmacokinetic parameters while retaining the potent CB<sub>1</sub>R inverse agonism. This molecule is under preclinical investigation.<a onclick="showRef(event, 'ref22 ref30'); return false;" href="javascript:void(0);" class="ref ref22 ref30">(22, 30)</a> Our approach was to replace the methyl group in ibipinabant not only to favor peripheral restriction but also potentially to utilize any additional beneficial therapeutic effects that could result from this replacement (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). This novel approach to ligand design has now led us to several compounds, which seem promising as a dual CB<sub>1</sub>/iNOS inhibitor with potential for treating fibrosis, diabetes, and obesity.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Dual-target peripherally restricted CB<sub>1</sub>R strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We recently disclosed our lead compound 4<i>S</i>-(<i>N</i>-1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-<i>N</i>′-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide which is under investigation for treatment of fibrotic conditions.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Herein we outline the synthesis and detailed SAR for the dual-target compounds that showed potency in in vivo models and that ultimately led to our lead compound. The synthesis of the novel compounds began with coupling of compound <b>1</b><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and sulfonyl compounds <b>2</b>, leading to sulfonylurea products <b>3</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Sulfonylurea <b>3</b> was subjected to PCl<sub>5</sub> treatment in refluxing chlorobenzene to yield a sensitive imidoyl chloride <b>4</b> which was immediately utilized in situ without purification to build novel compounds of the formula <b>A</b> bearing the revamped pharmacophore (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The compounds synthesized included a chiral center at the 4-position of the 3,4-diarylpyrazoline ring. Thus, the initial promising racemic compounds could be processed on to enantiomeric analogs for further investigations.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0014.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Various Sulfonylurea Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) toluene, reflux.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0015.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Substituted Analogs of the Formula <b>A</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PCl<sub>5</sub>, chlorobenzene reflux; (b) QNH<sub>2</sub>, MeOH–DCM, Et<sub>3</sub>N, −78 °C to room temp.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Biology and Pharmacology</h3><div class="NLM_p">The target compounds were evaluated in vitro at the CB<sub>1</sub> receptor utilizing radioligand binding assays and GTPγS functional assays. Our approach initially was to install <i>S</i>-methylisothiourea moiety, a potent iNOS inhibitor,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> to the parent scaffold to obtain compound <b>5a</b>. This compound however had a lower CB<sub>1</sub>R binding affinity (60 nM). We then switched the R group to methyl (Q moiety to an acetamidine), as this group is prevalent in selective iNOS inhibitors. When the putative iNOS-inhibiting component was changed to Me instead of SMe, the binding affinity for CB<sub>1</sub>R improved markedly for compound <b>6a</b>. The results are reported in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. This prompted us to change the R′ groups to glean the effect of steric and electronic effects on the CB<sub>1</sub>R binding affinity in the SMe and Me series. Interestingly, the 4-position at the R′ substituent contributed greatly to the binding CB<sub>1</sub>R affinities. Electron withdrawing bulky groups enhanced the CB<sub>1</sub>R affinities, whereas the affinities dropped considerably in the presence of smaller substituents like H, F or electron donating substituents like OMe, Me. Compound <b>5c</b> with a strong iNOS inhibitory pendant showed a CB<sub>1</sub>R binding affinity of 10 nM, whereas the 4-Cl substituent <b>5a</b> had a much lower binding affinity of 60 nM. The binding affinities for CB<sub>1</sub>R improved markedly for compounds <b>6a</b>–<b>d</b> in the comparable <b>5a</b>–<b>d</b> series (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Varying the 4-R′ substituents while keeping R = Me retained the inverse agonism functionality in the compounds tested. The SMe amidine compounds in the <b>5a</b>–<b>d</b> series also retained CB<sub>1</sub>R inverse agonism albeit with low binding affinity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro CB<sub>1</sub>R Binding Results of the Dual-Target Compounds<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0017.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R′</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub>(CB<sub>1</sub>) (nM)</th><th class="colsep0 rowsep0" align="center">GTPγS IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>i</sub>(CB<sub>2</sub>) (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rimonabant</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">1580<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ibipinabant</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left">7943<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">SMe</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">329</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">SMe</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">SMe</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="left">SMe</td><td class="colsep0 rowsep0" align="left">-(C<sub>4</sub>H<sub>8</sub>)-</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">2667</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">5.7</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">-(C<sub>4</sub>H<sub>8</sub>)-</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">686</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6f</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6g</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">87</td><td class="colsep0 rowsep0" align="left">113</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6h</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">114</td><td class="colsep0 rowsep0" align="left">2041</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6i</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">182</td><td class="colsep0 rowsep0" align="left">70</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6j</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">-(<i>tert</i>-butyl)</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6k</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">-(isopropyl)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6l</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">138</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left">>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Binding affinity was determined from binding displacement isotherms using [<sup>3</sup>H]CP55940 as the labeled ligand and plasma membranes from CB<sub>1</sub>R-expressing or CB<sub>2</sub>R-expressing CHO-K1 cells, respectively. <i>K</i><sub>i</sub> values were calculated using the Cheng–Prusoff equation. Data represent the mean ± SEM from three independent experiments performed in triplicate.</p></div></div></div><div class="NLM_p">To expand the scope of substituents tolerated, we next turned our attention to keeping the R′ substituent constant (4-Cl), and the R groups in the formula <b>A</b> were varied to incorporate additional easily accessible amidino-type moieties keeping in mind the physicochemical parameters and the possible synergism for a dual target. This led to interesting CB<sub>1</sub>R binding affinities and clear SAR from further functional studies (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro CB<sub>1</sub>R Binding Results of the Dual-Target 4-Chlorophenyl Compounds<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0018.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0019.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Binding affinity was determined from binding displacement isotherms using [<sup>3</sup>H]CP55940 as the labeled ligand and plasma membranes from CB<sub>1</sub>R-expressing or CB<sub>2</sub>R-expressing CHO-K1 cells, respectively. <i>K</i><sub>i</sub> values were calculated using the Cheng–Prusoff equation. Data represent the mean ± SEM from three independent experiments performed in triplicate.</p></div></div><div></div></div><div class="NLM_p">With the binding results in hand, it was clear that with replacement of the methyl group in ibipinabant with amidine substituted moiety, the CB<sub>1</sub>R high affinity was retained in many of the compounds tested. The in vitro functional assays revealed that like SMe and Me substituents at the R position, cyclopropyl and <i>tert</i>-butyl group retained the CB<sub>1</sub>R inverse agonism functionality. Replacing the alkyl R-groups with Ar-alkyl (benzene ring) switched the function to neutral antagonism for compounds <b>12</b>–<b>20</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). This was interesting particularly in the light of ibipinabant, as replacement of methyl group with bulky or aromatic amino groups could potentially lead to neutral brain-penetrant CB<sub>1</sub>R antagonists. Selected compounds were then tested for their iNOS inhibitory activity (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Determining in vitro inverse agonism versus neutral antagonism. Inverse agonism and neutral antagonism were assessed for compounds by GTPγS binding assay using mouse crude brain membrane preparation. Compounds were incubated in the absence of any CB<sub>1</sub>R agonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of iNOS by selected CB<sub>1</sub>R/iNOS antagonists: V (vehicle), rimonabant (Rim), ibipinabant (SLV). Effects of compounds on iNOS activity were determined by using RAW 264.7 cells, which are incubated with LPS (50 ng/mL) and γ-interferon (10 ng/mL) for 24 h prior to treatment. Positive control in the assay system is provided by the iNOS inhibitor diphenylene iodonium (DPI).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We initially picked compound <b>5c</b> for further in vivo studies due its good binding affinity for CB<sub>1</sub>R, dual-target synergism, and functional potency of 65 nM in GTPγS binding assay. However, solubility issues and bioavailability prevented further investigations on compound <b>5c</b> and its enantiomers (not shown). Having recently published our findings with compound <b>6b</b>,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> here we present data on compound <b>6a</b>. We turned our attention to compound <b>6a</b> and subjected it to chiral prep-HPLC giving pure enantiomers <b>7</b> and <b>7′</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Compound <b>7</b> binds stereoselectively to the CB<sub>1</sub>R in mouse brain as shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, and its potency as an inverse agonist is similar to ibipinabant and rimonabant. The X-ray structure of the eutomer, compound <b>7</b>, revealed the compound to be a 4<i>S</i>-enantiomer (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). In line with in vitro results, the in vivo CB<sub>1</sub>R antagonism of <b>7</b> was further confirmed by the dose-dependent reversal of arachidonyl-2′-chloroethylamide (ACEA) induced reduction in upper GI motility (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). To assess the brain penetrance of <b>7</b>, tissue distribution studies were performed and it revealed a very low brain penetrance (<3%) after acute or 28-day chronic oral administration of the near-maximally efficacious dose of 10 mg/kg, with high accumulation in the liver (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). The low brain penetrance of <b>7</b> was further confirmed even after 28-day chronic treatment by the absence of central CB<sub>1</sub>R-mediated anxiogenic behavior, typical of centrally acting rimonabant (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>).</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0016.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Chiral Prep-HPLC Separation for Compound <b>6a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>R</i>,<i>R</i>-Whelk-O/ethanol (100%).</p></p></figure><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. CB<sub>1</sub>R binding affinity of compound <b>7</b> and CB<sub>1</sub>R antagonism. (A) Binding affinity was determined from binding displacement isotherms using [<sup>3</sup>H]CP55940 as the labeled ligand. (B) Functional CB<sub>1</sub>R antagonism was determined using the agonist-stimulated [<sup>35</sup>S]GTPγS binding assay. The antagonists concentration-dependently antagonized the effect of CP55940 (1 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Single crystal X-ray of <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo peripheral CB<sub>1</sub>R blockade by compound <b>7</b>. Both rimonabant and compound <b>7</b> (1–10 mg/kg po) dose-dependently reversed the ACEA (CB<sub>1</sub>R agonist)-induced reduction in upper GI motility. Data represent the mean ± SEM from 4 to 5 mice per group. ∗ (<i>P</i> < 0.05) or # (<i>P</i> < 0.05) indicate significant difference from vehicle or ACEA + vehicle (V) group, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Tissue distribution of compound <b>7</b>. Tissue levels of compound <b>7</b> were measured 1 h after oral administration of acute (A) or 28-days chronic (B). Data represent the mean ± SEM from 3 mice per group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>7</b> is devoid of behavioral anxiogenic effect after 28 days of chronic oral administration. Rimonabant, but not <b>7</b> (10 mg kg<sup>–1</sup> day<sup>–1</sup> for 28 days), is anxiogenic in the elevated plus maze (EPM) test. EPM is performed 1 h after oral administration of last dosing following 28 days. Data represent the mean ± SEM from 6 mice per group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We then tested <b>7</b> for attenuating obesity and mitigating its metabolic consequences based on the previously known efficacy of centrally acting and peripherally restricted CB<sub>1</sub>R antagonists in mouse models of obesity.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In C57Bl6/J mice with high-fat diet-induced obesity (DIO), chronic treatment with <b>7</b> caused dose-dependent reductions in body weight, hepatic steatosis, and food intake and improved glucose tolerance (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>).</div><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effect of compound <b>7</b> on metabolic parameters in DIO mice. (A) Body weight was measured daily during 2 weeks of treatment with oral dosing of 10 mg/kg of compound <b>7</b>. (B) Hepatic triglyceride content was determined from post-mortem liver tissue. (C) Glucose tolerance and (D) insulin sensitivity test were determined 14 days after the chronic oral dosing of compound <b>7</b>. Data represent the mean ± SEM from 5 to 6 mice/group. ∗ (<i>P</i> < 0.05) indicates significant difference from control. <i>#</i> indicates significant treatment effect (<i>P</i> < 0.05) relative to high fat diet (HFD) vehicle group. Standard diet (STD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CCl<sub>4</sub>-induced fibrosis is the most commonly used experimental model of a toxin-induced liver fibrosis which leads to reversible centrilobular liver injury.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Due to the reversibility of fibrosis upon toxin discontinuation, this model is suitable only to determine drug-induced prevention but not reversal of fibrosis. Mice were treated twice weekly for 4 weeks with 1 mL/kg CCl<sub>4</sub> to induce liver fibrosis and simultaneously treated with vehicle, compound <b>7</b> (10 mg kg<sup>–1</sup> day<sup>–1</sup>), rimonabant (3 mgkg<sup>–1</sup> day<sup>–1</sup>), which are the equipotent in vivo CB<sub>1</sub>R antagonism doses as determined by upper GI motility assay (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). A fourth group of mice was treated with 10 mg/kg of compound <b>7′</b>, which inhibits iNOS (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>) but has much lower CB<sub>1</sub>R binding and in vivo inhibitory activity (<a class="ref internalNav" href="#fig5" aria-label="Figures 5">Figures 5</a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), as a further test for the role of iNOS in the observed effects of compound <b>7</b>. Fibrosis was assessed, and it was shown to be attenuated significantly more by an equipotent dose of <b>7</b> than by rimonabant, as documented histologically by Sirius red staining (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>A,C). In addition, compound <b>7′</b> was also able to reduce CCl<sub>4</sub> induced fibrosis alluding to the role of iNOS inhibition (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>A,C). Importantly, CCl<sub>4</sub>-induced elevation of iNOS immunostaining was dramatically attenuated by both compounds <b>7</b> and <b>7′</b> but not by rimonabant (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>B). This may suggest down-regulation of iNOS protein expression by following chronic inhibition of iNOS activity, which could contribute to the higher in vivo efficacy of compound <b>7</b> compared to rimonabant.</div><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0011.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Antifibrotic effect of compound <b>7</b> in CCl<sub>4</sub>-induced liver fibrosis. CCl<sub>4</sub>-induced liver fibrosis was generated by intraperitoneal injection of CCl<sub>4</sub> (1 mL/kg, diluted 1:10 corn oil) twice weekly. Mice were also treated by either vehicle, rimonabant, compound <b>7</b>, or compound <b>7′</b> orally for 4 weeks. Liver fibrosis was assessed histologically by Sirius red staining (A). Fibrosis area was analyzed by computerized morphometry (C). CCl<sub>4</sub>-induced elevation of iNOS immunostaining was attenuated by the compound <b>7</b> and compound <b>7′</b> but not with rimonabant (B). Data represent the mean ± SEM from 7 to 8 mice per group. ∗ (<i>P</i> < 0.05) indicates significant difference from control. # indicates significant treatment effect (<i>P</i> < 0.05) relative to CCl<sub>4</sub>-treated vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also used another model of liver fibrosis induced by bile duct ligation (BDL), which has different etiology, featuring biliary fibrosis with periportal hepatocyte death. BDL causes irreversible injury and fibrosis; therefore we used two different treatment paradigms, which are depicted in <a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a> and <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>, to assess for both prevention and regression of fibrosis. Compound <b>7</b> used at 10 mg kg<sup>–1</sup> day<sup>–1</sup> was significantly more efficacious than 3 mg kg<sup>–1</sup> day<sup>–1</sup> rimonabant in preventing the progression of surgical BDL-induced collagen deposition in the liver as quantified histologically by Picrosirius red staining (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). Moreover, BDL-induced fibrosis was less pronounced in CB<sub>1</sub>R<sup>–/–</sup> mice, where it could be further attenuated by compound <b>7</b> but not by rimonabant, attesting to the dual-target therapy (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). Furthermore, compound <b>7</b> but not rimonabant, was completely able to arrest the progression and even partially reverse BDL-induced liver fibrosis, when treatment was started on day 6 post-BDL (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>).</div><figure id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0012.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Effects of compound <b>7</b> and rimonabant on progression of BDL-induced liver fibrosis. Wild-type and CB<sub>1</sub>R<sup>–/–</sup> mice were treated with daily oral doses of 3 mg/kg rimonabant or 10 mg/kg of compound <b>7</b>, starting on the day of BDL. Liver fibrosis was assessed histologically by Sirius red staining and the fibrosis area analyzed by computerized morphometry. Data represent the mean ± SEM from 7 to 8 mice per group. ∗ (<i>P</i> < 0.05) indicates significant difference from control. <i>#</i> indicates significant treatment effect (<i>P</i> < 0.05) relative to BDL vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0013.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Effect of compound <b>7</b> on regression of BDL-induced liver fibrosis. Wild type mice were sacrificed on day 6 to determine grade of fibrosis or were treated oral doses of 3 mg/kg of rimonabant or 10 mg/kg of compound <b>7</b> starting on day 6 after BDL to determine efficacy on fibrosis regression. Liver fibrosis was assessed histologically by Sirius red staining. Data represent the mean ± SEM from 6 mice per group. * (<i>P</i> < 0.05) indicates significant difference from control. # indicates significant treatment effect (<i>P</i> < 0.05) relative to BDL vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The druggable properties of <b>7</b> were further assessed in a two-strain Ames test that was negative up to 125 μg/mL of <b>7</b> (Cyprotex) (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01504/suppl_file/jm6b01504_si_001.pdf" class="ext-link">Supporting Information</a>). The in vitro effects of <b>7</b> on the potassium channel current mediated by hERG (human ether-a-go-go-related gene) expressed in mammalian cells were evaluated at ambient temperature, using multiple concentrations (ChanTest). The IC<sub>50</sub> of <b>7</b> for inhibiting K<sup>+</sup> currents in this assay was 100 μM. The oral bioavailability of <b>7</b> was 55%, defined as the ratio of AUC following oral gavage vs intravenous administration of a dose of 10 mg/kg in Sprague-Dawley rats. Pharmacokinetic analyses indicated a plasma <i>t</i><sub>1/2</sub> of 2 h for orally administered <b>7</b> in both mice and rats (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Profile for Compound <b>7</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">compound <b>7</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MW</td><td class="colsep0 rowsep0" align="left">514.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLogP<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">6.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PSA<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">100.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CB<sub>1</sub>R (<i>K</i><sub>i</sub>, nM)</td><td class="colsep0 rowsep0" align="left">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> mouse (po), h</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> mouse (po), h</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> rat (po), min</td><td class="colsep0 rowsep0" align="left">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> mouse (po), h</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bioavailability (<i>F</i>, %) rat</td><td class="colsep0 rowsep0" align="left">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AMES test</td><td class="colsep0 rowsep0" align="left">negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma/brain</td><td class="colsep0 rowsep0" align="left">∼0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG, μM</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hCB<sub>1</sub>R/hCB<sub>2</sub>R selectivity</td><td class="colsep0 rowsep0" align="left">∼57</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Theoretical values.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82802" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82802" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Fibrosis is a multifactorial disease in which the current “single-target” therapeutic approaches yield only suboptimal benefits.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Polypharmacological interventions are needed and might present more promising avenues.<a onclick="showRef(event, 'ref15 ref34'); return false;" href="javascript:void(0);" class="ref ref15 ref34">(15, 34)</a> CB<sub>1</sub>R and iNOS are both validated targets that have individually shown promising results in experimental models of fibrosis. We have prepared a series of synthetic hydrid molecules <b>5</b>–<b>29</b> containing a CB<sub>1</sub>R scaffold and fragments that form the structural component for iNOS inhibitors. The resulting compounds were expected to act synergistically via CB<sub>1</sub>R modulation and iNOS inhibition. The compounds were designed to have limited brain penetrance to minimize the CNS side effects arising from central CB<sub>1</sub>R modulation. The tested compounds revealed strong to moderate nanomolar binding affinity, functional selectivity for CB<sub>1</sub>R, and micromolar inhibition for iNOS. SAR showed that molecules with alkyl-substituted amidine attachments to the main scaffold retained inverse agonism for CB<sub>1</sub> receptors, and a switch to aromatic-substituted amidine groups resulted in neutral antagonism for CB<sub>1</sub>R. Electron withdrawing and bulkier groups at the 4-position of the sulfonamide ring resulted in improved CB<sub>1</sub>R affinity, whereas the affinity dropped when 4-position had groups like H, OMe, and Me. Compound <b>7</b> was tested further, and it showed good in vitro PK profile and efficacy in mouse models of liver fibrosis.</div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63622" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63622" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div class="NLM_p last">Reagents available commercially were purchased and used as is. The amidine reagents were purchased as salts or synthesized based on literature procedures. Melting points were determined on a Buchi B-545 instrument and are uncorrected. Proton (<sup>1</sup>H NMR) spectra were recorded on a Varian 400 or Bruker 500 MHz spectrometer in CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> (unless otherwise noted) with the values given in ppm (TMS as internal standard) and <i>J</i> (Hz) assignments of <sup>1</sup>H resonance coupling. Mass spectra (HRMS) were recorded on a VG 7070E spectrometer or a JEOL SX102a mass spectrometer. Thin layer chromatography (TLC) analyses were carried out on Analtech silica gel GHLF 0.25 mm plates using various gradients of CHCl<sub>3</sub>/MeOH containing 1% NH<sub>4</sub>OH or gradients of EtOAc/<i>n</i>-hexane. Visualization was accomplished under UV light or by staining in an iodine chamber. Flash column chromatography was performed on Teledyne ISCO Combiflash system with PurIon mass detector. Product yields are unoptimized. All compounds tested had ≥95% purity. Purity and structural confirmation were analyzed by a combination of TLC, <sup>1</sup>H NMR, <sup>13</sup>C NMR, LC/MS, high-resolution mass spectrometry, elemental analysis, and X-ray (where indicated). LC–MS detection was carried out on Agilent 1200 using Luna C18 3 μm (3 mm × 75 mm). The mobile phase was 4–100% acetonitrile (0.05% TFA) standard gradient. The LC–MS chromatogram showed the correct molecular (MH<sup>+</sup>) ion as well as a single peak at UV (254 nm). Rotation values were obtained using PerkinElmer polarimeter (no. 341) under shown conditions. X-ray results were obtained utilizing the X-ray facility at University of California, San Diego. Gram-scale chiral separation of (<b>6a</b>) using SFC was carried out at Regis Technologies Inc.</div></div><div id="sec3_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> General Procedure A for the Synthesis of <b>2a</b>–<b>l</b>. Methyl ((4-Iodophenyl)sulfonyl)carbamate (<b>2c</b>)</h3><div class="NLM_p last">To a solution of 4-iodobenzenesulfonamide (5.0 g, 0.018 mol) stirred at 0 °C in anhydrous acetonitrile (50 mL), Et<sub>3</sub>N (4.5 g, 0.045 mol) was added, followed by the slow addition of methyl choroformate (2.0 mL, 0.027 mol). The resulting slurry was stirred overnight at room temperature. The acetonitrile solution was evaporated, and the residue was dissolved in EtOAc, and a saturated solution of NaHCO<sub>3</sub> was added. The aqueous layer was separated and ice was added to it followed by acidification with conc. HCl to give an oil that slowly solidified to a white precipitate. The precipitate was filtered, washed with water, and dried to give compound <b>2c</b> (5.5 g, 91%). Mp 108–112 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.91 (d, <i>J</i> = 8.4 Hz, 2H), 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 3.71 (s, 3H), 3.36 (s, 1H). HRMS (C<sub>8</sub>H<sub>9</sub>INO<sub>4</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 341.9302, calcd 341.9297.</div></div><div id="sec3_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Procedure B for the Synthesis of <b>3a</b>–<b>l</b>. 3-(4-Chlorophenyl)-<i>N</i>-((4-iodophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3c</b>)</h3><div class="NLM_p last">To a solution of <b>2c</b> (1.3 g 3.8 mmol) in toluene was added compound <b>1</b> (1.02 g, 4.0 mmol) and the resulting slurry was refluxed for 5 h. After cooling to room temperature, the toluene solution was evaporated and the slurry was triturated with isopropyl alcohol to obtain white slurry. The solution was filtered and washed with a mixture of cold IPA and hexanes (1:1) to give compound <b>3c</b> as a white solid (1.2 g, 81%). Mp 180–182 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.73 (s, 2H), 7.89 (q, <i>J</i> = 10.3 Hz, 4H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.30–7.27 (m, 4H), 7.17 (d, <i>J</i> = 7.6 Hz, 1H), 7.10 (d, <i>J</i> = 7.2 Hz, 2H), 4.70 (dd, <i>J</i> = 11.7, 5.5 Hz, 1H), 4.30 (t, <i>J</i> = 11.6 Hz, 1H), 3.89 (dd, <i>J</i> = 11.5, 5.5 Hz, 1H), 2.35–2.33 (m, 2H). HRMS (C<sub>22</sub>H<sub>18</sub>ClIN<sub>3</sub>O<sub>3</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 565.9802, calcd 565.9810.</div></div><div id="sec3_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Procedure C for the Synthesis of <b>5a</b>–<b>l</b>. Methyl ((3-(4-Chlorophenyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazol-1-yl)(((4-chlorophenyl)sulfonyl)imino)methyl)carbamimidothioate (<b>5a</b>)</h3><div class="NLM_p last">To a mixture of compound <b>3a</b> (500 mg, 1.05 mmol) and PCl<sub>5</sub> (247 mg, 1.2 mmol), chlorobenzene (5 mL) was added, and the mixture was refluxed for 2 h. The reaction mixture was then cooled, and chlorobenzene was removed in vacuo. The crude imidoyl chloride compound (<b>4a</b>) was dissolved in dichloromethane (10 mL), and to it was added a premixed mixture of excess <i>S</i>-methylisothiuronium iodide (455 mg, 2.1 mmol) in methanol/dichloromethane (2:1) and Et<sub>3</sub>N (606 mg, 6.0 mmol) at −78 °C dropwise and allowed to warm to room temperature overnight. The reaction mixture was extracted into dichloromethane, washed with water, and purified by flash chromatography using hexanes/EtOAC (6:4) followed by trituration with IPA to afford compound <b>5a</b> (250 mg, 43%) over two chemical steps as a white solid. Mp 195–198 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.88 (d, <i>J</i> = 6.3 Hz, 2H), 7.46 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.27 (t, <i>J</i> = 12.4 Hz, 3H), 7.19 (d, <i>J</i> = 8.5 Hz, 2H), 7.13 (s, 2H), 4.70 (t, <i>J</i> = 0.6 Hz, 1H), 4.55 (t, <i>J</i> = 11.8 Hz, 1H), 4.05 (dd, <i>J</i> = 12.2, 5.3 Hz, 1H), 2.28 (s, 3H). <sup>13</sup>C NMR (101 MHz; DMSO-<i>d</i><sub>6</sub>): δ 161.1, 157.5, 156.6, 156.5, 156.4, 142. 6, 140.0, 135.4, 134.4, 128.9, 128.7, 128.5, 128.3, 128.0, 127.4, 127.1, 56.1, 49.5, 13.2. HRMS (C<sub>24</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 546.0591, calcd 546.0586.</div></div><div id="sec3_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure D for the Synthesis of <b>6a</b>–<b>l</b> and <b>8</b>–<b>29</b>. <i>rac</i>-<i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6a</b>)</h3><div class="NLM_p last">To a mixture of compound <b>3a</b> (300 mg, 0.63 mmol) and PCl<sub>5</sub> (247 mg, 1.2 mmol), chlorobenzene (5 mL) was added, and the mixture was refluxed for 2 h. The reaction mixture was then cooled, and chlorobenzene was removed in vacuo. The crude imidoyl chloride compound (<b>4a</b>) was dissolved in dichloromethane (10 mL), and to it was added a premixed mixture of acetamidine hydrochloride (119 mg, 1.26 mmol) in methanol/dichloromethane (2:1) and Et<sub>3</sub>N (323 mg, 3.2 mmol) at −78 °C dropwise. The mixture was allowed to warm up to room temperature overnight. The reaction mixture was extracted into dichloromethane, washed with water, and purified by flash chromatography using hexanes/EtOAC (6:4) followed by trituration with IPA to afford compound <b>6a</b> (110 mg, 34%). Mp 238–240 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.86 (d, <i>J</i> = 7.8 Hz, 2H), 7.49 (d, <i>J</i> = 7.4 Hz, 2H), 7.27 (d, <i>J</i> = 6.5 Hz, 2H), 7.20–7.18 (m, 3H), 7.07 (d, <i>J</i> = 6.7 Hz, 2H), 6.90–6.88 (m, 2H), 4.71 (dt, <i>J</i> = 6.3, 0.9 Hz, 1H), 4.49 (t, <i>J</i> = 12.0 Hz, 1H), 4.11 (t, <i>J</i> = 6.7 Hz, 1H), 2.04 (s, 3H). <sup>13</sup>C NMR (101 MHz; CDCl<sub>3</sub>): δ 158.7, 139.2, 136.4, 129.5, 128.9, 128.78, 128.6, 128.6, 128.4, 128.0, 127.1, 77.3, 77.2, 77.0, 76.7, 56.4, 50.9, 20.6. HRMS (C<sub>24</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 514.0868, calcd 514.0866. Anal. Calcd (C<sub>24</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S·0.25 H<sub>2</sub>O): C, 55.55; H, 4.18; N, 13.50. Found: C, 55.48; H, 4.05; N, 13.13.</div></div><div id="sec3_6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Methyl ((4-Chlorophenyl)sulfonyl)carbamate (<b>2a</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Methyl ((4-Trifluoromethylphenyl)sulfonyl)carbamate (<b>2b</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">24</a>.</div></div><div id="sec3_6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Methyl ((4-Iodophenyl)sulfonyl)carbamate (<b>2c</b>)</h3><div class="NLM_p last">Refer to general procedure A.</div></div><div id="sec3_6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Methyl (Naphthalen-2-ylsulfonyl)carbamate (<b>2d</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Methyl ((4-fluorophenyl)sulfonyl)carbamate (<b>2e</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Methyl ((4-Bromophenyl)sulfonyl)carbamate (<b>2f</b>)</h3><div class="NLM_p last">Following general procedure A, 4-bromobenzenesulfonamide (5.0 g, 0.017 mol) gave <b>2f</b> (5.5 g, 62%) as a white solid. Mp 117–119 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.91 (d, <i>J</i> = 8.5 Hz, 2H), 7.69 (d, <i>J</i> = 8.5 Hz, 2H), 3.71 (s, 3H). HRMS (C<sub>8</sub>H<sub>9</sub>BrNO<sub>4</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 293.9438, calcd 293.9436.</div></div><div id="sec3_6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Methyl ((4-Methylphenyl)sulfonyl)carbamate (<b>2g</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Methyl (Phenylsulfonyl)carbamate (<b>2h</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Methyl ((4-Methoxyphenyl)sulfonyl)carbamate (<b>2i</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Methyl ((4-(<i>tert</i>-Butyl)phenyl)sulfonyl)carbamate (<b>2j</b>)</h3><div class="NLM_p last">Following general procedure A, 4-<i>tert</i>-butylbenzenesulfonamide (5.8 g, 0.027 mol) gave the carbamate <b>2j</b> (5.0 g, 68%) as a white solid. Mp 148–150 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.96 (d, <i>J</i> = 8.5 Hz, 2H), 7.55 (d, <i>J</i> = 8.5 Hz, 2H), 3.70 (s, 3H), 1.34 (s, 9H). HRMS (C<sub>12</sub>H<sub>18</sub>NO<sub>4</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 272.0958, calcd 272.0957.</div></div><div id="sec3_6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Methyl ((4-Isopropylphenyl)sulfonyl)carbamate (<b>2k</b>)</h3><div class="NLM_p last">Following general procedure A, 4-isopropylbenzenesulfonamide (5.0 g, 0.025 mol) gave the carbamate <b>2k</b> (4.5 g, 69%) as a white solid. Mp 99–102 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.95 (d, <i>J</i> = 8.3 Hz, 2H), 7.39 (d, <i>J</i> = 8.2 Hz, 2H), 3.70 (s, 3H), 2.99 (dt, <i>J</i> = 13.8, 6.9 Hz, 1H), 1.27 (d, <i>J</i> = 6.9 Hz, 6H). HRMS (C<sub>11</sub>H<sub>16</sub>NO<sub>4</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 258.0796, calcd 258.0800.</div></div><div id="sec3_6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Methyl ((4-(Trifluoromethoxy)phenyl)sulfonyl)carbamate (<b>2l</b>)</h3><div class="NLM_p last">Following general procedure A, 4-trifluoromethoxybenzenesulfonamide (6.45 g, 0.025 mol) gave the carbamate <b>2l</b> (5.0 g, 62%) as a white solid. Mp 87–90 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.11 (d, <i>J</i> = 8.9 Hz, 2H), 7.37 (d, <i>J</i> = 8.5 Hz, 2H), 3.72 (s, 3H). HRMS (C<sub>9</sub>H<sub>9</sub>F<sub>3</sub>NO<sub>5</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 300.0155, calcd 300.0154.</div></div><div id="sec3_6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3-(4-Chlorophenyl)-<i>N</i>-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3a</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3-(4-Chlorophenyl)-4-phenyl-<i>N</i>-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3b</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">24</a>.</div></div><div id="sec3_6_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 3-(4-Chlorophenyl)-<i>N</i>-((4-iodophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3c</b>)</h3><div class="NLM_p last">Refer to general procedure B. Mp 180–182 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.73 (s, 2H), 7.89 (q, <i>J</i> = 10.3 Hz, 4H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.30–7.27 (m, 4H), 7.17 (d, <i>J</i> = 7.6 Hz, 1H), 7.10 (d, <i>J</i> = 7.2 Hz, 2H), 4.70 (dd, <i>J</i> = 11.7, 5.5 Hz, 1H), 4.30 (t, <i>J</i> = 11.6 Hz, 1H), 3.89 (dd, <i>J</i> = 11.5, 5.5 Hz, 1H), 2.35–2.33 (m, 2H). HRMS (C<sub>22</sub>H<sub>18</sub>ClIN<sub>3</sub>O<sub>3</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 565.9802, calcd 565.9810.</div></div><div id="sec3_6_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 3-(4-Chlorophenyl)-<i>N</i>-(naphthalen-2-ylsulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3d</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.82 (s, 1H), 8.74 (s, 1H), 8.12 (d, <i>J</i> = 8.7 Hz, 1H), 8.01 (dd, <i>J</i> = 12.6, 8.5 Hz, 2H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 7.63 (td, <i>J</i> = 13.4, 5.5 Hz, 2H), 7.53 (d, <i>J</i> = 8.4 Hz, 2H), 7.28 (d, <i>J</i> = 7.5 Hz, 2H), 7.25 (d, <i>J</i> = 9.4 Hz, 5H), 7.17 (d, <i>J</i> = 7.7 Hz, 1H), 7.09 (d, <i>J</i> = 7.2 Hz, 2H), 4.68 (dd, <i>J</i> = 11.7, 5.5 Hz, 1H), 4.68 (dd, <i>J</i> = 11.7, 5.5 Hz, 1H), 4.28 (t, <i>J</i> = 11.6 Hz, 1H), 3.87 (dd). HRMS (C<sub>26</sub>H<sub>21</sub>ClN<sub>3</sub>O<sub>3</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 490.0994, calcd 490.0992.</div></div><div id="sec3_6_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 3-(4-Chlorophenyl)-<i>N</i>-((4-fluorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3e</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 3-(4-Chlorophenyl)-<i>N</i>-((4-bromophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3f)</b>)</h3><div class="NLM_p last">Following general procedure B, <b>2f</b> (1.00 g, 3.4 mmol) gave 1.25 g (71%) of <b>3f</b> as a white solid. Mp 205–207 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.75 (s, 1H), 8.02 (d, <i>J</i> = 8.1 Hz, 2H), 7.70–7.67 (m, 2H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.17 (d, <i>J</i> = 7.5 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 2H), 4.70 (dd, <i>J</i> = 11.8, 5.5 Hz, 1H), 4.30 (t, <i>J</i> = 11.7 Hz, 1H), 3.89 (dd, <i>J</i> = 11.4, 5.3 Hz, 1H), 2.35 (s, 1H). HRMS (C<sub>22</sub>H<sub>18</sub>BrClN<sub>3</sub>O<sub>3</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 517.9946, calcd 571.9941.</div></div><div id="sec3_6_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 3-(4-Chlorophenyl)-4-phenyl-<i>N</i>-tosyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3g</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 3-(4-Chlorophenyl)-4-phenyl-<i>N</i>-(phenylsulfonyl)-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3h</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 3-(4-chlorophenyl)-<i>N</i>-((4-methoxyphenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3i</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>.</div></div><div id="sec3_6_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3-(4-Chlorophenyl)-<i>N</i>-((4-<i>tert</i>-butylphenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3j</b>)</h3><div class="NLM_p last">Following general procedure B, <b>2j</b> (2.0 g, 7.3 mmol) gave 2.0 g (55%) of <b>3j</b> as a white solid. Mp 231–233 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.76 (s, 1H), 8.07 (d, <i>J</i> = 8.5 Hz, 2H), 7.54 (dd, <i>J</i> = 13.0, 8.5 Hz, 4H), 7.27 (dt, <i>J</i> = 9.2, 5.1 Hz, 6H), 7.11 (d, <i>J</i> = 7.2 Hz, 2H), 4.69 (dd, <i>J</i> = 11.7, 5.5 Hz, 1H), 4.30 (t, <i>J</i> = 11.6 Hz, 1H), 3.90 (dd, <i>J</i> = 11.5, 5.5 Hz, 1H), 1.34 (s, 9H). HRMS (C<sub>26</sub>H<sub>27</sub>ClN<sub>3</sub>O<sub>3</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 496.1466, calcd 496.1462.</div></div><div id="sec3_6_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3-(4-Chlorophenyl)-<i>N</i>-((4-isopropylphenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3k</b>)</h3><div class="NLM_p last">Following general procedure B, <b>2k</b> (1.5 g, 5.8 mmol) gave 1.8 g (64%) of <b>3k</b> as a white solid. Mp 230–232 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.77 (s, 1H), 8.07 (d, <i>J</i> = 8.3 Hz, 2H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.29–7.26 (m, 5H), 7.10 (d, <i>J</i> = 7.0 Hz, 2H), 4.69 (dd, <i>J</i> = 11.7, 5.5 Hz, 1H), 4.30 (t, <i>J</i> = 11.6 Hz, 1H), 3.90 (dd, <i>J</i> = 11.5, 5.5 Hz, 1H), 2.98 (dt, <i>J</i> = 13.8, 6.9 Hz, 1H), 1.27 (d, <i>J</i> = 6.9 Hz, 6H). HRMS (C<sub>25</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>3</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 482.1311, calcd 482.1305.</div></div><div id="sec3_6_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 3-(4-Chlorophenyl)-4-phenyl-<i>N</i>-((4-(trifluoromethoxy)phenyl)sulfonyl)-4,5-dihydro-1<i>H</i>-pyrazole-1-carboxamide (<b>3l</b>)</h3><div class="NLM_p last">Following general procedure B, <b>2l</b> (1.0 g, 3.4 mmol) gave 1.5 g (86%) of <b>3l</b> as a white solid. Mp 185–188 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.77 (s, 1H), 8.21 (s, 2H), 7.53 (d, <i>J</i> = 8.5 Hz, 2H), 7.37 (d, <i>J</i> = 8.3 Hz, 2H), 7.30–7.28 (m, 4H), 7.17 (d, <i>J</i> = 7.6 Hz, 1H), 7.11 (d, <i>J</i> = 7.0 Hz, 2H), 4.71 (dd, <i>J</i> = 11.7, 5.5 Hz, 1H), 4.31 (t, <i>J</i> = 11.6 Hz, 1H), 3.90 (dd, <i>J</i> = 11.5, 5.5 Hz, 1H), 2.35 (s, 2H). HRMS (C<sub>23</sub>H<sub>18</sub>ClF<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S) [M + H]<sup>+</sup> found <i>m</i>/<i>z</i> 524.0657, calcd 524.0659.</div></div><div id="sec3_6_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Methyl <i>N</i>′-((3-(4-Chlorophenyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazol-1-yl)(((4-chlorophenyl)sulfonyl)imino)methyl)carbamimidothioate (<b>5a</b>)</h3><div class="NLM_p last">Refer to general procedure C.</div></div><div id="sec3_6_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Methyl <i>N</i>′-(3-(4-Chlorophenyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazol-1-yl)(((4-(trifluoromethyl)phenyl)sulfonyl)imino)methyl)carbamimidothioate (<b>5b</b>)</h3><div class="NLM_p last">Following general procedure C, <b>3b</b> (200 mg, 0.39 mmol) gave compound <b>5b</b> (60 mg, 26%) as a white solid. Mp 213–215 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.55–8.46 (m, 1H), 7.91 (dt, <i>J</i> = 20.9, 12.1 Hz, 4H), 7.60–7.55 (m, 2H), 7.45 (d, <i>J</i> = 8.6 Hz, 2H), 7.28 (t, <i>J</i> = 5.0 Hz, 3H), 7.13 (s, 2H), 4.69–4.66 (m, 1H), 4.54 (t, <i>J</i> = 11.9 Hz, 1H), 4.12 (dd, <i>J</i> = 12.2, 5.1 Hz, 1H), 2.99–2.64 (m, 1H), 2.17 (s, 3H). HRMS (C<sub>25</sub>H<sub>21</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 580.0852, calcd 580.0850.</div></div><div id="sec3_6_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Methyl <i>N</i>′-(3-(4-Chlorophenyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazol-1-yl)(((4-iodophenyl)sulfonyl)imino)methyl)carbamimidothioate (<b>5c</b>)</h3><div class="NLM_p last">Following general procedure C, <b>3c</b> (200 mg, 0.35 mmol) gave compound <b>5c</b> (75 mg, 33%) as a white solid. Mp 219–241 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.78 (d, <i>J</i> = 8.2 Hz, 2H), 7.67 (d, <i>J</i> = 7.4 Hz, 2H), 7.47 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (t, <i>J</i> = 7.0 Hz, 3H), 7.21 (d, <i>J</i> = 8.4 Hz, 2H), 7.12 (s, 2H), 4.70–4.67 (m, 1H), 4.52 (t, <i>J</i> = 11.9 Hz, 1H), 4.09 (dd, <i>J</i> = 12.2, 5.0 Hz, 1H), 2.31 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 158.6, 139.3, 137.4, 136.4, 129.5, 128.83, 128.75, 128.73, 128.71, 128.69, 128.64, 128.0, 127.3, 110.0, 56.9, 50.9, 14.2. HRMS (C<sub>24</sub>H<sub>22</sub>ClIN<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 637.9943, calcd 637.9943.</div></div><div id="sec3_6_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Methyl <i>N</i>′-((3-(4-Chlorophenyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazol-1-yl)((naphthalen-2-ylsulfonyl)imino)methyl)carbamimidothioate (<b>5d</b>)</h3><div class="NLM_p last">Following general procedure C, <b>3d</b> (200 mg, 0.4 mmol) gave compound <b>5d</b> (70 mg, 31%) as a white solid. Mp 230–232 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.08 (d, <i>J</i> = 7.0 Hz, 2H), 7.71 (d, <i>J</i> = 8.1 Hz, 2H), 7.47–7.45 (m, 2H), 7.31 (q, <i>J</i> = 7.0 Hz, 4H), 7.18 (t, <i>J</i> = 14.9 Hz, 4H), 5.23 (s, 2H), 4.68 (s, 1H), 4.56–4.50 (m, 1H), 4.11 (dd, <i>J</i> = 12.2, 4.9 Hz, 1H), 2.28 (s, 3H). <sup>13</sup>C NMR (101 MHz; CDCl<sub>3</sub>): δ 158.9, 139.2, 136.5, 129.5, 128.85, 128.78, 128.5, 128.0, 127.2, 125.43, 125.41, 125.38, 124.9, 122.2, 56.7, 51.0, 14.2. HRMS (C<sub>28</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 562.1136, calcd 562.1133.</div></div><div id="sec3_6_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6a</b>)</h3><div class="NLM_p last">Refer to general procedure D.</div></div><div id="sec3_6_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-<i>N</i>′-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6b</b>)</h3><div class="NLM_p last">Synthesized as outlined in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">24</a>. Mp °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.05 (d, <i>J</i> = 5.7 Hz, 2H), 7.69–7.68 (m, 2H), 7.50 (d, <i>J</i> = 8.0 Hz, 2H), 7.29 (d, <i>J</i> = 7.2 Hz, 2H), 7.21 (d, <i>J</i> = 8.0 Hz, 3H), 7.09–7.08 (m, 2H), 4.73–4.71 (m, 1H), 4.51 (t, <i>J</i> = 11.5 Hz, 1H), 3.87 (d, <i>J</i> = 5.1 Hz, 1H), 2.09 (s, 3H). HRMS (C<sub>25</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 548.1132, calcd 548.1129.</div></div><div id="sec3_6_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-iodophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6c</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3c</b> (100 mg, 0.17 mmol) gave compound <b>6c</b> (35 mg, 33%) as a white solid. Mp 216–218 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.77 (d, <i>J</i> = 8.0 Hz, 2H), 7.67–7.64 (m, 2H), 7.51 (d, <i>J</i> = 7.7 Hz, 2H), 7.30 (s, 3H), 7.23–7.21 (m, 2H), 7.09–7.08 (m, 2H), 5.14 (s, 1H), 4.71 (d, <i>J</i> = 8.0 Hz, 1H), 4.51–4.46 (m, 1H), 4.10 (d, <i>J</i> = 10.6 Hz, 1H), 2.08 (s, 3H). HRMS (C<sub>24</sub>H<sub>22</sub>ClIN<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 606.0222, calcd 606.0222.</div></div><div id="sec3_6_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-(4-Chlorophenyl)-<i>N</i>-(1-iminoethyl)-<i>N</i>′-(naphthalen-2-ylsulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6d</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3d</b> (400 mg, 0.81 mmol) gave compound <b>6d</b> (200 mg, 46%) as a white solid. Mp 207–209 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.48 (s, 1H), 7.96 (d, <i>J</i> = 8.4 Hz, 1H), 7.92–7.91 (m, 1H), 7.87 (t, <i>J</i> = 7.4 Hz, 2H), 7.58–7.52 (m, 2H), 7.48 (d, <i>J</i> = 8.4 Hz, 3H), 7.28 (s, 2H), 7.18 (d, <i>J</i> = 7.7 Hz, 2H), 7.08 (d, <i>J</i> = 6.9 Hz, 2H), 5.22 (s, 1H), 4.70–4.69 (m, 1H), 4.51 (t, <i>J</i> = 12.0 Hz, 1H), 4.14–4.11 (m, 1H), 2.04 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 158.3, 157.1, 152.5, 146.7, 139.3, 136.3, 134.4, 132.1, 129.5, 129.1, 128.8, 128.7, 128.6, 128.59, 128.3, 127.9, 127.8, 127.7, 127.1, 126.8, 123.5, 56.5, 50.9, 20.6. HRMS [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 530.1412, calcd 530.1412.</div></div><div id="sec3_6_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-fluorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6e</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3e</b> (80 mg, 0.18 mmol) gave compound <b>6e</b> (21 mg, 24%) as a white solid. Mp 225–227 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.95–7.93 (m, 2H), 7.51 (d, <i>J</i> = 8.0 Hz, 2H), 7.29 (d, <i>J</i> = 7.0 Hz, 2H), 7.21 (d, <i>J</i> = 8.3 Hz, 3H), 7.09 (t, <i>J</i> = 7.3 Hz, 4H), 5.29 (bs, 2H), 4.71 (dd, <i>J</i> = 11.4, 4.9 Hz, 1H), 4.49 (t, <i>J</i> = 11.9 Hz, 1H), 4.11–4.09 (m, 1H), 2.08 (s, 3H). HRMS (C<sub>24</sub>H<sub>22</sub>CFIN<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 498.1161, calcd 498.1161.</div></div><div id="sec3_6_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-(1-Aminoethylidene)-<i>N</i>′-((4-bromophenyl)sulfonyl)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6f</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3f</b> (100 mg, 0.19 mmol) gave compound <b>6f</b> (40 mg, 37%) as a white solid. Mp 247–249 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.80 (d, <i>J</i> = 7.5 Hz, 2H), 7.55 (d, <i>J</i> = 8.3 Hz, 2H), 7.51 (d, <i>J</i> = 8.5 Hz, 2H), 7.30 (d, <i>J</i> = 7.6 Hz, 3H), 7.22 (d, <i>J</i> = 8.5 Hz, 2H), 7.09–7.08 (m, 2H), 5.11 (bs, 2H), 4.71 (dt, <i>J</i> = 6.3, 0.9 Hz, 1H), 4.49 (t, <i>J</i> = 12.0 Hz, 1H), 4.11 (t, <i>J</i> = 6.7 Hz, 1H), 2.08 (s, 3H). HRMS (C<sub>24</sub>H<sub>22</sub>ClBrN<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 558.0363, calcd 558.0361.</div></div><div id="sec3_6_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-<i>N</i>′-tosyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6g</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3g</b> (350 mg, 0.77 mmol) gave compound <b>6g</b> (80 mg, 21%) as a white solid. Mp 200–203 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 7.8 Hz, 2H), 7.47 (d, <i>J</i> = 8.5 Hz, 2H), 7.25–7.22 (m, 3H), 7.18 (dd, <i>J</i> = 12.0, 8.4 Hz, 4H), 7.06 (d, <i>J</i> = 7.0 Hz, 2H), 5.82 (s, 1H), 4.68 (dd, <i>J</i> = 11.2, 4.8 Hz, 1H), 4.49 (t, <i>J</i> = 11.3 Hz, 1H), 4.06 (t, <i>J</i> = 6.6 Hz, 1H), 2.35 (s, 3H), 2.00 (s, 3H). HRMS (C<sub>25</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 494.1412, calcd 494.1412.</div></div><div id="sec3_6_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-<i>N</i>′-(phenylsulfonyl)-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6h</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3h</b> (100 mg, 0.22 mmol) gave compound <b>6h</b> (38 mg, 35%) as a white solid. Mp 194–196 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.94 (d, <i>J</i> = 7.1 Hz, 2H), 7.50 (d, <i>J</i> = 8.3 Hz, 2H), 7.46 (d, <i>J</i> = 6.7 Hz, 2H), 7.42 (t, <i>J</i> = 7.2 Hz, 2H), 7.30 (t, <i>J</i> = 7.1 Hz, 2H), 7.21 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.08 (m, 2H), 5.19 (bs, 1H), 4.72–4.69 (m, 1H), 4.50 (t, <i>J</i> = 12.0 Hz, 1H), 4.13–4.10. HRMS C<sub>24</sub>H<sub>23</sub>ClN<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 480.1259, calcd 480.1255.</div></div><div id="sec3_6_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-methoxyphenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6i</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3i</b> (200 mg, 0.43 mmol) gave compound <b>6i</b> (48 mg, 22%) as a white solid. Mp 200–203 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.86 (d, <i>J</i> = 7.8 Hz, 2H), 7.49 (d, <i>J</i> = 7.4 Hz, 2H), 7.27 (d, <i>J</i> = 6.5 Hz, 3H), 7.20–7.18 (m, 2H), 7.07 (d, <i>J</i> = 6.7 Hz, 2H), 6.90–6.88 (m, 2H), 4.70–4.67 (m, 1H), 4.51–4.46 (m, 1H), 4.07 (s, 1H), 3.82 (s, 3H), 2.03 (s, 3H). HRMS (C<sub>25</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>3</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 510.1363, calcd 510.1361.</div></div><div id="sec3_6_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>N</i>-(1-Aminoethylidene)-<i>N</i>′-((4-(<i>tert</i>-butyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6j</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3j</b> (500 mg, 1.01 mmol) gave compound <b>6j</b> (120 mg, 22%) as a white solid. Mp 215–217 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.85 (d, <i>J</i> = 8.4 Hz, 2H), 7.50 (d, <i>J</i> = 8.5 Hz, 2H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (t, <i>J</i> = 7.1 Hz, 3H), 7.20 (d, <i>J</i> = 8.6 Hz, 2H), 7.09 (d, <i>J</i> = 7.1 Hz, 2H), 5.26 (s, 2H), 4.69 (dd, <i>J</i> = 11.5, 5.2 Hz, 1H), 4.51 (d, <i>J</i> = 12.2 Hz, 1H), 4.10 (dd, <i>J</i> = 12.4, 5.1 Hz, 1H), 2.06 (s, 3H), 1.31 (s, 9H). HRMS (C<sub>28</sub>H<sub>31</sub>ClN<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 536.1893, calcd 536.1887.</div></div><div id="sec3_6_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-isopropylphenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6k</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3k</b> (500 mg, 1.03 mmol) gave compound <b>6k</b> (160 mg, 30%) as a white solid. Mp 215–218 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.85 (d, <i>J</i> = 8.3 Hz, 2H), 7.49 (s, 2H), 7.31–7.27 (m, 3H), 7.25 (s, 2H), 7.20 (d, <i>J</i> = 8.6 Hz, 2H), 7.09 (d, <i>J</i> = 6.8 Hz, 2H), 4.69 (dd, <i>J</i> = 11.5, 5.2 Hz, 1H), 4.49 (t, <i>J</i> = 12.0 Hz, 1H), 4.11 (dd, <i>J</i> = 12.5, 5.3 Hz, 1H), 2.93 (dt, <i>J</i> = 13.8, 6.9 Hz, 1H), 2.06 (s, 3H), 1.24 (d, <i>J</i> = 6.9 Hz, 6H). HRMS (C<sub>27</sub>H<sub>29</sub>ClN<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 522.1731, calcd 522.1731.</div></div><div id="sec3_6_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-<i>N</i>′-((4-(trifluoromethoxy)phenyl)sulfonyl)-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>6l</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3l</b> (400 mg, 0.76 mmol) gave compound <b>6l</b> (130 mg, 30%) as a white solid. Mp 208–210 °C. <sup>1</sup>H NMR <b>(</b>400 MHz, CDCl<sub>3</sub>): δ 7.98 (d, <i>J</i> = 8.7 Hz, 2H), 7.51 (d, <i>J</i> = 8.6 Hz, 2H), 7.32–7.27 (m, 4H), 7.22 (t, <i>J</i> = 5.9 Hz, 3H), 7.09 (d, <i>J</i> = 6.8 Hz, 2H), 5.21 (s, 2H), 4.71 (dd, <i>J</i> = 11.5, 5.2 Hz, 1H), 4.50 (t, <i>J</i> = 12.0 Hz, 1H), 4.10 (dd, <i>J</i> = 12.4, 5.0 Hz, 1H), 2.08 (s, 3H). HRMS (C<sub>25</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 564.1074, calcd 564.1084.</div></div><div id="sec3_6_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (4<i>S</i>)-(−)-<i>N</i>-(1-Aminoethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (7) and (<i>4R</i>)-(−)-<i>N</i>-(1-aminoethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>7′</b>)</h3><div class="NLM_p">Refer to general procedure D. The racemic compound <b>6a</b> was further subjected to chiral preparatory HPLC or chiral SFC using (<i>R</i>,<i>R</i>)-Whelk-O1 to afford enantiomers E1 (−)-<b>7</b> and E2 (+)-<b>7′</b>. Analytical: (<i>R</i>,<i>R</i>)-Whelk-O1 (250 mm × 4.6 mm) 4.68 min E1, 5.85 min. E2 solvent: ethanol (100%). Flow rate: 1 mL/min.</div><div class="NLM_p">E1 (<b>7</b>). Mp 226–228 °C. [α<sub class="stack">D</sub><sup class="stack">25</sup>] −8° (<i>c</i> 0.1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.87 (d, <i>J</i> = 8.0 Hz, 2H), 7.49 (d, <i>J</i> = 8.3 Hz, 2H), 7.38 (d, <i>J</i> = 8.2 Hz, 2H), 7.27 (d, <i>J</i> = 10.8 Hz, 3H), 7.20 (d, <i>J</i> = 8.3 Hz, 2H), 7.08 (d, <i>J</i> = 6.8 Hz, 2H), 5.52 (bs, 2H), 4.70 (dd, <i>J</i> = 11.1, 4.7 Hz, 1H), 4.50 (t, <i>J</i> = 11.7 Hz, 1H), 4.07 (d, <i>J</i> = 7.5 Hz, 1H), 2.06 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 160.3, 158.7, 158.3, 141.8, 139.4, 137.6, 136.4, 129.5, 128.87, 128.70, 128.66, 128.4, 128.0, 127.2, 56.5, 51.0, 20.7. HRMS (C<sub>24</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 514.0868, calcd 514.0866.</div><div class="NLM_p last">E2 (<b>7′</b>). Mp 226–228 °C. [α] +8° (<i>c</i> 0.1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.87 (d, <i>J</i> = 8.0 Hz, 2H), 7.49 (d, <i>J</i> = 8.3 Hz, 2H), 7.38 (d, <i>J</i> = 8.2 Hz, 2H), 7.27 (d, <i>J</i> = 10.8 Hz, 3H), 7.20 (d, <i>J</i> = 8.3 Hz, 2H), 7.08 (d, <i>J</i> = 6.8 Hz, 2H), 5.52 (bs, 2H), 4.70 (dd, <i>J</i> = 11.1, 4.7 Hz, 1H), 4.50 (t, <i>J</i> = 11.7 Hz, 1H), 4.07 (d, <i>J</i> = 7.5 Hz, 1H), 2.06 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 160.3, 158.7, 158.3, 141.8, 139.4, 137.6, 136.4, 129.5, 128.87, 128.70, 128.66, 128.4, 128.0, 127.2, 56.5, 51.0, 20.7. HRMS (C<sub>24</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 514.0868, calcd 514.0866.</div></div><div id="sec3_6_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> X-ray Crystallographic Analysis of (−)-(<b>7</b>)</h3><div class="NLM_p last">Suitable crystals of <b>7</b> were obtained by recrystallization of the compound from IPA and water (9:1) by slow evaporation of the solvent. The single crystal X-ray diffraction studies were carried out on a Bruker Kappa APEX-II CCD diffractometer equipped with Cu Kα radiation (λ = 1.5478). A 0.471 mm × 0.035 mm × 0.031 mm colorless needle was mounted on a Cryoloop with Paratone oil. Data were collected in a nitrogen gas stream at 100(2) K using ϕ and ω scans. Crystal-to-detector distance was 40 mm using variable exposure time (5–10 s) depending on θ with a scan width of 1.0°. Data collection was 99.8% complete to 68.00° in θ. A total of 33 614 reflections were collected covering the indices −23 ≤ <i>h</i> ≤ 23, −23 ≤ <i>k</i> ≤ 23, −7 ≤ <i>l</i> ≤ 6. 3996 reflections were found to be symmetry independent, with a <i>R</i><sub>int</sub> of 0.0457. Indexing and unit cell refinement indicated a primitive, tetragonal lattice. The space group was found to be <i>P</i>4<sub>3</sub>. The data were integrated using the Bruker SAINT software program and scaled using the SADABS software program. Solution by direct methods (SHELXT) produced a complete phasing model consistent with the proposed structure. Atomic coordinates for (−)-(<b>7</b>) have been deposited with the Cambridge Crystallographic Data Centre (deposition number 1507425). Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, U.K. [fax, + 44(0)-1223–336033; e-mail, <a href="/cdn-cgi/l/email-protection#93f7f6e3fce0fae7d3f0f0f7f0bdf0f2febdf2f0bde6f8"><span class="__cf_email__" data-cfemail="4d29283d223e24390d2e2e292e632e2c20632c2e633826">[email protected]</span></a>].</div></div><div id="sec3_6_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>N</i>-(1-Amino-2,2-dimethylpropylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>8</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (200 mg, 0.42 mmol) and <i>tert</i>-butylamidine·HCl (1.5 equiv) gave compound <b>8</b> (62 mg, 26%) as a white solid. Mp 133–135 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.95 (d, <i>J</i> = 6.6 Hz, 2H), 7.48 (dd, <i>J</i> = 26.1, 8.3 Hz, 2H), 7.36 (d, <i>J</i> = 6.4 Hz, 2H), 7.32 (d, <i>J</i> = 7.1 Hz, 3H), 7.26 (d, <i>J</i> = 8.3 Hz, 2H), 7.20 (s, 2H), 5.52 (d, <i>J</i> = 0.4 Hz, 1H), 4.80 (s, 1H), 4.67 (s, 1H), 4.07 (dd, <i>J</i> = 12.2, 5.8 Hz, 1H), 1.32 (s, 9H). HRMS (C<sub>27</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 556.1340, calcd 556.1335.</div></div><div id="sec3_6_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>N</i>-(1-Amino(cyclopropyl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>9</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (100 mg, 0.21 mmol) and cyclopropylamidine hydrochloride (1.5 equiv) gave compound <b>9</b> (32 mg, 28%) as a white solid. Mp 96–98 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.87 (d, <i>J</i> = 7.8 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.28 (d, <i>J</i> = 7.5 Hz, 3H), 7.24 (d, <i>J</i> = 7.4 Hz, 2H), 7.18 (d, <i>J</i> = 8.1 Hz, 2H), 7.10 (d, <i>J</i> = 6.7 Hz, 2H), 4.65 (t, <i>J</i> = 0.9 Hz, 1H), 4.48 (t, <i>J</i> = 11.6 Hz, 1H), 4.00 (dd, <i>J</i> = 10.9, 4.1 Hz, 1H), 1.25 (s, 2H), 0.98 (d, <i>J</i> = 3.6 Hz, 1H), 0.87 (t, <i>J</i> = 2.2 Hz, 2H). HRMS (C<sub>26</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 540.1028, calcd 540.1022.</div></div><div id="sec3_6_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> <i>N</i>-(1-Amino-2-methylpropylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>10</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (80 mg, 0.17 mmol) and isopropylamidine hydrochloride (1.5 equiv) gave compound <b>10</b> (22 mg, 24%) as a white solid. Mp 128–130 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.87–7.87 (m, 2H), 7.48 (d, <i>J</i> = 8.6 Hz, 2H), 7.40–7.38 (m, 2H), 7.31–7.29 (m, 3H), 7.22–7.20 (m, 2H), 7.10 (dd, <i>J</i> = 2.7, 1.1 Hz, 2H), 5.06 (s, 2H), 4.71 (dd, <i>J</i> = 2.3, 1.3 Hz, 1H), 4.50 (t, <i>J</i> = 11.9 Hz, 1H), 4.08 (d, <i>J</i> = 12.2 Hz, 1H), 2.58 (s, 1H), 1.28 (s, 6H). HRMS (C<sub>26</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 542.1182, calcd 542.1179.</div></div><div id="sec3_6_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 3-(4-Chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-<i>N</i>-((<i>E</i>)-piperidin-2-ylidene)-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>11</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (150 mg, 0.32 mmol) and 2-iminopiperidine hydrochloride (1.5 equiv) gave compound <b>11</b> (40 mg, 23%) as a white solid. Mp 139–141 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.87 (d, <i>J</i> = 7.6 Hz, 2H), 7.49 (s, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 2H), 7.29 (d, <i>J</i> = 7.4 Hz, 3H), 7.20 (d, <i>J</i> = 8.3 Hz, 2H), 7.10–7.08 (m, 2H), 4.70 (s, 1H), 4.55–4.50 (m, 1H), 4.10 (dd, <i>J</i> = 12.5, 4.7 Hz, 1H), 3.41 (s, 2H), 2.46 (s, 2H), 1.77 (dd, <i>J</i> = 20.3, 0.5 Hz, 4H). HRMS (C<sub>27</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 554.1185, calcd 554.1179.</div></div><div id="sec3_6_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>-(Adamantan-1-yl(amino)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>12</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (150 mg, 0.32 mmol) and adamantyl-1-carboxamidine hydrochloride (1.5 equiv) gave compound <b>12</b> (30 mg, 15%) as a white solid. Mp 243–246 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90 (d, <i>J</i> = 5.8 Hz, 2H), 7.45 (d, <i>J</i> = 8.6 Hz, 2H), 7.39 (d, <i>J</i> = 8.3 Hz, 2H), 7.30–7.26 (m, 3H), 7.20 (d, <i>J</i> = 8.3 Hz, 3H), 7.12 (s, 1H), 4.69 (t, <i>J</i> = 1.6 Hz, 1H), 4.54 (t, <i>J</i> = 11.9 Hz, 1H), 4.04 (dd, <i>J</i> = 12.3, 5.6 Hz, 1H), 2.08 (s, 4H), 1.88 (s, 5H), 1.78–1.69 (m, 5H), 1.62 (t, <i>J</i> = 0.5 Hz, 1H). HRMS (C<sub>33</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 634.1807, calcd 634.1805.</div></div><div id="sec3_6_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>N</i>-(Amino(phenyl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>13</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (340 mg, 0.72 mmol) and benzamidine hydrochloride (1.5 equiv) gave compound <b>13</b> (200 mg, 48%) as a white solid. Mp 138–140 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.91 (d, <i>J</i> = 7.5 Hz, 2H), 7.77 (d, <i>J</i> = 7.7 Hz, 2H), 7.55 (t, <i>J</i> = 6.9 Hz, 2H), 7.43 (t, <i>J</i> = 7.4 Hz, 5H), 7.38 (d, <i>J</i> = 7.9 Hz, 2H), 7.19 (d, <i>J</i> = 8.0 Hz, 5H), 6.61 (s, 1H), 5.69 (s, 1H), 4.55–4.53 (m, 1H), 4.39–4.38 (m, 1H), 3.97–3.94 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.03, 157.88, 142.8, 140.3, 136.4, 135.2, 134.6, 131.7, 129.42, 129.37, 129.23, 129.16, 129.07, 128.87, 128.86, 128.7, 127.7, 127.6, 127.3, 56.6, 49.8, 25.6. HRMS [M + H]<sup>+</sup> (C<sub>29</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S): found <i>m</i>/<i>z</i> 576.1024, calcd 576.1022.</div></div><div id="sec3_6_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>N</i>-(Amino(4-fluorophenyl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>14</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (800 mg, 1.7 mmol) and 4-fluorobenzamidine hydrochloride (1.5 equiv) gave compound <b>14</b> (300 mg, 30%) as a white solid. Mp 156–158 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90 (d, <i>J</i> = 7.7 Hz, 2H), 7.80 (dd, <i>J</i> = 8.6, 5.2 Hz, 2H), 7.43–7.38 (m, 4H), 7.20 (t, <i>J</i> = 7.9 Hz, 3H), 7.10 (t, <i>J</i> = 8.5 Hz, 2H), 6.66 (s, 1H), 5.76 (s, 1H), 4.57 (d, <i>J</i> = 7.0 Hz, 1H), 4.39 (d, <i>J</i> = 3.6 Hz, 1H), 3.96 (s, 1H). HRMS (C<sub>29</sub>H<sub>23</sub>Cl<sub>2</sub>FN<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 594.0931, calcd 594.0928.</div></div><div id="sec3_6_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>N</i>-(Amino(4-chlorophenyl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>15</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (800 mg, 1.7 mmol) and 4-chlorobenzamidine hydrochloride (1.5 equiv) gave compound <b>15</b> (250 mg, 24%) as a white solid. Mp 150–152 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90 (d, <i>J</i> = 7.6 Hz, 2H), 7.72 (d, <i>J</i> = 8.0 Hz, 3H), 7.40–7.38 (m, 6H), 7.20 (t, <i>J</i> = 8.5 Hz, 6H), 6.61 (bs, 1H), 5.95 (s, 1H), 4.57–4.56 (m, 1H), 4.38 (t, <i>J</i> = 12.0 Hz, 1H), 3.93 (d, <i>J</i> = 3.0 Hz, 1H). HRMS (C<sub>29</sub>H<sub>23</sub>Cl<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 610.0637, calcd 610.0633.</div></div><div id="sec3_6_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>N</i>-(Amino(4-bromophenyl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>16</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (200 mg, 0.42 mmol) and 4-bromobenzamidine hydrochloride (1.5 equiv) gave compound <b>16</b> (58 mg, 23%) as a white solid. Mp 169–172 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90–7.89 (m, 2H), 7.65 (d, <i>J</i> = 8.1 Hz, 3H), 7.56 (d, <i>J</i> = 8.0 Hz, 3H), 7.40 (s, 5H), 7.20 (d, <i>J</i> = 8.4 Hz, 3H), 6.63 (s, 1H), 5.77 (s, 1H), 4.55 (s, 1H), 4.37 (s, 1H), 3.94 (s, 1H). HRMS (C<sub>29</sub>H<sub>23</sub>BrCl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 654.0126, calcd 654.0127.</div></div><div id="sec3_6_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>N</i>′-(3-(4-Chlorophenyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazol-1-yl)(((4-chlorophenyl)sulfonyl)imino)methyl)isonicotinimidamide (<b>17</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (200 mg, 0.42 mmol) and isonicotinamidamide (1.5 equiv) gave compound <b>17</b> (70 mg, 29%) as a white solid. Mp 241–243 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.72 (s, 2H), 7.86 (d, <i>J</i> = 5.8 Hz, 2H), 7.65 (s, 2H), 7.41–7.38 (m, 6H), 7.20 (t, <i>J</i> = 7.6 Hz, 5H), 6.68 (s, 1H), 6.04 (bs, 1H), 4.60–4.58 (m, 1H), 4.42–4.38 (m, 1H), 3.95–3.93 (m, 1H). HRMS (C<sub>28</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 577.0981, calcd 577.0975.</div></div><div id="sec3_6_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>N</i>-(Amino(2,4-difluorophenyl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>18</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (100 mg, 0.21 mmol) and 2,4-difluorobenzamidine hydrochloride (1.5 equiv) gave compound <b>18</b> (25 mg, 19%) as a white solid. Mp 219–222 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.87 (d, <i>J</i> = 6.9 Hz, 2H), 7.45–7.44 (m, 2H), 7.37 (d, <i>J</i> = 7.6 Hz, 2H), 7.20 (d, <i>J</i> = 13.2 Hz, 8H), 6.94 (t, <i>J</i> = 7.3 Hz, 1H), 6.87 (d, <i>J</i> = 10.8 Hz, 1H), 6.76 (s, 1H), 6.21 (s, 1H), 4.63 (d, <i>J</i> = 6.3 Hz, 1H), 4.48 (d, <i>J</i> = 8.5 Hz, 1H), 3.98–3.96 (m, 1H). HRMS (C<sub>29</sub>H<sub>22</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 612.0834, calcd 612.0834.</div></div><div id="sec3_6_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> <i>N</i>-(Amino(3-bromophenyl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>19</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (100 mg, 0.21 mmol) and 3-bromobenzamidine hydrochloride (1.5 equiv) gave compound <b>19</b> (25 mg, 18%) as a white solid. Mp 150–152 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.87–7.83 (m, 3H), 7.71 (d, <i>J</i> = 7.6 Hz, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.41 (t, <i>J</i> = 8.7 Hz, 3H), 7.29 (dd, <i>J</i> = 9.8, 6.1 Hz, 2H), 7.23 (s, 4H), 7.18 (d, <i>J</i> = 8.4 Hz, 3H), 6.82 (s, 1H), 5.84 (s, 1H), 4.64–4.62 (m, 1H), 4.47 (t, <i>J</i> = 10.4 Hz, 1H), 3.99 (d, <i>J</i> = 2.9 Hz, 1H). HRMS (C<sub>29</sub>H<sub>23</sub>BrCl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 654.0131, calcd 654.0127.</div></div><div id="sec3_6_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>N</i>-(Amino(2-fluorophenyl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>20</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (100 mg, 0.21 mmol) and 2-fluorobenzamidine hydrochloride (1.5 equiv) gave compound <b>20</b> (30 mg, 24%) as a white solid. Mp 188–190 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.94–7.90 (m, 3H), 7.52–7.46 (m, 4H), 7.38 (d, <i>J</i> = 7.1 Hz, 3H), 7.21–7.18 (m, 5H), 7.13 (dd, <i>J</i> = 11.2, 8.4 Hz, 2H), 6.73 (s, 1H), 5.87 (s, 1H), 4.61–4.60 (m, 1H), 4.43–4.42 (m, 1H), 4.02–4.01 (m, 1H). HRMS (C<sub>29</sub>H<sub>23</sub>Cl<sub>2</sub>FN<sub>5</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 594.0930, calcd 594.0928.</div></div><div id="sec3_6_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> <i>N</i>-(Amino(3-methoxyphenyl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>21</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (80 mg, 0.17 mmol) and 3-methoxybenzamidine hydrochloride (1.5 equiv) gave compound <b>21</b> (20 mg, 20%) as a white solid. Mp 135–137 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.91 (d, <i>J</i> = 7.9 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 4H), 7.33–7.29 (m, 4H), 7.18 (d, <i>J</i> = 8.4 Hz, 5H), 7.06 (s, 2H), 6.61 (s, 1H), 5.87 (s, 1H), 4.52 (s, 1H), 4.37 (s, 1H), 3.95 (s, 1H), 3.75 (s, 3H). HRMS (C<sub>30</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>3</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 606.1131, calcd 606.1128.</div></div><div id="sec3_6_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> <i>N</i>-((3-(4-Chlorophenyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazol-1-yl)(((4-chlorophenyl)sulfonyl)imino)methyl)picolinimidamide (<b>22</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (80 mg, 0.17 mmol) and picolinimidamide hydrochloride (1.5 equiv) gave compound <b>22</b> (22 mg, 22%) as a white solid. Mp 175–178 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.97 (s, 1H), 8.65 (d, <i>J</i> = 4.1 Hz, 2H), 8.34 (d, <i>J</i> = 7.8 Hz, 2H), 7.86 (d, <i>J</i> = 7.7 Hz, 3H), 7.51 (d, <i>J</i> = 5.7 Hz, 2H), 7.32 (t, <i>J</i> = 7.0 Hz, 3H), 7.16 (s, 4H), 4.73 (s, 1H), 4.64 (s, 1H), 4.20 (s, 1H). HRMS (C<sub>28</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 577.0980, calcd 577.0975.</div></div><div id="sec3_6_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> <i>N</i>-(1-Amino-2-phenoxyethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>23</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (100 mg, 0.21 mmol) and 2-phenoxyacetamidine hydrochloride (1.5 equiv) gave compound <b>23</b> (40 mg, 31%) as a white solid. Mp 134–136 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.88–7.87 (m, 2H), 7.51 (d, <i>J</i> = 8.1 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.34–7.31 (m, 2H), 7.31–7.28 (m, 2H), 7.21 (d, <i>J</i> = 8.6 Hz, 2H), 7.07 (d, <i>J</i> = 15.4 Hz, 2H), 7.04 (t, <i>J</i> = 7.3 Hz, 2H), 6.93 (d, <i>J</i> = 8.0 Hz, 2H), 4.74 (dd, <i>J</i> = 10.1, 1.0 Hz, 3H), 4.54 (t, <i>J</i> = 12.0 Hz, 1H), 4.10 (dd, <i>J</i> = 12.4, 5.2 Hz, 1H). HRMS (C<sub>30</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>3</sub>S) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 606.1135, calcd 606.1128.</div></div><div id="sec3_6_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> <i>N</i>-(Amino(thiophen-2-yl)methylene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>24</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (300 mg, 0.63 mmol) gave compound <b>7</b> (80 mg, 22%) as a white solid. Mp 230 °C dec. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.91 (d, <i>J</i> = 7.0 Hz, 2H), 7.59 (t, <i>J</i> = 1.0 Hz, 1H), 7.52 (d, <i>J</i> = 4.8 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (d, <i>J</i> = 8.1 Hz, 2H), 7.27 (s, 6H), 7.16 (s, 2H), 7.13–7.09 (m, 1H), 7.00–6.99 (m, 2H), 5.74–5.47 (m, 2H), 4.65 (dd, <i>J</i> = 11.2, 4.9 Hz, 1H), 4.53 (d, <i>J</i> = 0.7 Hz, 1H), 4.11–4.09 (m, 1H). HRMS (C<sub>27</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 582.0581, calcd 582.0592.</div></div><div id="sec3_6_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> <i>N</i>-(1-Amino-2-(ethylthio)ethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>25</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (100 mg, 0.21 mmol) and <i>S</i>-ethylisothiourea hydrobromide (1.5 equiv) gave compound <b>24</b> (25 mg, 21%) as a white solid. Mp 109–111 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90–7.88 (m, 2H), 7.48 (d, <i>J</i> = 8.5 Hz, 2H), 7.40 (d, <i>J</i> = 8.3 Hz, 2H), 7.30 (d, <i>J</i> = 7.4 Hz, 2H), 7.26 (d, <i>J</i> = 7.0 Hz, 1H), 7.21 (d, <i>J</i> = 8.5 Hz, 2H), 7.14 (t, <i>J</i> = 0.5 Hz, 2H), 4.70 (d, <i>J</i> = 10.3 Hz, 1H), 4.54 (t, <i>J</i> = 11.8 Hz, 1H), 4.09 (dd, <i>J</i> = 12.2, 5.1 Hz, 1H), 2.83 (s, 2H), 1.31 (t, <i>J</i> = 7.1 Hz, 4H). HRMS (C<sub>25</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 560.0745, calcd 560.0745.</div></div><div id="sec3_6_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> <i>N</i>-(1-Amino-2-(isopropylthio)ethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>26</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (50 mg, 0.11 mmol) and isopropyl carbamimidothioate hydrobromide<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (1.5 equiv) gave compound <b>25</b> (20 mg, 33%) as a white solid. Mp 149–151 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90–7.89 (m, 2H), 7.48 (d, <i>J</i> = 7.6 Hz, 2H), 7.41 (d, <i>J</i> = 7.6 Hz, 2H), 7.31 (d, <i>J</i> = 6.8 Hz, 2H), 7.21 (d, <i>J</i> = 7.7 Hz, 2H), 7.12 (s, 3H), 5.12 (bs, 1H), 4.70–4.68 (m, 1H), 4.52–4.50 (m, 1H), 4.13–4.09 (m, 1H), 3.23 (m, 1H), (1.37–1.33 (m, 6H). HRMS (C<sub>26</sub>H<sub>25</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 574.0903, calcd 574.0899.</div></div><div id="sec3_6_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> <i>N</i>-(1-Amino-2-(benzylthio)ethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>27</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (100 mg, 0.21 mmol) and benzyl carbamimidothioate hydrobromide<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (1.5 equiv) gave compound <b>26</b> (32 mg, 25%) as a white solid. Mp 148–150 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.88 (t, <i>J</i> = 1.1 Hz, 2H), 7.38 (d, <i>J</i> = 8.1 Hz, 4H), 7.31 (s, 5H), 7.17 (d, <i>J</i> = 8.4 Hz, 4H), 7.10 (s, 3H), 4.71 (s, 1H), 4.57–4.55 (m, 1H), 4.06–3.99 (m, 3H). HRMS (C<sub>30</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 622.0915, calcd 622.0917.</div></div><div id="sec3_6_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> <i>N</i>-(1-Amino-2-(phenethylthio)ethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>28</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (100 mg, 0.21 mmol) and phenethyl carbamimidothioate hydrobromide<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (1.5 equiv) gave compound <b>27</b> (27 mg, 20%) as a white solid. Mp 98–100 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.89 (d, <i>J</i> = 1.6 Hz, 2H), 7.47 (d, <i>J</i> = 7.8 Hz, 2H), 7.37 (d, <i>J</i> = 6.9 Hz, 2H), 7.30 (d, <i>J</i> = 6.8 Hz, 3H), 7.23–7.22 (m, 3H), 7.18 (d, <i>J</i> = 8.1 Hz, 3H), 7.11 (s, 3H), 4.70 (s, 1H), 4.54 (t, <i>J</i> = 11.6 Hz, 1H), 4.11–4.08 (m, 1H), 3.03 (s, 2H), 2.97 (s, 2H). HRMS (C<sub>31</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 636.1061, calcd 636.1056.</div></div><div id="sec3_6_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> <i>N</i>-((1-Amino-2-((3-phenylpropyl)thio)ethylidene)-3-(4-chlorophenyl)-<i>N</i>′-((4-chlorophenyl)sulfonyl)4-phenyl-4,5-dihydro-1<i>H</i>-pyrazole-1-carboximidamide (<b>29</b>)</h3><div class="NLM_p last">Following general procedure D, <b>3a</b> (80 mg, 0.17 mmol) and phenpropyl carbamimidothioate hydrobromide<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (1.5 equiv) gave compound <b>7</b> (15 mg, 14%) as a white solid. Mp 107–109 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.86 (s, 2H), 7.39 (d, <i>J</i> = 18.6 Hz, 3H), 7.29 (s, 3H), 7.20 (d, <i>J</i> = 6.6 Hz, 2H), 7.17 (d, <i>J</i> = 6.4 Hz, 2H), 7.10 (s, 6H), 4.71 (s, 1H), 4.56–4.51 (m, 1H), 4.06 (s, 1H), 2.72 (s, 1H), 2.64 (d, <i>J</i> = 5.9 Hz, 2H), 1.97 (s, 3H). HRMS (C<sub>31</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub>) [M + H]<sup>+</sup>: found <i>m</i>/<i>z</i> 650.1219, calcd 650.1212.</div></div><div id="sec3_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> In Vitro Assays. Materials for in Vitro Assays</h3><div class="NLM_p last">Rimonabant and CP-55,940 were obtained from the National Institute of Drug Abuse Drug Supply Program (Research Triangle Park, NC, USA). [<sup>3</sup>H]CP55,940 and [<sup>35</sup>S]GTPγS were from PerkinElmer (Waltham, MA). Arachidonoyl-2′-chloroethylamide (ACEA) was purchased from Cayman (Ann Arbor, MI). All other chemicals were from Sigma-Aldrich (St. Louis, MO).</div></div><div id="sec3_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> CB<sub>1</sub>R Binding Assay</h3><div class="NLM_p last">The assay was performed as described previously.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec3_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> GTPγS Binding Assay</h3><div class="NLM_p last">The assay was performed as described previously.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec3_7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> CB<sub>2</sub>R Binding Assay</h3><div class="NLM_p last">The binding affinities of compounds for CB<sub>2</sub>R were determined in radioligand displacement assays using 0.5 nM [<sup>3</sup>H]CP55940 as the agonist radioligand and 8 μg of plasma membrane preparations from CB<sub>2</sub>R expressing CHO-K1 cells (PerkinElmer,Waltham, MA). <i>K</i><sub>i</sub> values were derived by computerized curve fitting and using the Cheng–Prusoff equation to account for the affinity of the radioligand. Nonspecific binding was determined in the presence of 1 μM AM630.</div></div><div id="sec3_7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Fluorimetric iNOS Activity Assay</h3><div class="NLM_p last">The assay was performed as described previously.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec3_7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Picrosirius Red Staining and Histology Data Analysis</h3><div class="NLM_p last">The assay was performed as described previously.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec3_7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Hepatic Trigliceride (TG) Measurement</h3><div class="NLM_p last">Liver tissue was extracted as described earlier (Tam et al.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>) and its TG content measured by the EnzyChrom triglyceride assay kit (BioAssay Systems).</div></div><div id="sec3_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Animal Studies and in Vivo Assays. Animals</h3><div class="NLM_p last">Animal protocols were approved by the Institutional Animal Care and Use Committee of the NIAAA, NIH. Male 6- to 7-week-old C57BL/6J mice were obtained from The Jackson Laboratory. To generate diet-induced obesity (DIO), C57BL/6J mice were fed a high-fat diet (D12492, Research Diets, Inc., New Brunswick, NJ, 60% of calories as fat) for 14 weeks. Lean mice as controls were kept on a standard laboratory diet (STD, NIH-31 rodent diet) for the same duration. To induce liver fibrosis, 10- to 12-week-old mice were subjected either to bile-duct ligation (BDL) surgery or carbon tetrachloride (CCl<sub>4</sub>) treatment as indicated. <i>Cnr1</i><sup><i>–/–</i></sup> mice were generated as described on C57Bl/6J genetic background.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div></div><div id="sec3_8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Induction of Liver Fibrosis by CCl<sub>4</sub></h3><div class="NLM_p last">The model was performed as described previously.<a onclick="showRef(event, 'ref24 ref37'); return false;" href="javascript:void(0);" class="ref ref24 ref37">(24, 37)</a></div></div><div id="sec3_8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Induction of Liver Fibrosis by BDL</h3><div class="NLM_p last">The model was performed as described previously.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec3_8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Glucose Tolerance and Insulin Sensitivity Tests</h3><div class="NLM_p last">The assays were performed as described previously<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> following 2 weeks of daily oral doses of compound <b>7</b>, as described. ipGTT was performed after overnight fasting by intraperitoneal administration of glucose at 1.5 mg/kg and subsequent sampling of tail blood at 15 min intervals. ipIST was performed on the next day after a 6 h fast by treating mice with a bolus dose of insulin (0.75 U/kg). Blood glucose levels were measured from tail blood.</div></div><div id="sec3_8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Upper Gastrointestinal (GI) Motility Assay</h3><div class="NLM_p last">The assay was performed as described previously.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec3_8_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Elevated plus Maze Test (EPM)</h3><div class="NLM_p last">EPM was used to assess the anxiety-related behavior as described previously.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec3_8_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> Tissue Levels of Drugs</h3><div class="NLM_p last">Tissues and plasma were extracted as described<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and compound <b>7</b> levels were determined by LC–MS/MS using an Agilent 6410 triple quadrupole mass spectrometer (Agilent Technologies) coupled to an Agilent 1200 LC system (Agilent Technologies). Chromatographic and mass spectrometer conditions were set as described.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Levels of compound <b>7</b> were analyzed by multiple reactions monitoring (MRM). The molecular ion and fragments were measured as follows: <i>m</i>/<i>z</i> 514.1 → 110.9 and <i>m</i>/<i>z</i> 514.1 → 174.9 (CID energy of 60 and 28 V, respectively).</div></div><div id="sec3_8_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Statistics</h3><div class="NLM_p last">Values shown are expressed as the mean ± SEM. Statistical analysis was performed by unpaired two-tailed Student’s <i>t</i> test or by one-way ANOVA, as appropriate. <i>P</i> < 0.05 was considered significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01504">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01504" class="ext-link">10.1021/acs.jmedchem.6b01504</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">NMR spectra, HPLC chromatogram, crystallographic data, and effects of <b>7</b> on mutagenicity test and hERG potassium channels (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01504/suppl_file/jm6b01504_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01504/suppl_file/jm6b01504_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01504/suppl_file/jm6b01504_si_001.pdf">jm6b01504_si_001.pdf (746.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01504/suppl_file/jm6b01504_si_002.csv">jm6b01504_si_002.csv (3.87 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01504" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Malliga R. Iyer</span> - <span class="hlFld-Affiliation affiliation">†Laboratory
of Physiologic Studies, and ‡Laboratory of Cardiovascular Physiology
and Tissue Injury, National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0116-4619" title="Orcid link">http://orcid.org/0000-0002-0116-4619</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#276a464b4b4e4046096e5e425567494e4f09404851"><span class="__cf_email__" data-cfemail="216c404d4d4846400f68584453614f48490f464e57">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George Kunos</span> - <span class="hlFld-Affiliation affiliation">†Laboratory
of Physiologic Studies, and ‡Laboratory of Cardiovascular Physiology
and Tissue Injury, National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b3f4d6dcc1d4d69df8c6dddcc0f3dddadb9dd4dcc5"><span class="__cf_email__" data-cfemail="5b1c3e34293c3e75102e3534281b353233753c342d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Resat Cinar</span> - <span class="hlFld-Affiliation affiliation">†Laboratory
of Physiologic Studies, and ‡Laboratory of Cardiovascular Physiology
and Tissue Injury, National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexis Katz</span> - <span class="hlFld-Affiliation affiliation">†Laboratory
of Physiologic Studies, and ‡Laboratory of Cardiovascular Physiology
and Tissue Injury, National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Gao</span> - <span class="hlFld-Affiliation affiliation">†Laboratory
of Physiologic Studies, and ‡Laboratory of Cardiovascular Physiology
and Tissue Injury, National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katalin Erdelyi</span> - <span class="hlFld-Affiliation affiliation">†Laboratory
of Physiologic Studies, and ‡Laboratory of Cardiovascular Physiology
and Tissue Injury, National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tony Jourdan</span> - <span class="hlFld-Affiliation affiliation">†Laboratory
of Physiologic Studies, and ‡Laboratory of Cardiovascular Physiology
and Tissue Injury, National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathan J. Coffey</span> - <span class="hlFld-Affiliation affiliation">†Laboratory
of Physiologic Studies, and ‡Laboratory of Cardiovascular Physiology
and Tissue Injury, National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pal Pacher</span> - <span class="hlFld-Affiliation affiliation">†Laboratory
of Physiologic Studies, and ‡Laboratory of Cardiovascular Physiology
and Tissue Injury, National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, Maryland 20852, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.R.I. and R.C. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">M. R. Iyer, R. Cinar, and G. Kunos are listed as co-inventors on a U.S. patent application covering compounds in the present publication.</p></div></li></ul></div><div class="ack" id="ACK-d52e6246-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by intramural funds from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to M.R.I, R.C, P.P., and G.K. Resources from National Institute on Drug Abuse (NIDA) is gratefully acknowledged. Helpful advice and suggestions from Dr. Kenner C. Rice are acknowledged. John Lloyd, Noel Whittaker, and Bill Leister are acknowledged for supplying MS data and providing help with LC/MS data.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i101" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i101"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i102" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i102"> Abbreviations Used</h2><tr><td class="NLM_term">iNOS</td><td class="NLM_def"><p class="first last">inducible nitric oxide synthase</p></td></tr><tr><td class="NLM_term">EC</td><td class="NLM_def"><p class="first last">endocannabinoid</p></td></tr><tr><td class="NLM_term">CB<sub>1</sub>R</td><td class="NLM_def"><p class="first last">cannabinoid-1 receptor</p></td></tr><tr><td class="NLM_term">CB<sub>2</sub>R</td><td class="NLM_def"><p class="first last">cannabinoid-2 receptor</p></td></tr><tr><td class="NLM_term">BDL</td><td class="NLM_def"><p class="first last">bile duct ligation</p></td></tr><tr><td class="NLM_term">DIO</td><td class="NLM_def"><p class="first last">diet induced obesity</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">gastrointestinal</p></td></tr><tr><td class="NLM_term">HFD</td><td class="NLM_def"><p class="first last">high fat diet</p></td></tr><tr><td class="NLM_term">ACEA</td><td class="NLM_def"><p class="first last">arachidonoyl-2′-chloroethylamide</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65743" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65743" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Pacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bátkai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">The Endocannabinoid System as an Emerging Target of Pharmacotherapy</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span><span class="refDoi"> DOI: 10.1124/pr.58.3.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1124%2Fpr.58.3.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=16968947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=389-462&author=P.+Pacherauthor=S.+B%C3%A1tkaiauthor=G.+Kunos&title=The+Endocannabinoid+System+as+an+Emerging+Target+of+Pharmacotherapy&doi=10.1124%2Fpr.58.3.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as an emerging target of pharmacotherapy</span></div><div class="casAuthors">Pacher, Pal; Batkai, Sandor; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-462</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease.  Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metab. and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase.  In the past decade, the endocannabinoid system has been implicated in a growing no. of physiol. functions, both in the central and peripheral nervous systems and in peripheral organs.  More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathol. conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson's and Huntington's disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few.  An impediment to the development of cannabinoid medications has been the socially unacceptable psychoactive properties of plant-derived or synthetic agonists, mediated by CB1 receptors.  However, this problem does not arise when the therapeutic aim is achieved by treatment with a CB1 receptor antagonist, such as in obesity, and may also be absent when the action of endocannabinoids is enhanced indirectly through blocking their metab. or transport.  The use of selective CB2 receptor agonists, which lack psychoactive properties, could represent another promising avenue for certain conditions.  The abuse potential of plant-derived cannabinoids may also be limited through the use of prepns. with controlled compn. and the careful selection of does and route of administration.  The growing no. of preclin. studies and clin. trials with compds. that modulate the endocannabinoid system will probably result in novel therapeutic approaches in a no. of diseases for which current treatments do not fully address the patients' need.  Here, we provide a comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN_yobbKbuLbVg90H21EOLACvtfcHk0lhWFU2-eFaM4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfO&md5=f54e6d1303645a1c63809879ef2813f3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.2%26sid%3Dliteratum%253Aachs%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DB%25C3%25A1tkai%26aufirst%3DS.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DThe%2520Endocannabinoid%2520System%2520as%2520an%2520Emerging%2520Target%2520of%2520Pharmacotherapy%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D389%26epage%3D462%26doi%3D10.1124%2Fpr.58.3.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Howlett, A. C.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1124/pr.54.2.161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlett&title=International+Union+of+Pharmacology.+XXVII.+Classification+of+Cannabinoid+Receptors&doi=10.1124%2Fpr.54.2.161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0lhWFU2-eFaM4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXVII.%2520Classification%2520of%2520Cannabinoid%2520Receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202%26doi%3D10.1124%2Fpr.54.2.161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Rodríguez de Fonseca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Arco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bermudez-Silva, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilbao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cippitelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, M.</span><span> </span><span class="NLM_article-title">The Endocannabinoid System: Physiology and Pharmacology</span> <span class="citation_source-journal">Alcohol. Alcohol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1093/alcalc/agh110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1093%2Falcalc%2Fagh110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=15550444" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2004&pages=2-14&author=F.+Rodr%C3%ADguez+de+Fonsecaauthor=I.+Del+Arcoauthor=F.+J.+Bermudez-Silvaauthor=A.+Bilbaoauthor=A.+Cippitelliauthor=M.+Navarro&title=The+Endocannabinoid+System%3A+Physiology+and+Pharmacology&doi=10.1093%2Falcalc%2Fagh110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Falcalc%2Fagh110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Falcalc%252Fagh110%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez%2Bde%2BFonseca%26aufirst%3DF.%26aulast%3DDel%2BArco%26aufirst%3DI.%26aulast%3DBermudez-Silva%26aufirst%3DF.%2BJ.%26aulast%3DBilbao%26aufirst%3DA.%26aulast%3DCippitelli%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DM.%26atitle%3DThe%2520Endocannabinoid%2520System%253A%2520Physiology%2520and%2520Pharmacology%26jtitle%3DAlcohol.%2520Alcohol.%26date%3D2004%26volume%3D40%26spage%3D2%26epage%3D14%26doi%3D10.1093%2Falcalc%2Fagh110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Zimmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herkenham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, T. I.</span><span> </span><span class="NLM_article-title">Increased Mortality, Hypoactivity, and Hypoalgesia in Cannabinoid CB1 Receptor Knockout Mice</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">5780</span><span class="NLM_x">–</span> <span class="NLM_lpage">5785</span><span class="refDoi"> DOI: 10.1073/pnas.96.10.5780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1073%2Fpnas.96.10.5780" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=5780-5785&author=A.+Zimmerauthor=A.+M.+Zimmerauthor=A.+G.+Hohmannauthor=M.+Herkenhamauthor=T.+I.+Bonner&title=Increased+Mortality%2C+Hypoactivity%2C+and+Hypoalgesia+in+Cannabinoid+CB1+Receptor+Knockout+Mice&doi=10.1073%2Fpnas.96.10.5780"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.10.5780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.10.5780%26sid%3Dliteratum%253Aachs%26aulast%3DZimmer%26aufirst%3DA.%26aulast%3DZimmer%26aufirst%3DA.%2BM.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26atitle%3DIncreased%2520Mortality%252C%2520Hypoactivity%252C%2520and%2520Hypoalgesia%2520in%2520Cannabinoid%2520CB1%2520Receptor%2520Knockout%2520Mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D5780%26epage%3D5785%26doi%3D10.1073%2Fpnas.96.10.5780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Galiègue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussossoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrière, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carayon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouaboula, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span> </span><span class="NLM_article-title">Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1111/j.1432-1033.1995.tb20780.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1111%2Fj.1432-1033.1995.tb20780.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=7556170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADyaK2MXnvVKksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=1995&pages=54-61&author=S.+Gali%C3%A8gueauthor=S.+Maryauthor=J.+Marchandauthor=D.+Dussossoyauthor=D.+Carri%C3%A8reauthor=P.+Carayonauthor=M.+Bouaboulaauthor=D.+Shireauthor=G.+Le+Furauthor=P.+Casellas&title=Expression+of+Central+and+Peripheral+Cannabinoid+Receptors+in+Human+Immune+Tissues+and+Leukocyte+Subpopulations&doi=10.1111%2Fj.1432-1033.1995.tb20780.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations</span></div><div class="casAuthors">Galiegue, Sylvaine; Mary, Sophie; Marchand, Jean; Dussossoy, Danielle; Carriere, Dominique; Carayon, Pierre; Bouaboula, Monsif; Shire, David; Le Fur, Gerard; Casellas, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Two proteins with 7 transmembrane-spanning domains typical of guanosine-nucleotide-binding-protein-coupled receptors have been identified as cannabinoid receptors; the central cannabinoid receptor, CB1, and the peripheral cannabinoid receptor, CB2, initially described in rat brain and spleen, resp.  The distribution patterns for both CB1 and CB2 transcripts in human immune cells and in several human tissues are reported, as analyzed by a PCR-based method.  CB1 was mainly expressed in the central nervous system and, to a lower extent, in several peripheral tissues such as adrenal gland, heart, lung, prostate, uterus, ovary, testis, bone marrow, thymus and tonsils.  The CB2 gene, which is not expressed in the brain, was particularly abundant in immune tissues, with an expression level 10-100-fold higher than that of CB1.  Although CB2 mRNA was also detected in some other peripheral tissues, its level remained very low.  In spleen and tonsils, the CB2 mRNA content was equiv. to that of CB1 mRNA in the central nervous system.  Among the main human blood cell subpopulations, the distribution pattern of the CB2 mRNA displayed important variations.  The rank order of CB2 mRNA levels in these cells was B-cells > natural killer cells » monocytes > polymorphonuclear neutrophil cells > T8 cells > T4 cells.  The same rank order was also established in human cell lines belonging to the myeloid, monocytic and lymphoid lineages.  The prevailing expression of the CB2 gene in immune tissues was confirmed by Northern-blot anal.  The expression of the CB2 protein was demonstrated by an immunohistol. anal. performed on tonsil sections by specific anti-(human CB2) IgG; this expt. showed that CB2 expression was restricted to B-lymphocyte-enriched areas of the mantle of secondary lymphoid follicles.  Thus, CB1 and CB2 can be considered as tissue-selective antigens of the central nervous system and immune system, resp., and cannabinoids may exert specific receptor-mediated actions on the immune system through the CB2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwC6x6XdvbW7Vg90H21EOLACvtfcHk0lintWBvZTsFig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvVKksL8%253D&md5=ff4c2f420824fdbef66c94ea9d129288</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1995.tb20780.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1995.tb20780.x%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8gue%26aufirst%3DS.%26aulast%3DMary%26aufirst%3DS.%26aulast%3DMarchand%26aufirst%3DJ.%26aulast%3DDussossoy%26aufirst%3DD.%26aulast%3DCarri%25C3%25A8re%26aufirst%3DD.%26aulast%3DCarayon%26aufirst%3DP.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DLe%2BFur%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26atitle%3DExpression%2520of%2520Central%2520and%2520Peripheral%2520Cannabinoid%2520Receptors%2520in%2520Human%2520Immune%2520Tissues%2520and%2520Leukocyte%2520Subpopulations%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1995%26volume%3D232%26spage%3D54%26epage%3D61%26doi%3D10.1111%2Fj.1432-1033.1995.tb20780.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Klein, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, H.</span><span> </span><span class="NLM_article-title">Cannabinoids and the Immune System</span> <span class="citation_source-journal">Pain. Res. Manag.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1155/2001/326867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1155%2F2001%2F326867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=11854771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A280%3ADC%252BD387itVWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=95-101&author=T.+W.+Kleinauthor=C.+A.+Newtonauthor=H.+Friedman&title=Cannabinoids+and+the+Immune+System&doi=10.1155%2F2001%2F326867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids and the immune system</span></div><div class="casAuthors">Klein T W; Newton C A; Friedman H</div><div class="citationInfo"><span class="NLM_cas:title">Pain research & management</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-101</span>
        ISSN:<span class="NLM_cas:issn">1203-6765</span>.
    </div><div class="casAbstract">The effect of cannabimimetic agents on the function of immune cells such as T and B lymphocytes, natural killer cells and macrophages has been extensively studied over the past several decades using human and animal paradigms involving whole animal models as well as tissue culture systems.  From this work, it can be concluded that these drugs have subtle yet complex effects on immune cell function and that some of the drug activity is mediated by cannabinoid receptors expressed on the various immune cell subtypes.  However, the overall role of the cannabinoid system of receptors and ligands in human health and disease is still unclear and requires extensive elucidation.  Further studies will define the precise structure and function of the putative immunocannabinoid system, the potential therapeutic usefulness of these drugs in chronic diseases such as acquired immune deficiency syndrome and multiple sclerosis, the effects of these agents on tumour growth and induction of apoptosis, and the potential anti-inflammatory and proinflammatory properties of cannabimimetic compounds.  It is likely that the cannabinoid system, along with other neuroimmune systems, has a subtle but significant role in the regulation of immunity and that this role can eventually be exploited in the management of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEM49hz1c8YWLFM_lbR1VmfW6udTcc2eYgf8gUvpnLOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387itVWguw%253D%253D&md5=168076ffbf5e6c305b687252d51939c3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1155%2F2001%2F326867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2001%252F326867%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DT.%2BW.%26aulast%3DNewton%26aufirst%3DC.%2BA.%26aulast%3DFriedman%26aufirst%3DH.%26atitle%3DCannabinoids%2520and%2520the%2520Immune%2520System%26jtitle%3DPain.%2520Res.%2520Manag.%26date%3D2001%26volume%3D6%26spage%3D95%26epage%3D101%26doi%3D10.1155%2F2001%2F326867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Mackie, K.</span><span> </span><span class="NLM_article-title">Cannabinoid Receptors: Where They Are and What They Do</span> <span class="citation_source-journal">J. Neuroendocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1111/j.1365-2826.2008.01671.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1111%2Fj.1365-2826.2008.01671.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=18426493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsl2itbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=10-14&issue=Suppl.+1&author=K.+Mackie&title=Cannabinoid+Receptors%3A+Where+They+Are+and+What+They+Do&doi=10.1111%2Fj.1365-2826.2008.01671.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors: where they are and what they do</span></div><div class="casAuthors">Mackie, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">10-14</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system consists of the endogenous cannabinoids (endocannabinoids), cannabinoid receptors and the enzymes that synthesize and degrade endocannabinoids.  Many of the effects of cannabinoids and endocannabinoids are mediated by two G protein-coupled receptors (GPCRs), CB1 and CB2, although addnl. receptors may be involved.  CB1 receptors are present in very high levels in several brain regions and in lower amts. in a more wide-spread fashion.  These receptors mediate many of the psychoactive effects of cannabinoids.  CB2 receptors have a more restricted distribution, being found in a no. of immune cells and in a few neurons.  Both CB1 and CB2 couple primarily to inhibitory G proteins and are subject to the same pharmacol. influences as other GPCRs.  Thus, partial agonism, functional selectivity and inverse agonism all play important roles in detg. the cellular response to specific cannabinoid receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE3tJevcn32LVg90H21EOLACvtfcHk0lgtnvrcw_QbiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsl2itbs%253D&md5=e87a4821e2475ef50f57f26507c2dc7f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2008.01671.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2008.01671.x%26sid%3Dliteratum%253Aachs%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DCannabinoid%2520Receptors%253A%2520Where%2520They%2520Are%2520and%2520What%2520They%2520Do%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2008%26volume%3D20%26issue%3DSuppl.%25201%26spage%3D10%26epage%3D14%26doi%3D10.1111%2Fj.1365-2826.2008.01671.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hungund, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basavarajappa, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vadasz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez de Fonseca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span> </span><span class="NLM_article-title">Ethanol, Endocannabinoids, and the Cannabinoidergic Signaling System</span> <span class="citation_source-journal">Alcohol.: Clin. Exp. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">574</span><span class="refDoi"> DOI: 10.1111/j.1530-0277.2002.tb02575.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1111%2Fj.1530-0277.2002.tb02575.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=11981134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVSmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=565-574&author=B.+L.+Hungundauthor=B.+S.+Basavarajappaauthor=C.+Vadaszauthor=G.+Kunosauthor=F.+Rodriguez+de+Fonsecaauthor=G.+Colomboauthor=S.+Serraauthor=L.+Parsonsauthor=G.+F.+Koob&title=Ethanol%2C+Endocannabinoids%2C+and+the+Cannabinoidergic+Signaling+System&doi=10.1111%2Fj.1530-0277.2002.tb02575.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ethanol, endocannabinoids, and the cannabinoidergic signaling system</span></div><div class="casAuthors">Hungund, Basalingappa L.; Basavarajappa, Balapal S.; Vadasz, Csaba; Kunos, George; Rodriguez de Fonseca, Fernando; Colombo, Giancarlo; Serra, Salvatore; Parsons, Loren; Koob, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical and Experimental Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  This article represents the proceedings of a symposium at the 2001 annual meeting of the Research Society on Alcoholism in Montreal, Canada.  The chairpersons were Appa Hungund and George Koob.  The presentations were (1) role of endocannabinoids in ethanol tolerance, by Appa Hungund; (2) modulation of cannabinoid receptor and its signal transduction in chronic alcoholism, by B. S. Basavarajappa; (3) endocannabinoid involvement in the control of appetitive behavior, by George Kunos; (4) regulation of voluntary ethanol intake by cannabinoid receptor agonists and antagonists in alc.-preferring sP rats, by Giancarlo Colombo; (5) role of endogenous cannabinoid system in alcoholism, by Fernado Rodriguez de Fonseca; and (6) Endocannabinoids and dopamine interactions in vivo, by Loren Parsons and George Koob.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL6exDvhzxF7Vg90H21EOLACvtfcHk0lgtnvrcw_QbiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVSmsLY%253D&md5=a747925f1fbc11eac8b5158e46bfd5b4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2002.tb02575.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2002.tb02575.x%26sid%3Dliteratum%253Aachs%26aulast%3DHungund%26aufirst%3DB.%2BL.%26aulast%3DBasavarajappa%26aufirst%3DB.%2BS.%26aulast%3DVadasz%26aufirst%3DC.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DRodriguez%2Bde%2BFonseca%26aufirst%3DF.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%26aulast%3DParsons%26aufirst%3DL.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26atitle%3DEthanol%252C%2520Endocannabinoids%252C%2520and%2520the%2520Cannabinoidergic%2520Signaling%2520System%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2002%26volume%3D26%26spage%3D565%26epage%3D574%26doi%3D10.1111%2Fj.1530-0277.2002.tb02575.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Le Foll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, S. R.</span><span> </span><span class="NLM_article-title">Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">883</span><span class="refDoi"> DOI: 10.1124/jpet.104.077974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1124%2Fjpet.104.077974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=15525797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVOhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=875-883&author=B.+Le+Follauthor=S.+R.+Goldberg&title=Cannabinoid+CB1+Receptor+Antagonists+as+Promising+New+Medications+for+Drug+Dependence&doi=10.1124%2Fjpet.104.077974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence</span></div><div class="casAuthors">Le Foll, Bernard; Goldberg, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">875-883</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This review examines the development of cannabinoid CB1 receptor antagonists as a new class of therapeutic agents for drug addiction.  Abused drugs [alc., opiates, Δ9-tetrahydrocannabinol (Δ9-THC), and psychostimulants, including nicotine] elicit a variety of chronically relapsing disorders by interacting with endogenous neural pathways in the brain.  In particular, they share the common property of activating mesolimbic dopamine brain reward systems, and virtually all abused drugs elevate dopamine levels in the nucleus accumbens.  Cannabinoid CB1 receptors are expressed in this brain reward circuit and modulate the dopamine-releasing effects of Δ9-THC and nicotine.  Rimonabant (SR141716), a CB1 receptor antagonist, blocks both the dopamine-releasing and discriminative and rewarding effects of Δ9-THC in animals.  Blockade of CB1 receptor activity by genetic invalidation also decreases rewarding effects of opiates and alc. in animals.  Although CB1 receptor blockade is generally ineffective in reducing the self-administration of cocaine in rodents and primates, it reduces the reinstatement of extinguished cocaine-seeking behavior produced by cocaine-assocd. conditioned stimuli and cocaine-priming injections.  Likewise, CB1 receptor blockade is effective in reducing nicotine-seeking behavior induced by re-exposure to nicotine-assocd. stimuli.  Some of these findings have been recently validated in humans.  In clin. trials, Rimonabant blocks the subjective effects of Δ9-THC in humans and prevents relapse to smoking in ex-smokers.  Findings from both clin. and preclin. studies suggest that ligands blocking CB1 receptors offer a novel approach for patients suffering from drug dependence that may be efficacious across different classes of abused drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBmGfksQ6N0LVg90H21EOLACvtfcHk0lgtnvrcw_QbiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVOhtbo%253D&md5=c147d69b248ce0da7078ac98f327e79b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.077974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.077974%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26atitle%3DCannabinoid%2520CB1%2520Receptor%2520Antagonists%2520as%2520Promising%2520New%2520Medications%2520for%2520Drug%2520Dependence%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D875%26epage%3D883%26doi%3D10.1124%2Fjpet.104.077974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">Cannabinoids and the Gastrointestinal Tract</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span><span class="refDoi"> DOI: 10.1136/gut.48.6.859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1136%2Fgut.48.6.859" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2001&pages=859-867&author=R.+G.+Pertwee&title=Cannabinoids+and+the+Gastrointestinal+Tract&doi=10.1136%2Fgut.48.6.859"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1136%2Fgut.48.6.859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.48.6.859%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DCannabinoids%2520and%2520the%2520Gastrointestinal%2520Tract%26jtitle%3DGut%26date%3D2001%26volume%3D48%26spage%3D859%26epage%3D867%26doi%3D10.1136%2Fgut.48.6.859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1553</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span><span class="refDoi"> DOI: 10.1517/13543784.9.7.1553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1517%2F13543784.9.7.1553" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=1553-1571&author=R.+G.+Pertwee&title=Cannabinoid+Receptor+Ligands%3A+Clinical+and+Neuropharmacological+Considerations%2C+Relevant+to+Future+Drug+Discovery+and+Development&doi=10.1517%2F13543784.9.7.1553"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F13543784.9.7.1553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.9.7.1553%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DCannabinoid%2520Receptor%2520Ligands%253A%2520Clinical%2520and%2520Neuropharmacological%2520Considerations%252C%2520Relevant%2520to%2520Future%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2000%26volume%3D9%26spage%3D1553%26epage%3D1571%26doi%3D10.1517%2F13543784.9.7.1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Black, S. C.</span><span> </span><span class="NLM_article-title">Cannabinoid Receptor Antagonists and Obesity</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=389-394&author=S.+C.+Black&title=Cannabinoid+Receptor+Antagonists+and+Obesity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DS.%2BC.%26atitle%3DCannabinoid%2520Receptor%2520Antagonists%2520and%2520Obesity%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs.%26date%3D2004%26volume%3D5%26spage%3D389%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Giannone, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldassarre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domenicali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaccherini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevisani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caraceni, P.</span><span> </span><span class="NLM_article-title">Reversal of Liver Fibrosis by the Antagonism of Endocannabinoid CB1 Receptor in a Rat Model of CCl(4)-Induced Advanced Cirrhosis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">384</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span><span class="refDoi"> DOI: 10.1038/labinvest.2011.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Flabinvest.2011.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=22184091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=384-395&author=F.+A.+Giannoneauthor=M.+Baldassarreauthor=M.+Domenicaliauthor=G.+Zaccheriniauthor=F.+Trevisaniauthor=M.+Bernardiauthor=P.+Caraceni&title=Reversal+of+Liver+Fibrosis+by+the+Antagonism+of+Endocannabinoid+CB1+Receptor+in+a+Rat+Model+of+CCl%284%29-Induced+Advanced+Cirrhosis&doi=10.1038%2Flabinvest.2011.191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis</span></div><div class="casAuthors">Giannone, Ferdinando A.; Baldassarre, Maurizio; Domenicali, Marco; Zaccherini, Giacomo; Trevisani, Franco; Bernardi, Mauro; Caraceni, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-395</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The endocannabinoid system is involved in the pathogenesis of liver fibrosis.  Although many substances have been proved to reduce fibrosis in exptl. models of chronic liver injury, most of them appear to be effective only if given as a prophylactic or early treatment.  This study aimed to explore the effect of pharmacol. antagonism of the endocannabinoid cannabinoid type 1 (CB1) receptor started after the stage of full-blown cirrhosis had been reached.  Wistar-Han rats with carbon tetrachloride (CCl4)-induced cirrhosis were randomized to receive the CB1 receptor antagonist Rimonabant (10 mg/kg/day) or the vehicle for 2 wk.  Age-matched healthy rats served as controls.  Liver fibrosis was assessed using Sirius red staining, hydroxyproline concn. and α-smooth muscle actin expression.  Hepatic gene expression of mediators of fibrogenesis and inflammation were evaluated by real-time PCR.  We also assessed the hepatic expression of CB1 and CB2 receptors and that of the enzymes implicated in the endocannabinoid metab.  Fibrosis was significantly reduced in rats treated with Rimonabant compared with rats receiving the vehicle.  CB1 receptor antagonism limited the gene upregulation of fibrogenic and inflammatory mediators occurring in untreated cirrhotic rats.  CB1 and CB2 receptor expression was increased in cirrhotic animals.  Interestingly, pharmacol. CB1 receptor antagonism was assocd. with a further induction of the CB2 receptor expression.  Regression of fibrosis can be achieved by pharmacol. blockade of the CB1 receptor even when started in an advanced stage of the disease.  This effect is assocd. with the suppression of pro-fibrogenic and inflammatory mediators and may have been indirectly favored by the induction of CB2 receptor expression.  Lab. Investigation (2012) 92, 384-395; doi:10.1038/labinvest.2011.191; published online 19 Dec. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPmVZMX8omDbVg90H21EOLACvtfcHk0lj8NS8b2o6ajA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOjtbg%253D&md5=3e4d30f78fe6daa045b628e0c24b0d0e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2011.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2011.191%26sid%3Dliteratum%253Aachs%26aulast%3DGiannone%26aufirst%3DF.%2BA.%26aulast%3DBaldassarre%26aufirst%3DM.%26aulast%3DDomenicali%26aufirst%3DM.%26aulast%3DZaccherini%26aufirst%3DG.%26aulast%3DTrevisani%26aufirst%3DF.%26aulast%3DBernardi%26aufirst%3DM.%26aulast%3DCaraceni%26aufirst%3DP.%26atitle%3DReversal%2520of%2520Liver%2520Fibrosis%2520by%2520the%2520Antagonism%2520of%2520Endocannabinoid%2520CB1%2520Receptor%2520in%2520a%2520Rat%2520Model%2520of%2520CCl%25284%2529-Induced%2520Advanced%2520Cirrhosis%26jtitle%3DLab.%2520Invest.%26date%3D2012%26volume%3D92%26spage%3D384%26epage%3D395%26doi%3D10.1038%2Flabinvest.2011.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Teixeira-Clerc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julien, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran Van Nhieu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deveaux, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serriere-Lanneau, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotersztajn, S.</span><span> </span><span class="NLM_article-title">CB1 Cannabinoid Receptor Antagonism: A New Strategy for the Treatment of Liver Fibrosis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span><span class="refDoi"> DOI: 10.1038/nm1421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Fnm1421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=16715087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlOjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=671-676&author=F.+Teixeira-Clercauthor=B.+Julienauthor=P.+Grenardauthor=J.+Tran+Van+Nhieuauthor=V.+Deveauxauthor=L.+Liauthor=V.+Serriere-Lanneauauthor=C.+Ledentauthor=A.+Mallatauthor=S.+Lotersztajn&title=CB1+Cannabinoid+Receptor+Antagonism%3A+A+New+Strategy+for+the+Treatment+of+Liver+Fibrosis&doi=10.1038%2Fnm1421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis</span></div><div class="casAuthors">Teixeira-Clerc, Fatima; Julien, Boris; Grenard, Pascale; Van Nhieu, Jeanne Tran; Deveaux, Vanessa; Li, Liying; Serriere-Lanneau, Valerie; Ledent, Catherine; Mallat, Ariane; Lotersztajn, Sophie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-676</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatic fibrosis, the common response assocd. with chronic liver diseases, ultimately leads to cirrhosis, a major public health problem worldwide.  We recently showed that activation of hepatic cannabinoid CB2 receptors limits progression of exptl. liver fibrosis.  We also found that during the course of chronic hepatitis C, daily cannabis use is an independent predictor of fibrosis progression.  Overall, these results suggest that endocannabinoids may drive both CB2-mediated antifibrogenic effects and CB2-independent profibrogenic effects.  Here we investigated whether activation of cannabinoid CB1 receptors (encoded by Cnr1) promotes progression of fibrosis.  CB1 receptors were highly induced in human cirrhotic samples and in liver fibrogenic cells.  Treatment with the CB1 receptor antagonist SR141716A decreased the wound-healing response to acute liver injury and inhibited progression of fibrosis in three models of chronic liver injury.  We saw similar changes in Cnr1-/- mice as compared to wild-type mice.  Genetic or pharmacol. inactivation of CB1 receptors decreased fibrogenesis by lowering hepatic transforming growth factor (TGF)-β1 and reducing accumulation of fibrogenic cells in the liver after apoptosis and growth inhibition of hepatic myofibroblasts.  In conclusion, our study shows that CB1 receptor antagonists hold promise for the treatment of liver fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaGl6D8ATtLLVg90H21EOLACvtfcHk0lj8NS8b2o6ajA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlOjtrw%253D&md5=c1e3eb1af474600c3d0d0a4fd9ae2013</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnm1421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1421%26sid%3Dliteratum%253Aachs%26aulast%3DTeixeira-Clerc%26aufirst%3DF.%26aulast%3DJulien%26aufirst%3DB.%26aulast%3DGrenard%26aufirst%3DP.%26aulast%3DTran%2BVan%2BNhieu%26aufirst%3DJ.%26aulast%3DDeveaux%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSerriere-Lanneau%26aufirst%3DV.%26aulast%3DLedent%26aufirst%3DC.%26aulast%3DMallat%26aufirst%3DA.%26aulast%3DLotersztajn%26aufirst%3DS.%26atitle%3DCB1%2520Cannabinoid%2520Receptor%2520Antagonism%253A%2520A%2520New%2520Strategy%2520for%2520the%2520Treatment%2520of%2520Liver%2520Fibrosis%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D671%26epage%3D676%26doi%3D10.1038%2Fnm1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Nanthakumar, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauldie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J.</span><span> </span><span class="NLM_article-title">Dissecting Fibrosis: Therapeutic Insights from the Small-Molecule Toolbox</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span><span class="refDoi"> DOI: 10.1038/nrd4592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Fnrd4592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=26338155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=693-720&author=C.+B.+Nanthakumarauthor=R.+J.+Hatleyauthor=S.+Lemmaauthor=J.+Gauldieauthor=R.+P.+Marshallauthor=S.+J.+Macdonald&title=Dissecting+Fibrosis%3A+Therapeutic+Insights+from+the+Small-Molecule+Toolbox&doi=10.1038%2Fnrd4592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span></div><div class="casAuthors">Nanthakumar, Carmel B.; Hatley, Richard J. D.; Lemma, Seble; Gauldie, Jack; Marshall, Richard P.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-720</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis, which leads to progressive loss of tissue function and eventual organ failure, has been estd. to contribute to ∼45% of deaths in the developed world, and so new therapeutics to modulate fibrosis are urgently needed.  Major advances in our understanding of the mechanisms underlying pathol. fibrosis are supporting the search for such therapeutics, and the recent approval of two anti-fibrotic drugs for idiopathic pulmonary fibrosis has demonstrated the tractability of this area for drug discovery.  This Review examines the pharmacol. and structural information for small mols. being evaluated for lung, liver, kidney and skin fibrosis.  In particular, we discuss the insights gained from the use of these pharmacol. tools, and how these entities can inform, and probe, emerging insights into disease mechanisms, including the potential for future drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk6pfSk3gsCrVg90H21EOLACvtfcHk0lj8NS8b2o6ajA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ&md5=b05a37db6ede2acc0f5c65826aa344f3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrd4592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4592%26sid%3Dliteratum%253Aachs%26aulast%3DNanthakumar%26aufirst%3DC.%2BB.%26aulast%3DHatley%26aufirst%3DR.%2BJ.%26aulast%3DLemma%26aufirst%3DS.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26atitle%3DDissecting%2520Fibrosis%253A%2520Therapeutic%2520Insights%2520from%2520the%2520Small-Molecule%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D693%26epage%3D720%26doi%3D10.1038%2Fnrd4592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Janero, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span> </span><span class="NLM_article-title">Cannabinoid Receptor Antagonists: Pharmacological Opportunities, Clinical Experience, and Translational Prognosis</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.1517/14728210902736568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1517%2F14728210902736568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=19249987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivFSmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=43-65&author=D.+R.+Janeroauthor=A.+Makriyannis&title=Cannabinoid+Receptor+Antagonists%3A+Pharmacological+Opportunities%2C+Clinical+Experience%2C+and+Translational+Prognosis&doi=10.1517%2F14728210902736568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis</span></div><div class="casAuthors">Janero, David R.; Makriyannis, Alexandros</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-65</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The endogenous cannabinoid (CB) (endocannabinoid) signaling system is involved in a variety of (patho)physiol. processes, primarily by virtue of natural, arachidonic acid-derived lipids (endocannabinoids) that activate G protein-coupled CB1 and CB2 receptors.  A hyperactive endocannabinoid system appears to contribute to the etiol. of several disease states that constitute significant global threats to human health.  Consequently, mounting interest surrounds the design and profiling of receptor-targeted CB antagonists as pharmacotherapeutics that attenuate endocannabinoid transmission for salutary gain.  Exptl. and clin. evidence supports the therapeutic potential of CB1 receptor antagonists to treat overweight/obesity, obesity-related cardiometabolic disorders, and substance abuse.  Lab. data suggest that CB2 receptor antagonists might be effective immunomodulatory and, perhaps, anti-inflammatory drugs.  One CB1 receptor antagonist/inverse agonist, rimon-abant, has emerged as the first-in-class drug approved outside the United States for wt. control.  Select follow-on agents (taranabant, otenabant, surinabant, rosonabant, SLV-319, AVE1625, V24343) have also been studied in the clinic.  However, rimonabant's market withdrawal in the European Union and suspension of rimonabant's, taranabant's, and otenabant's ongoing development programs have highlighted some adverse clin. side effects (esp. nausea and psychiatric disturbances) of CB1 receptor antagonists/inverse agonists.  Novel CB1 receptor ligands that are peripherally directed and/or exhibit neutral antagonism (the latter not affecting constitutive CB1 receptor signaling) may optimize the benefits of CB1 receptor antagonists while minimizing any risk.  Indeed, CB1 receptor-neutral antagonists appear from preclin. data to offer efficacy comparable to or better than that of prototype CB1 receptor antagonists/inverse agonists, with less propensity to induce nausea.  Continued pharmacol. profiling, as the prelude to first-in-man testing of CB1 receptor antagonists with unique modes of targeting/pharmacol. action, represents an exciting translational frontier in the crit. path to CB receptor blockers as medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCAfak12FUrVg90H21EOLACvtfcHk0lie1jmSD67NCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivFSmtbc%253D&md5=7d862d2ded309124a4d753e568b275fa</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F14728210902736568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728210902736568%26sid%3Dliteratum%253Aachs%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DMakriyannis%26aufirst%3DA.%26atitle%3DCannabinoid%2520Receptor%2520Antagonists%253A%2520Pharmacological%2520Opportunities%252C%2520Clinical%2520Experience%252C%2520and%2520Translational%2520Prognosis%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2009%26volume%3D14%26spage%3D43%26epage%3D65%26doi%3D10.1517%2F14728210902736568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Patel, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, R.</span><span> </span><span class="NLM_article-title">Rimonabant: A Novel Selective Cannabinoid-1 Receptor Antagonist for Treatment of Obesity</span> <span class="citation_source-journal">Am. J. Health-Syst. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span><span class="refDoi"> DOI: 10.2146/060258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.2146%2F060258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=17322160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsF2nsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=481-489&author=P.+N.+Patelauthor=R.+Pathak&title=Rimonabant%3A+A+Novel+Selective+Cannabinoid-1+Receptor+Antagonist+for+Treatment+of+Obesity&doi=10.2146%2F060258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity</span></div><div class="casAuthors">Patel, Priti N.; Pathak, Rolee</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-489</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">A review.  Purpose: The pharmacol., pharmacokinetics, clin. efficacy, safety, drug interactions, and dosage and administration of rimonabant in the treatment of obesity and related metabolic factors are reviewed.  Summary: Discovery of the cannabinoid receptors has led to the development of rimonabant, a cannabinoid-1 (CB1) antagonist.  Selective blockade of this receptor has been shown to lead to decreased appetite and food intake in animal models.  Clin. studies have shown that rimonabant 20 mg once daily produces significant decreases in wt. and waist circumference in obese human subjects and improves the lipid profile and glucose control.  The frequency of metabolic syndrome also decreased significantly with rimonabant 20 mg daily.  Limited data are available regarding the pharmacokinetics and pharmacodynamics of rimonabant.  Preclin. data have demonstrated a long duration of action.  As of yet, no drug-drug, drug-food, or drug-disease interactions have been identified with rimonabant.  Adverse reactions occurred rarely, with nausea, dizziness, diarrhea, arthralgia, and back pain being the most common.  Psychiatric disorders, including depression and anxiety, were the most common reasons for subjects to withdraw from rimonabant studies.  Rimonabant has been shown to be safe for up to two years of treatment.  Further research will clarify currently unknown areas, including pharmacokinetics, drug interactions, and the drug's role in std. therapy.  Conclusion: Rimonabant, a selective CB1 antagonist, is a novel treatment option for obese and overweight individuals.  Significant wt. loss, decrease in waist circumference, and improvements in lipid profile and glucose control have been shown in clin. trials of rimonabant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgzvUSUcPsmLVg90H21EOLACvtfcHk0lie1jmSD67NCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsF2nsbw%253D&md5=43fd1adda4b9d606cb761fe965b08b8d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2146%2F060258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252F060258%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BN.%26aulast%3DPathak%26aufirst%3DR.%26atitle%3DRimonabant%253A%2520A%2520Novel%2520Selective%2520Cannabinoid-1%2520Receptor%2520Antagonist%2520for%2520Treatment%2520of%2520Obesity%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2007%26volume%3D64%26spage%3D481%26epage%3D489%26doi%3D10.2146%2F060258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ward, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffa, R. B.</span><span> </span><span class="NLM_article-title">Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral-Antagonist/inverse-Agonist Therapies</span> <span class="citation_source-journal">Obesity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1325</span><span class="NLM_x">–</span> <span class="NLM_lpage">1334</span><span class="refDoi"> DOI: 10.1038/oby.2011.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Foby.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=21475141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnjt1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1325-1334&author=S.+J.+Wardauthor=R.+B.+Raffa&title=Rimonabant+Redux+and+Strategies+to+Improve+the+Future+Outlook+of+CB1+Receptor+Neutral-Antagonist%2Finverse-Agonist+Therapies&doi=10.1038%2Foby.2011.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies</span></div><div class="casAuthors">Ward Sara Jane; Raffa Robert B</div><div class="citationInfo"><span class="NLM_cas:title">Obesity (Silver Spring, Md.)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1325-34</span>
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTq32LoUyLn5Ptos8R3JUhXfW6udTcc2eYd3fhwW6MXFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnjt1OisQ%253D%253D&md5=17cafba99c5cc057e96c9bc3437f944a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Foby.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DS.%2BJ.%26aulast%3DRaffa%26aufirst%3DR.%2BB.%26atitle%3DRimonabant%2520Redux%2520and%2520Strategies%2520to%2520Improve%2520the%2520Future%2520Outlook%2520of%2520CB1%2520Receptor%2520Neutral-Antagonist%252Finverse-Agonist%2520Therapies%26jtitle%3DObesity%26date%3D2011%26volume%3D19%26spage%3D1325%26epage%3D1334%26doi%3D10.1038%2Foby.2011.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Chorvat, R. J.</span><span> </span><span class="NLM_article-title">Peripherally Restricted CB1 Receptor Blockers</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4751</span><span class="NLM_x">–</span> <span class="NLM_lpage">4760</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2Fj.bmcl.2013.06.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=23902803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Sjtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4751-4760&author=R.+J.+Chorvat&title=Peripherally+Restricted+CB1+Receptor+Blockers&doi=10.1016%2Fj.bmcl.2013.06.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Peripherally restricted CB1 receptor blockers</span></div><div class="casAuthors">Chorvat, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4751-4760</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antagonists (inverse agonists) of the cannabinoid-1 (CB1) receptor showed promise as new therapies for controlling obesity and related metabolic function/liver disease.  These agents, representing diverse chem. series, shared the property of brain penetration due to the initial belief that therapeutic benefit was mainly based on brain receptor interaction.  However, undesirable CNS-based side effects of the only marketed agent in this class, rimonabant, led to its removal, and termination of the development of other clin. candidates soon followed.  Re-evaluation of this approach has focused on neutral or peripherally restricted (PR) antagonists.  Supporting these strategies, pharmacol. evidence indicates most if not all of the properties of globally acting agents may be captured by mols. with little brain presence.  Methodol. that can be used to eliminate BBB penetration and the means (in vitro assays, tissue distribution and receptor occupancy detns., behavioral paradigms) to identify potential agents with little brain presence is discussed.  Focus will be on the pharmacol. supporting the contention that reported agents are truly peripherally restricted.  Notable examples of these types of compds. are: TM38837 (structure not disclosed); AM6545 (8); JD5037 (15b); RTI-12 (19).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVjNs61m-GtLVg90H21EOLACvtfcHk0lj-_u8WIU4HTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Sjtb3O&md5=b124aabace6d82a2fd23fa75681786d4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.066%26sid%3Dliteratum%253Aachs%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26atitle%3DPeripherally%2520Restricted%2520CB1%2520Receptor%2520Blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4751%26epage%3D4760%26doi%3D10.1016%2Fj.bmcl.2013.06.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Fulp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortoff, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marusich, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seltzman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitra, R.</span><span> </span><span class="NLM_article-title">Peripherally Selective Diphenyl Purine Antagonist of the CB1 Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8066</span><span class="NLM_x">–</span> <span class="NLM_lpage">8072</span><span class="refDoi"> DOI: 10.1021/jm401129n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401129n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8066-8072&author=A.+Fulpauthor=K.+Bortoffauthor=Y.+Zhangauthor=R.+Snyderauthor=T.+Fennellauthor=J.+A.+Marusichauthor=J.+L.+Wileyauthor=H.+Seltzmanauthor=R.+Maitra&title=Peripherally+Selective+Diphenyl+Purine+Antagonist+of+the+CB1+Receptor&doi=10.1021%2Fjm401129n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm401129n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401129n%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMarusich%26aufirst%3DJ.%2BA.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DPeripherally%2520Selective%2520Diphenyl%2520Purine%2520Antagonist%2520of%2520the%2520CB1%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8066%26epage%3D8072%26doi%3D10.1021%2Fjm401129n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zhu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macielag, M. J.</span><span> </span><span class="NLM_article-title">Tetrahydropyrazolo[4,3-c]pyridine Derivatives as Potent and Peripherally Selective Cannabinoid-1 (CB1) Receptor Inverse Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5597</span><span class="NLM_x">–</span> <span class="NLM_lpage">5601</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2Fj.bmcl.2016.09.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5597-5601&author=B.+Zhuauthor=J.+M.+Matthewsauthor=M.+Xiaauthor=S.+Blackauthor=C.+Chenauthor=C.+Houauthor=Y.+Liangauthor=Y.+Tangauthor=M.+J.+Macielag&title=Tetrahydropyrazolo%5B4%2C3-c%5Dpyridine+Derivatives+as+Potent+and+Peripherally+Selective+Cannabinoid-1+%28CB1%29+Receptor+Inverse+Agonists&doi=10.1016%2Fj.bmcl.2016.09.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DB.%26aulast%3DMatthews%26aufirst%3DJ.%2BM.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DMacielag%26aufirst%3DM.%2BJ.%26atitle%3DTetrahydropyrazolo%255B4%252C3-c%255Dpyridine%2520Derivatives%2520as%2520Potent%2520and%2520Peripherally%2520Selective%2520Cannabinoid-1%2520%2528CB1%2529%2520Receptor%2520Inverse%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5597%26epage%3D5601%26doi%3D10.1016%2Fj.bmcl.2016.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Tam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szanda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chedester, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liow, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innis, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschamps, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorvat, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance</span> <span class="citation_source-journal">Cell Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.1016/j.cmet.2012.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2Fj.cmet.2012.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=22841573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=167-179&author=J.+Tamauthor=R.+Cinarauthor=J.+Liuauthor=G.+Godlewskiauthor=D.+Wesleyauthor=T.+Jourdanauthor=G.+Szandaauthor=B.+Mukhopadhyayauthor=L.+Chedesterauthor=J.+S.+Liowauthor=R.+B.+Innisauthor=K.+Chengauthor=K.+C.+Riceauthor=J.+R.+Deschampsauthor=R.+J.+Chorvatauthor=J.+F.+McElroyauthor=G.+Kunos&title=Peripheral+Cannabinoid-1+Receptor+Inverse+Agonism+Reduces+Obesity+by+Reversing+Leptin+Resistance&doi=10.1016%2Fj.cmet.2012.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance</span></div><div class="casAuthors">Tam, Joseph; Cinar, Resat; Liu, Jie; Godlewski, Grzegorz; Wesley, Daniel; Jourdan, Tony; Szanda, Gergo; Mukhopadhyay, Bani; Chedester, Lee; Liow, Jeih-San; Innis, Robert B.; Cheng, Kejun; Rice, Kenner C.; Deschamps, Jeffrey R.; Chorvat, Robert J.; McElroy, John F.; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-179</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Obesity-related leptin resistance manifests in loss of leptin's ability to reduce appetite and increase energy expenditure.  Obesity is also assocd. with increased activity of the endocannabinoid system, and CB1 receptor (CB1R) inverse agonists reduce body wt. and the assocd. metabolic complications, although adverse neuropsychiatric effects halted their therapeutic development.  In mice with diet-induced obesity (DIO), the peripherally restricted CB1R inverse agonist JD5037 is equieffective with its brain-penetrant parent compd. in reducing appetite, body wt., hepatic steatosis, and insulin resistance, even though it does not occupy central CB1R or induce related behaviors.  Appetite and wt. redn. by JD5037 are mediated by resensitizing DIO mice to endogenous leptin through reversing the hyperleptinemia by decreasing leptin expression and secretion by adipocytes and increasing leptin clearance via the kidney.  Thus, inverse agonism at peripheral CB1R not only improves cardiometabolic risk in obesity but has antiobesity effects by reversing leptin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXZCRIXdM8qLVg90H21EOLACvtfcHk0lj-_u8WIU4HTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahsL%252FO&md5=412b24018a9a1620ebf533f5195b1659</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2012.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2012.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DWesley%26aufirst%3DD.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DChedester%26aufirst%3DL.%26aulast%3DLiow%26aufirst%3DJ.%2BS.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520Cannabinoid-1%2520Receptor%2520Inverse%2520Agonism%2520Reduces%2520Obesity%2520by%2520Reversing%2520Leptin%2520Resistance%26jtitle%3DCell%2520Metab.%26date%3D2012%26volume%3D16%26spage%3D167%26epage%3D179%26doi%3D10.1016%2Fj.cmet.2012.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Tam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vemuri, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bátkai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osei-Hyiaman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohnuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambudkar, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Peripheral CB1 Cannabinoid Receptor Blockade Improves Cardiometabolic Risk in Mouse Models of Obesity</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2953</span><span class="NLM_x">–</span> <span class="NLM_lpage">2966</span><span class="refDoi"> DOI: 10.1172/JCI42551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1172%2FJCI42551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=20664173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaiurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=2953-2966&author=J.+Tamauthor=V.+K.+Vemuriauthor=J.+Liuauthor=S.+B%C3%A1tkaiauthor=B.+Mukhopadhyayauthor=G.+Godlewskiauthor=D.+Osei-Hyiamanauthor=S.+Ohnumaauthor=S.+V.+Ambudkarauthor=J.+Pickelauthor=A.+Makriyannisauthor=G.+Kunos&title=Peripheral+CB1+Cannabinoid+Receptor+Blockade+Improves+Cardiometabolic+Risk+in+Mouse+Models+of+Obesity&doi=10.1172%2FJCI42551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity</span></div><div class="casAuthors">Tam, Joseph; Vemuri, V. Kiran; Liu, Jie; Batkai, Sandor; Mukhopadhyay, Bani; Godlewski, Grzegorz; Osei-Hyiaman, Douglas; Ohnuma, Shinobu; Ambudkar, Suresh V.; Pickel, James; Makriyannis, Alexandros; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2953-2966</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Obesity and its metabolic consequences are a major public health concern worldwide.  Obesity is assocd. with overactivity of the endocannabinoid system, which is involved in the regulation of appetite, lipogenesis, and insulin resistance.  Cannabinoid-1 receptor (CB1R) antagonists reduce body wt. and improve cardiometabolic abnormalities in exptl. and human obesity, but their therapeutic potential is limited by neuropsychiatric side effects.  Here we have demonstrated that a CB1R neutral antagonist largely restricted to the periphery does not affect behavioral responses mediated by CB1R in the brains of mice with genetic or diet-induced obesity, but it does cause wt.-independent improvements in glucose homeostasis, fatty liver, and plasma lipid profile.  These effects were due to blockade of CB1R in peripheral tissues, including the liver, as verified through the use of CB1R-deficient mice with or without transgenic expression of CB1R in the liver.  These results suggest that targeting peripheral CB1R has therapeutic potential for alleviating cardiometabolic risk in obese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0VCuCx5tmorVg90H21EOLACvtfcHk0lh-QhsjKStM9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaiurzM&md5=ba383f0abb4642df9843f6ee5784ecb4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1172%2FJCI42551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI42551%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DVemuri%26aufirst%3DV.%2BK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DB%25C3%25A1tkai%26aufirst%3DS.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DOsei-Hyiaman%26aufirst%3DD.%26aulast%3DOhnuma%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DPickel%26aufirst%3DJ.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520CB1%2520Cannabinoid%2520Receptor%2520Blockade%2520Improves%2520Cardiometabolic%2520Risk%2520in%2520Mouse%2520Models%2520of%2520Obesity%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D2953%26epage%3D2966%26doi%3D10.1172%2FJCI42551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Cinar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdelyi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szanda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, A. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenz, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innis, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Hybrid Inhibitor of Peripheral Cannabinoid-1 Receptors and Inducible Nitric Oxide Synthase Mitigates Liver Fibrosis</span> <span class="citation_source-journal">JCI. Insight</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e87336</span><span class="refDoi"> DOI: 10.1172/jci.insight.87336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1172%2Fjci.insight.87336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e87336&author=R.+Cinarauthor=M.+R.+Iyerauthor=Z.+Liuauthor=Z.+Caoauthor=T.+Jourdanauthor=K.+Erdelyiauthor=G.+Godlewskiauthor=G.+Szandaauthor=J.+Liuauthor=J.+K.+Parkauthor=B.+Mukhopadhyayauthor=A.+Z.+Rosenbergauthor=J.+Lieowauthor=R.+G.+Lorenzauthor=P.+Pacherauthor=R.+B.+Innisauthor=G.+Kunos&title=Hybrid+Inhibitor+of+Peripheral+Cannabinoid-1+Receptors+and+Inducible+Nitric+Oxide+Synthase+Mitigates+Liver+Fibrosis&doi=10.1172%2Fjci.insight.87336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.87336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.87336%26sid%3Dliteratum%253Aachs%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DErdelyi%26aufirst%3DK.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DRosenberg%26aufirst%3DA.%2BZ.%26aulast%3DLieow%26aufirst%3DJ.%26aulast%3DLorenz%26aufirst%3DR.%2BG.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DHybrid%2520Inhibitor%2520of%2520Peripheral%2520Cannabinoid-1%2520Receptors%2520and%2520Inducible%2520Nitric%2520Oxide%2520Synthase%2520Mitigates%2520Liver%2520Fibrosis%26jtitle%3DJCI.%2520Insight%26date%3D2016%26volume%3D1%26spage%3De87336%26doi%3D10.1172%2Fjci.insight.87336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Lange, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coolen, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Stuivenberg, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijksman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herremans, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronken, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keizer, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreary, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veerman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wals, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stork, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verveer, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Hartog, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jong, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolfs, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogendoorn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB(1) Cannabinoid Receptor Antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1021/jm031019q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031019q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=627-643&author=J.+H.+Langeauthor=H.+K.+Coolenauthor=H.+H.+van+Stuivenbergauthor=J.+A.+Dijksmanauthor=A.+H.+Herremansauthor=E.+Ronkenauthor=H.+G.+Keizerauthor=K.+Tipkerauthor=A.+C.+McCrearyauthor=W.+Veermanauthor=H.+C.+Walsauthor=B.+Storkauthor=P.+C.+Verveerauthor=A.+P.+den+Hartogauthor=N.+M.+de+Jongauthor=T.+J.+Adolfsauthor=J.+Hoogendoornauthor=C.+G.+Kruse&title=Synthesis%2C+Biological+Properties%2C+and+Molecular+Modeling+Investigations+of+Novel+3%2C4-Diarylpyrazolines+as+Potent+and+Selective+CB%281%29+Cannabinoid+Receptor+Antagonists&doi=10.1021%2Fjm031019q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm031019q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031019q%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%26aulast%3DCoolen%26aufirst%3DH.%2BK.%26aulast%3Dvan%2BStuivenberg%26aufirst%3DH.%2BH.%26aulast%3DDijksman%26aufirst%3DJ.%2BA.%26aulast%3DHerremans%26aufirst%3DA.%2BH.%26aulast%3DRonken%26aufirst%3DE.%26aulast%3DKeizer%26aufirst%3DH.%2BG.%26aulast%3DTipker%26aufirst%3DK.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DVeerman%26aufirst%3DW.%26aulast%3DWals%26aufirst%3DH.%2BC.%26aulast%3DStork%26aufirst%3DB.%26aulast%3DVerveer%26aufirst%3DP.%2BC.%26aulast%3Dden%2BHartog%26aufirst%3DA.%2BP.%26aulast%3Dde%2BJong%26aufirst%3DN.%2BM.%26aulast%3DAdolfs%26aufirst%3DT.%2BJ.%26aulast%3DHoogendoorn%26aufirst%3DJ.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DSynthesis%252C%2520Biological%2520Properties%252C%2520and%2520Molecular%2520Modeling%2520Investigations%2520of%2520Novel%25203%252C4-Diarylpyrazolines%2520as%2520Potent%2520and%2520Selective%2520CB%25281%2529%2520Cannabinoid%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D627%26epage%3D643%26doi%3D10.1021%2Fjm031019q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Dai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span> </span><span class="NLM_article-title">Rimonabant Inhibits Proliferation, Collagen Secretion and Induces Apoptosis in Hepatic Stellate Cells</span> <span class="citation_source-journal">Hepatogastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2052</span><span class="NLM_x">–</span> <span class="NLM_lpage">2061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=25713910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A280%3ADC%252BC2MroslGhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=2052-2061&author=E.+Daiauthor=J.+Zhangauthor=D.+Zhangauthor=L.+Yangauthor=Y.+Wangauthor=X.+Jiangauthor=L.+Yeauthor=X.+Liauthor=H.+Liuauthor=J.+Maauthor=H.+Jiang&title=Rimonabant+Inhibits+Proliferation%2C+Collagen+Secretion+and+Induces+Apoptosis+in+Hepatic+Stellate+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in hepatic stellate cells</span></div><div class="casAuthors">Dai Erhei; Zhang Jian; Zhang Di; Yang Li; Wang Yan; Jiang Xiaoyu; Ye Lihong; Li Xiaojun; Liu Huimin; Ma Junji; Jiang Huiqing</div><div class="citationInfo"><span class="NLM_cas:title">Hepato-gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">135</span>),
    <span class="NLM_cas:pages">2052-61</span>
        ISSN:<span class="NLM_cas:issn">0172-6390</span>.
    </div><div class="casAbstract">BACKGROUND/AIMS:  Liver fibrosis represents a significant health problem worldwide.  Hepatic stellate cells (HSCs) play a critical role in the live fibrosis.  Rimonabant (SR141716) is cannabinoid receptor type 1 (CB1) antagonist.  The pharmacological effects of rimonabant on HSCs are not well characterized in HSCs.  METHODS:  CB1 receptor was detected by immunohistochemistry in human liver fibrosis specimens.  Cell proliferation was detected by MTT assay.  Cell apoptosis, caspase-3 protein expression and cell cycle were detected by TEM and flow cytometry, respectively.  Caspase-3 activity was measured using caspase-3 activity assay kit.  Collagen secretion was evaluated by radioimmunoassay.  CB1 receptor and signaling molecules were evaluated by qRTPCR and Western blot.  RESULTS:  Immunohistochemistry showed a discrete, punctuated CB1 immunoreactivity in human liver fibrosis specimens.  Rimonabant reduced HSC proliferation and increased HSC apoptosis.  Cell cycle analysis showed a decrease in G2/M phase cells and an increase in G0/G1 phase cells in HSC-T6 cells treated with rimonabant.  Caspase-3 protein expression and activity were increased by rimonabant.  Rimonabant decreased collagen secretion in HSC-T6 cells.  Moreover, rimonabant inhibited the expression of phosphorylated FAK and ERK and down-regulated CB1 mRNA expression.  CONCLUSION:  The study provides new insights toward the pharmacological effect of rimonabant on HSCs in vitro.  Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in HSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTa5dwEoYu4sz69zv1FsJFMfW6udTcc2eZD2PkYOLCQ4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MroslGhsQ%253D%253D&md5=fff8cd2bfe46c26a9d43a76316ab76f9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26atitle%3DRimonabant%2520Inhibits%2520Proliferation%252C%2520Collagen%2520Secretion%2520and%2520Induces%2520Apoptosis%2520in%2520Hepatic%2520Stellate%2520Cells%26jtitle%3DHepatogastroenterology%26date%3D2014%26volume%3D61%26spage%3D2052%26epage%3D2061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Anavi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg-Bord, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn-Obercyger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirosh, O.</span><span> </span><span class="NLM_article-title">The Role of iNOS in Cholesterol-Induced Liver Fibrosis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">914</span><span class="NLM_x">–</span> <span class="NLM_lpage">924</span><span class="refDoi"> DOI: 10.1038/labinvest.2015.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Flabinvest.2015.67" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=914-924&author=S.+Anaviauthor=M.+Eisenberg-Bordauthor=M.+Hahn-Obercygerauthor=O.+Geninauthor=M.+Pinesauthor=O.+Tirosh&title=The+Role+of+iNOS+in+Cholesterol-Induced+Liver+Fibrosis&doi=10.1038%2Flabinvest.2015.67"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2015.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2015.67%26sid%3Dliteratum%253Aachs%26aulast%3DAnavi%26aufirst%3DS.%26aulast%3DEisenberg-Bord%26aufirst%3DM.%26aulast%3DHahn-Obercyger%26aufirst%3DM.%26aulast%3DGenin%26aufirst%3DO.%26aulast%3DPines%26aufirst%3DM.%26aulast%3DTirosh%26aufirst%3DO.%26atitle%3DThe%2520Role%2520of%2520iNOS%2520in%2520Cholesterol-Induced%2520Liver%2520Fibrosis%26jtitle%3DLab.%2520Invest.%26date%3D2015%26volume%3D95%26spage%3D914%26epage%3D924%26doi%3D10.1038%2Flabinvest.2015.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Tipoe, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liong, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tom, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanji, A. A.</span><span> </span><span class="NLM_article-title">Inhibitors of Inducible Nitric Oxide (NO) Synthase Are More Effective than an NO Donor in Reducing Carbon-Tetrachloride Induced Acute Liver Injury</span> <span class="citation_source-journal">Histol. Histopathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=16874658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlant7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=1157-1165&author=G.+L.+Tipoeauthor=T.+M.+Leungauthor=E.+Liongauthor=H.+Soauthor=K.+M.+Leungauthor=T.+Y.+Lauauthor=W.+M.+Tomauthor=M.+L.+Fungauthor=S.+T.+Fanauthor=A.+A.+Nanji&title=Inhibitors+of+Inducible+Nitric+Oxide+%28NO%29+Synthase+Are+More+Effective+than+an+NO+Donor+in+Reducing+Carbon-Tetrachloride+Induced+Acute+Liver+Injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of inducible nitric oxide (NO) synthase are more effective than an NO donor in reducing carbon-tetrachloride induced acute liver injury</span></div><div class="casAuthors">Tipoe, G. L.; Leung, T. M.; Liong, E.; So, H.; Leung, K. M.; Lau, T. Y. H.; Tom, W. M.; Fung, M. L.; Fan, S. T.; Nanji, A. A.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10,11 and 12</span>),
    <span class="NLM_cas:pages">1157-1165</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">The exact functional role of nitric oxide (NO) in liver injury is currently a source of controversy.  NO is enzymically synthesized by nitric oxide synthase (NOS).  In this study, we assessed the role of inducible NOS (iNOS) in carbon tetrachloride (CCl4)-induced acute liver injury using inhibitors of iNOS, and an NO donor.  Adult ICR mice were injected with CCl4 with or without the iNOS inhibitors (5-methylisothiourea hemisulfate [SMT] and 1-N6-(1-iminoethyl)-lysine [L-NIL]) and an NO donor (Sodium Nitroprusside [SNP]).  Blood and liver tissues were collected for anal.  Immunohistochem. (IHC), serum alanine aminotransferase (ALT), serum total 8-isoprostane anal., RT-PCR, Western Blotting (WB) and EMSA were done.  The results showed increased levels of ALT, necrosis, total 8-isoprostane and nitrotyrosine after CCl4 administration.  INOS inhibitors and SNP abrogated these effects but the effect was more pronounced with SMT and L-NIL.  RT-PCR, WB, and IHC in CCl4-treated mice demonstrated upregulation of TNF-α, iNOS, and COX-2.  The administration of iNOS inhibitors with CCl4 diminished the expression of these proinflammatory mediators.  NF-κB was also upregulated in CCl4-treated mice and was reversed in mice pretreated with iNOS inhibitors.  SNP pretreated mice also showed a lower expression of COX-2 when compared with CCl4 treated mice but TNF-α, iNOS and NF-κB activity were unaffected.  We propose that a high level of nitric oxide is assocd. with CCl4-induced acute liver injury and the liver injury can be ameliorated by decreasing the NO level with iNOS inhibitors and an NO donor with the former more effective in reducing CCl4-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXF80dL-7BabVg90H21EOLACvtfcHk0lgCmv3FodD2Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlant7nM&md5=744fe40d5eb2b45681e0857ef7bfe9d0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTipoe%26aufirst%3DG.%2BL.%26aulast%3DLeung%26aufirst%3DT.%2BM.%26aulast%3DLiong%26aufirst%3DE.%26aulast%3DSo%26aufirst%3DH.%26aulast%3DLeung%26aufirst%3DK.%2BM.%26aulast%3DLau%26aufirst%3DT.%2BY.%26aulast%3DTom%26aufirst%3DW.%2BM.%26aulast%3DFung%26aufirst%3DM.%2BL.%26aulast%3DFan%26aufirst%3DS.%2BT.%26aulast%3DNanji%26aufirst%3DA.%2BA.%26atitle%3DInhibitors%2520of%2520Inducible%2520Nitric%2520Oxide%2520%2528NO%2529%2520Synthase%2520Are%2520More%2520Effective%2520than%2520an%2520NO%2520Donor%2520in%2520Reducing%2520Carbon-Tetrachloride%2520Induced%2520Acute%2520Liver%2520Injury%26jtitle%3DHistol.%2520Histopathol.%26date%3D2006%26volume%3D21%26spage%3D1157%26epage%3D1165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wilcock, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Nostrand, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Previti, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharkholonarehe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitek, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colton, C. A.</span><span> </span><span class="NLM_article-title">Progression of Amyloid Pathology to Alzheimer’s Disease Pathology in an Amyloid Precursor Protein Transgenic Mouse Model by Removal of Nitric Oxide Synthase 2</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1537</span><span class="NLM_x">–</span> <span class="NLM_lpage">1545</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.5066-07.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1523%2FJNEUROSCI.5066-07.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=18272675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVSrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=1537-1545&author=D.+M.+Wilcockauthor=M.+R.+Lewisauthor=W.+E.+Van+Nostrandauthor=J.+Davisauthor=M.+L.+Previtiauthor=N.+Gharkholonareheauthor=M.+P.+Vitekauthor=C.+A.+Colton&title=Progression+of+Amyloid+Pathology+to+Alzheimer%E2%80%99s+Disease+Pathology+in+an+Amyloid+Precursor+Protein+Transgenic+Mouse+Model+by+Removal+of+Nitric+Oxide+Synthase+2&doi=10.1523%2FJNEUROSCI.5066-07.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2</span></div><div class="casAuthors">Wilcock, Donna M.; Lewis, Matthew R.; Van Nostrand, William E.; Davis, Judianne; Previti, Mary Lou; Gharkholonarehe, Nastaran; Vitek, Michael P.; Colton, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1537-1545</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by three primary pathologies in the brain: amyloid plaques, neurofibrillary tangles, and neuron loss.  Mouse models have been useful for studying components of AD but are limited in their ability to fully recapitulate all pathologies.  We crossed the APPSwDI transgenic mouse, which develops amyloid β (Aβ)-protein deposits only, with a nitric oxide synthase 2 (NOS2) knock-out mouse, which develops no AD-like pathol.  APPSwDI/NOS2-/- mice displayed impaired spatial memory compared with the APPSwDI mice, yet they have unaltered levels of Aβ.  APPSwDI mice do not show tau pathol., whereas APPSwDI/NOS2-/- mice displayed extensive tau pathol. assocd. with regions of dense microvascular amyloid deposition.  Also, APPSwDI mice do not have any neuron loss, whereas the APPSwDI/NOS2-/- mice have significant neuron loss in the hippocampus and subiculum.  Neuropeptide Y neurons have been shown to be particularly vulnerable in AD.  These neurons appear to be particularly vulnerable in the APPSwDI/NOS2-/- mice as we observe a dramatic redn. in the no. of NPY neurons in the hippocampus and subiculum.  These data show that removal of NOS2 from an APP transgenic mouse results in development of a much greater spectrum of AD-like pathol. and behavioral impairments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU_6m33MZwf7Vg90H21EOLACvtfcHk0liJ0Lf4yXRgVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVSrtrw%253D&md5=380f882e4ff5f7c84caeac589d2cdb5d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5066-07.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5066-07.2008%26sid%3Dliteratum%253Aachs%26aulast%3DWilcock%26aufirst%3DD.%2BM.%26aulast%3DLewis%26aufirst%3DM.%2BR.%26aulast%3DVan%2BNostrand%26aufirst%3DW.%2BE.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DPreviti%26aufirst%3DM.%2BL.%26aulast%3DGharkholonarehe%26aufirst%3DN.%26aulast%3DVitek%26aufirst%3DM.%2BP.%26aulast%3DColton%26aufirst%3DC.%2BA.%26atitle%3DProgression%2520of%2520Amyloid%2520Pathology%2520to%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Pathology%2520in%2520an%2520Amyloid%2520Precursor%2520Protein%2520Transgenic%2520Mouse%2520Model%2520by%2520Removal%2520of%2520Nitric%2520Oxide%2520Synthase%25202%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D1537%26epage%3D1545%26doi%3D10.1523%2FJNEUROSCI.5066-07.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Chorvat, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berbaum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seriacki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, J. F.</span><span> </span><span class="NLM_article-title">JD-5006 and JD-5037: Peripherally Restricted (PR) Cannabinoid-1 Receptor Blockers Related to SLV-319 (Ibipinabant) as Metabolic Disorder Therapeutics Devoid of CNS Liabilities</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6173</span><span class="NLM_x">–</span> <span class="NLM_lpage">6180</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2Fj.bmcl.2012.08.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6173-6180&author=R.+J.+Chorvatauthor=J.+Berbaumauthor=K.+Seriackiauthor=J.+F.+McElroy&title=JD-5006+and+JD-5037%3A+Peripherally+Restricted+%28PR%29+Cannabinoid-1+Receptor+Blockers+Related+to+SLV-319+%28Ibipinabant%29+as+Metabolic+Disorder+Therapeutics+Devoid+of+CNS+Liabilities&doi=10.1016%2Fj.bmcl.2012.08.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DBerbaum%26aufirst%3DJ.%26aulast%3DSeriacki%26aufirst%3DK.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26atitle%3DJD-5006%2520and%2520JD-5037%253A%2520Peripherally%2520Restricted%2520%2528PR%2529%2520Cannabinoid-1%2520Receptor%2520Blockers%2520Related%2520to%2520SLV-319%2520%2528Ibipinabant%2529%2520as%2520Metabolic%2520Disorder%2520Therapeutics%2520Devoid%2520of%2520CNS%2520Liabilities%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6173%26epage%3D6180%26doi%3D10.1016%2Fj.bmcl.2012.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Grosscurt, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellinga, K.</span><span> </span><span class="NLM_article-title">1-Phenylcarbamoyl-2-Pyrazolines, a New Class of Insecticides. 3. Synthesis and Insecticidal Properties of 3,4-Diphenyl-1-Phenylcarbamoyl-2-Pyrazolines</span> <span class="citation_source-journal">J. Agric. Food Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span><span class="refDoi"> DOI: 10.1021/jf60222a061</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf60222a061" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1979&pages=406-409&author=A.+C.+Grosscurtauthor=R.+Van+Hesauthor=K.+Wellinga&title=1-Phenylcarbamoyl-2-Pyrazolines%2C+a+New+Class+of+Insecticides.+3.+Synthesis+and+Insecticidal+Properties+of+3%2C4-Diphenyl-1-Phenylcarbamoyl-2-Pyrazolines&doi=10.1021%2Fjf60222a061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjf60222a061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf60222a061%26sid%3Dliteratum%253Aachs%26aulast%3DGrosscurt%26aufirst%3DA.%2BC.%26aulast%3DVan%2BHes%26aufirst%3DR.%26aulast%3DWellinga%26aufirst%3DK.%26atitle%3D1-Phenylcarbamoyl-2-Pyrazolines%252C%2520a%2520New%2520Class%2520of%2520Insecticides.%25203.%2520Synthesis%2520and%2520Insecticidal%2520Properties%2520of%25203%252C4-Diphenyl-1-Phenylcarbamoyl-2-Pyrazolines%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D1979%26volume%3D27%26spage%3D406%26epage%3D409%26doi%3D10.1021%2Fjf60222a061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabó, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiemermann, C.</span><span> </span><span class="NLM_article-title">Isothioureas: Potent Inhibitors of Nitric Oxide Synthases with Variable Isoform Selectivity</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">510</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.1995.tb13256.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1111%2Fj.1476-5381.1995.tb13256.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=7533622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADyaK2MXjt12ltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1995&pages=510-516&author=G.+J.+Southanauthor=C.+Szab%C3%B3author=C.+Thiemermann&title=Isothioureas%3A+Potent+Inhibitors+of+Nitric+Oxide+Synthases+with+Variable+Isoform+Selectivity&doi=10.1111%2Fj.1476-5381.1995.tb13256.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity</span></div><div class="casAuthors">Southan, Garry J.; Szabo, Csaba; Thiemermann, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">510-16</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The induction of a calcium-independent isoform of nitric oxide (NO) synthase (iNOS) and a subsequent enhanced formation of NO has been implicated in the pathophysiol. of a variety of diseases including inflammation and circulatory shock.  Here the authors demonstrate that the S-substituted isothioureas, S-methylisothiourea (SMT), S-(2-aminoethyl)isothiourea (aminoethyl-TU), S-ethylisothiourea (ethyl-TU) and S-isopropylisothiourea (isopropyl-TU) potently inhibit iNOS activity in J774.2 macrophages activated with bacterial endotoxin with EC50 values 8-24 times lower than that of NG-methyl-L-arginine (MeArg) and 200-times lower than that of NG-nitro-L-arginine (L-NO2Arg).  The inhibition of iNOS activity by these S-substituted isothioureas is dose-dependently prevented by excess of L-arginine, suggesting that these isothioureas are competitive inhibitors of iNOS at the L-arginine binding site.  Ethyl-TU and isopropyl-TU are 4-6 times more potent than MeArg in inhibiting the constitutive NOS activity in homogenates of bovine aortic endothelial cells (eNOS) and are more potent pressor agents than MeArg in the anesthetized rat.  SMT is equipotent with MeArg, whereas aminoethyl-TU is 6-times less potent in inhibiting eNOS activity in vitro.  Both SMT and aminoethyl-TU, however, elicit only weak pressor responses (approx. 15 mmHg at 10 mg kg-1, i.v.) in vivo.  A comparison of the potencies of ethyl-, isopropyl-, n-propyl-, t-butyl- and n-butyl-isothioureas on iNOS activity shows that the inhibitory activity of S-substituted isothioureas declines sharply if the side chain exceeds 2 carbon atoms in length.  Similarly, substitution of the ethylene side chain of ethyl-TU also results in a diminished potency.  Substitution of either one or both nitrogens of SMT with either amino or alkyl groups also substantially reduce its NOS inhibitory potency.  In conclusion, isothioureas represent a new class of NOS inhibitors which includes the most potent inhibitors of iNOS activity reported to date.  Some members of this class (ethyl-TU and isopropyl-TU) are potent inhibitors of eNOS and iNOS with little selectivity towards either isoform, while others (SMT and aminoethyl-TU) are relatively selective inhibitors of iNOS activity.  These latter agents may become useful tools for studying the role of iNOS in various disease models and may be useful in the therapy of diseases that are assocd. with an enhanced formation of NO due to iNOS induction, such as inflammation, circulatory shock or cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4rARv43bRL7Vg90H21EOLACvtfcHk0liJ0Lf4yXRgVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjt12ltLc%253D&md5=bb597041836fc523fdabfe4fc0a1beca</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1995.tb13256.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1995.tb13256.x%26sid%3Dliteratum%253Aachs%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DSzab%25C3%25B3%26aufirst%3DC.%26aulast%3DThiemermann%26aufirst%3DC.%26atitle%3DIsothioureas%253A%2520Potent%2520Inhibitors%2520of%2520Nitric%2520Oxide%2520Synthases%2520with%2520Variable%2520Isoform%2520Selectivity%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D114%26spage%3D510%26epage%3D516%26doi%3D10.1111%2Fj.1476-5381.1995.tb13256.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Liedtke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauerbruch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streetz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolba, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trautwein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trebicka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiskirchen, R.</span><span> </span><span class="NLM_article-title">Experimental Liver Fibrosis Research: Update on Animal Models, Legal Issues and Translational Aspects</span> <span class="citation_source-journal">Fibrog. Tissue Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="refDoi"> DOI: 10.1186/1755-1536-6-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1186%2F1755-1536-6-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=24274743" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=19&author=C.+Liedtkeauthor=T.+Lueddeauthor=T.+Sauerbruchauthor=D.+Scholtenauthor=K.+Streetzauthor=F.+Tackeauthor=R.+Tolbaauthor=C.+Trautweinauthor=J.+Trebickaauthor=R.+Weiskirchen&title=Experimental+Liver+Fibrosis+Research%3A+Update+on+Animal+Models%2C+Legal+Issues+and+Translational+Aspects&doi=10.1186%2F1755-1536-6-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-6-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-6-19%26sid%3Dliteratum%253Aachs%26aulast%3DLiedtke%26aufirst%3DC.%26aulast%3DLuedde%26aufirst%3DT.%26aulast%3DSauerbruch%26aufirst%3DT.%26aulast%3DScholten%26aufirst%3DD.%26aulast%3DStreetz%26aufirst%3DK.%26aulast%3DTacke%26aufirst%3DF.%26aulast%3DTolba%26aufirst%3DR.%26aulast%3DTrautwein%26aufirst%3DC.%26aulast%3DTrebicka%26aufirst%3DJ.%26aulast%3DWeiskirchen%26aufirst%3DR.%26atitle%3DExperimental%2520Liver%2520Fibrosis%2520Research%253A%2520Update%2520on%2520Animal%2520Models%252C%2520Legal%2520Issues%2520and%2520Translational%2520Aspects%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2013%26volume%3D6%26spage%3D19%26doi%3D10.1186%2F1755-1536-6-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Reddy, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span> </span><span class="NLM_article-title">Polypharmacology: Drug Discovery for the Future</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1586/ecp.12.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-47&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+Drug+Discovery+for+the+Future&doi=10.1586%2Fecp.12.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lj6xYlVztvLlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520Drug%2520Discovery%2520for%2520the%2520Future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26spage%3D41%26epage%3D47%26doi%3D10.1586%2Fecp.12.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Tal, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlish, S. J. D.</span><span> </span><span class="NLM_article-title">Synthesis of a Novel Series of Arylmethylisothiouronium Derivatives</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3823</span><span class="NLM_x">–</span> <span class="NLM_lpage">3830</span><span class="refDoi"> DOI: 10.1016/0040-4020(95)00105-H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2F0040-4020%2895%2900105-H" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1995&pages=3823-3830&author=D.+M.+Talauthor=S.+J.+D.+Karlish&title=Synthesis+of+a+Novel+Series+of+Arylmethylisothiouronium+Derivatives&doi=10.1016%2F0040-4020%2895%2900105-H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2895%2900105-H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252895%252900105-H%26sid%3Dliteratum%253Aachs%26aulast%3DTal%26aufirst%3DD.%2BM.%26aulast%3DKarlish%26aufirst%3DS.%2BJ.%2BD.%26atitle%3DSynthesis%2520of%2520a%2520Novel%2520Series%2520of%2520Arylmethylisothiouronium%2520Derivatives%26jtitle%3DTetrahedron%26date%3D1995%26volume%3D51%26spage%3D3823%26epage%3D3830%26doi%3D10.1016%2F0040-4020%2895%2900105-H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Iyer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szanda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puhl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschamps, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbach, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1124/mol.115.098541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1124%2Fmol.115.098541" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=238-244&author=M.+R.+Iyerauthor=R.+Cinarauthor=J.+Liuauthor=G.+Godlewskiauthor=G.+Szandaauthor=H.+Puhlauthor=S.+R.+Ikedaauthor=J.+Deschampsauthor=Y.+S.+Leeauthor=P.+J.+Steinbachauthor=G.+Kunos&title=Structural+Basis+of+Species-Dependent+Differential+Affinity+of+6-Alkoxy-5-Aryl-3-Pyridinecarboxamide+Cannabinoid-1+Receptor+Antagonists&doi=10.1124%2Fmol.115.098541"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.098541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.098541%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DPuhl%26aufirst%3DH.%26aulast%3DIkeda%26aufirst%3DS.%2BR.%26aulast%3DDeschamps%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DSteinbach%26aufirst%3DP.%2BJ.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DStructural%2520Basis%2520of%2520Species-Dependent%2520Differential%2520Affinity%2520of%25206-Alkoxy-5-Aryl-3-Pyridinecarboxamide%2520Cannabinoid-1%2520Receptor%2520Antagonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D88%26spage%3D238%26epage%3D244%26doi%3D10.1124%2Fmol.115.098541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Mukhopadhyay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajesh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horváth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdelyi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holovac, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaudet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamdaoui, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafdil, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haskó, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulares, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacher, P.</span><span> </span><span class="NLM_article-title">Poly (ADP-Ribose) Polymerase-1 Is a Key Mediator of Liver Inflammation and Fibrosis</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1998</span><span class="NLM_x">–</span> <span class="NLM_lpage">2009</span><span class="refDoi"> DOI: 10.1002/hep.26763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1002%2Fhep.26763" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1998-2009&author=P.+Mukhopadhyayauthor=M.+Rajeshauthor=Z.+Caoauthor=B.+Horv%C3%A1thauthor=O.+Parkauthor=H.+Wangauthor=K.+Erdelyiauthor=E.+Holovacauthor=Y.+Wangauthor=L.+Liaudetauthor=N.+Hamdaouiauthor=F.+Lafdilauthor=G.+Hask%C3%B3author=C.+Szaboauthor=A.+H.+Boularesauthor=B.+Gaoauthor=P.+Pacher&title=Poly+%28ADP-Ribose%29+Polymerase-1+Is+a+Key+Mediator+of+Liver+Inflammation+and+Fibrosis&doi=10.1002%2Fhep.26763"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fhep.26763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26763%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DP.%26aulast%3DRajesh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DHorv%25C3%25A1th%26aufirst%3DB.%26aulast%3DPark%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DErdelyi%26aufirst%3DK.%26aulast%3DHolovac%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiaudet%26aufirst%3DL.%26aulast%3DHamdaoui%26aufirst%3DN.%26aulast%3DLafdil%26aufirst%3DF.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DBoulares%26aufirst%3DA.%2BH.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DPacher%26aufirst%3DP.%26atitle%3DPoly%2520%2528ADP-Ribose%2529%2520Polymerase-1%2520Is%2520a%2520Key%2520Mediator%2520of%2520Liver%2520Inflammation%2520and%2520Fibrosis%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D1998%26epage%3D2009%26doi%3D10.1002%2Fhep.26763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Cinar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey-White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Hepatic Cannabinoid-1 Receptors Mediate Diet-Induced Insulin Resistance by Increasing de Novo Synthesis of Long-Chain Ceramides</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1002/hep.26606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1002%2Fhep.26606" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=143-153&author=R.+Cinarauthor=G.+Godlewskiauthor=J.+Liuauthor=J.+Tamauthor=T.+Jourdanauthor=B.+Mukhopadhyayauthor=J.+Harvey-Whiteauthor=G.+Kunos&title=Hepatic+Cannabinoid-1+Receptors+Mediate+Diet-Induced+Insulin+Resistance+by+Increasing+de+Novo+Synthesis+of+Long-Chain+Ceramides&doi=10.1002%2Fhep.26606"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fhep.26606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26606%26sid%3Dliteratum%253Aachs%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DHarvey-White%26aufirst%3DJ.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DHepatic%2520Cannabinoid-1%2520Receptors%2520Mediate%2520Diet-Induced%2520Insulin%2520Resistance%2520by%2520Increasing%2520de%2520Novo%2520Synthesis%2520of%2520Long-Chain%2520Ceramides%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D143%26epage%3D153%26doi%3D10.1002%2Fhep.26606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yinuo Wu, Quan Wang, Mei-Yan Jiang, Yi-You Huang, Ziran Zhu, Chuan Han, Yi-Jing Tian, Bei Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Hai-Bin Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9537-9549. <a href="https://doi.org/10.1021/acs.jmedchem.1c00862" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00862%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252BPhosphodiesterase-9%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatic%252BFibrosis%26aulast%3DWu%26aufirst%3DYinuo%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D12052021%26date%3D18062021%26volume%3D64%26issue%3D13%26spage%3D9537%26epage%3D9549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hongyan Liu, Zengfen Pang, Liqiang Hao, Jian Sun, Zheng Zhang, Fuqiang Wen, <span class="NLM_string-name hlFld-ContribAuthor">Chengcai Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Sulfonylimination of Proline with Sulfonylazides Involving Aldehyde-Induced Decarboxylation Coupling. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (4)
                                     , 1234-1238. <a href="https://doi.org/10.1021/acs.orglett.0c04187" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c04187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c04187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c04187%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSulfonylimination%252Bof%252BProline%252Bwith%252BSulfonylazides%252BInvolving%252BAldehyde-Induced%252BDecarboxylation%252BCoupling%26aulast%3DLiu%26aufirst%3DHongyan%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D18122020%26date%3D09022021%26volume%3D23%26issue%3D4%26spage%3D1234%26epage%3D1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue-Mei Zhang, Michael Greco, Tonya Le Blanc, Wensheng Lang, Jack Kauffman, John Masucci, William V. Murray, Keith Demarest, <span class="NLM_string-name hlFld-ContribAuthor">Mark Joseph Macielag</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB1R Inverse Agonists. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2504-2509. <a href="https://doi.org/10.1021/acsmedchemlett.0c00495" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00495</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00495%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPEGylated%252B6-Benzhydryl-4-amino-quinazolines%252Bas%252BPeripherally%252BRestricted%252BCB1R%252BInverse%252BAgonists%26aulast%3DZhang%26aufirst%3DYue-Mei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10092020%26date%3D02112020%26date%3D03112020%26volume%3D11%26issue%3D12%26spage%3D2504%26epage%3D2509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue-Mei Zhang, Michael N. Greco, Mark J. Macielag, Christopher A. Teleha, Renee L. DesJarlais, Yuting Tang, George Ho, Cuifen Hou, Cailin Chen, Shuyuan Zhao, Jack Kauffman, Raul Camacho, Jenson Qi, William Murray, Keith Demarest, <span class="NLM_string-name hlFld-ContribAuthor">James Leonard</span>. </span><span class="cited-content_cbyCitation_article-title">6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 10276-10298. <a href="https://doi.org/10.1021/acs.jmedchem.8b01467" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01467%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D6-Benzhydryl-4-amino-quinolin-2-ones%252Bas%252BPotent%252BCannabinoid%252BType%252B1%252B%252528CB1%252529%252BReceptor%252BInverse%252BAgonists%252Band%252BChemical%252BModifications%252Bfor%252BPeripheral%252BSelectivity%26aulast%3DZhang%26aufirst%3DYue-Mei%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D20092018%26date%3D31102018%26date%3D19102018%26volume%3D61%26issue%3D22%26spage%3D10276%26epage%3D10298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Myriam  Dao</span>, <span class="hlFld-ContribAuthor ">Helene  François</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Endocrinology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fendo.2021.720734" title="DOI URL">https://doi.org/10.3389/fendo.2021.720734</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fendo.2021.720734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffendo.2021.720734%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Endocrinology%26atitle%3DCannabinoid%252BReceptor%252B1%252BInhibition%252Bin%252BChronic%252BKidney%252BDisease%25253A%252BA%252BNew%252BTherapeutic%252BToolbox%26aulast%3DDao%26aufirst%3DMyriam%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Long-Qing  Zhu</span>, <span class="hlFld-ContribAuthor ">Xiao-Hong  Fan</span>, <span class="hlFld-ContribAuthor ">Jun-Fang  Li</span>, <span class="hlFld-ContribAuthor ">Jin-Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Liang</span>, <span class="hlFld-ContribAuthor ">Xiao-Ling  Hu</span>, <span class="hlFld-ContribAuthor ">Shu-Meng  Ma</span>, <span class="hlFld-ContribAuthor ">Xiang-Yong  Hao</span>, <span class="hlFld-ContribAuthor ">Tao  Shi</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a novel inhibitor of nitric oxide production with potential therapeutic effect on acute inflammation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>44 </em>, 128106. <a href="https://doi.org/10.1016/j.bmcl.2021.128106" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128106%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bnovel%252Binhibitor%252Bof%252Bnitric%252Boxide%252Bproduction%252Bwith%252Bpotential%252Btherapeutic%252Beffect%252Bon%252Bacute%252Binflammation%26aulast%3DZhu%26aufirst%3DLong-Qing%26date%3D2021%26volume%3D44%26spage%3D128106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji Hye  Han</span>, <span class="hlFld-ContribAuthor ">Wook  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Peripheral CB1R as a modulator of metabolic inflammation. </span><span class="cited-content_cbyCitation_journal-name">The FASEB Journal</span><span> <strong>2021,</strong> <em>35 </em>
                                    (4)
                                     <a href="https://doi.org/10.1096/fj.202001960R" title="DOI URL">https://doi.org/10.1096/fj.202001960R</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1096/fj.202001960R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1096%2Ffj.202001960R%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FASEB%2520Journal%26atitle%3DPeripheral%252BCB1R%252Bas%252Ba%252Bmodulator%252Bof%252Bmetabolic%252Binflammation%26aulast%3DHan%26aufirst%3DJi%2BHye%26date%3D2021%26date%3D2021%26volume%3D35%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farah  Deeba</span>, <span class="hlFld-ContribAuthor ">Ashish  Kumar</span>, <span class="hlFld-ContribAuthor ">Monalisa  Mukherjee</span>, <span class="hlFld-ContribAuthor ">Arun K.  Sharma</span>, <span class="hlFld-ContribAuthor ">Manju  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the endocannabinoid system in diabesity: Fact or fiction?. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>77 </em><a href="https://doi.org/10.1016/j.drudis.2021.03.022" title="DOI URL">https://doi.org/10.1016/j.drudis.2021.03.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2021.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2021.03.022%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DTargeting%252Bthe%252Bendocannabinoid%252Bsystem%252Bin%252Bdiabesity%25253A%252BFact%252Bor%252Bfiction%25253F%26aulast%3DDeeba%26aufirst%3DFarah%26date%3D2021%26volume%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carmelo  Quarta</span>, <span class="hlFld-ContribAuthor ">Daniela  Cota</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Obesity</span><span> <strong>2020,</strong> <em>44 </em>
                                    (11)
                                     , 2179-2193. <a href="https://doi.org/10.1038/s41366-020-0577-8" title="DOI URL">https://doi.org/10.1038/s41366-020-0577-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41366-020-0577-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41366-020-0577-8%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Obesity%26atitle%3DAnti-obesity%252Btherapy%252Bwith%252Bperipheral%252BCB1%252Bblockers%25253A%252Bfrom%252Bpromise%252Bto%252Bsafe%252528%25253F%252529%252Bpractice%26aulast%3DQuarta%26aufirst%3DCarmelo%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D11%26spage%3D2179%26epage%3D2193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoting  Li</span>, <span class="hlFld-ContribAuthor ">Ling  Shen</span>, <span class="hlFld-ContribAuthor ">Tian  Hua</span>, <span class="hlFld-ContribAuthor ">Zhi-Jie  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Structural and Functional Insights into Cannabinoid Receptors. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2020,</strong> <em>41 </em>
                                    (9)
                                     , 665-677. <a href="https://doi.org/10.1016/j.tips.2020.06.010" title="DOI URL">https://doi.org/10.1016/j.tips.2020.06.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2020.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2020.06.010%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DStructural%252Band%252BFunctional%252BInsights%252Binto%252BCannabinoid%252BReceptors%26aulast%3DLi%26aufirst%3DXiaoting%26date%3D2020%26volume%3D41%26issue%3D9%26spage%3D665%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Patricia  Rivera</span>, <span class="hlFld-ContribAuthor ">Antonio  Vargas</span>, <span class="hlFld-ContribAuthor ">Antoni  Pastor</span>, <span class="hlFld-ContribAuthor ">Anna  Boronat</span>, <span class="hlFld-ContribAuthor ">Antonio Jesús  López‐Gambero</span>, <span class="hlFld-ContribAuthor ">Laura  Sánchez‐Marín</span>, <span class="hlFld-ContribAuthor ">Dina  Medina‐Vera</span>, <span class="hlFld-ContribAuthor ">Antonia  Serrano</span>, <span class="hlFld-ContribAuthor ">Francisco Javier  Pavón</span>, <span class="hlFld-ContribAuthor ">Rafael  Torre</span>, <span class="hlFld-ContribAuthor ">Ekaitz  Agirregoitia</span>, <span class="hlFld-ContribAuthor ">María Isabel  Lucena</span>, <span class="hlFld-ContribAuthor ">Fernando  Rodríguez de Fonseca</span>, <span class="hlFld-ContribAuthor ">Juan  Decara</span>, <span class="hlFld-ContribAuthor ">Juan  Suárez</span>. </span><span class="cited-content_cbyCitation_article-title">Differential hepatoprotective role of the cannabinoid CB
              1
              and CB
              2
              receptors in paracetamol‐induced liver injury. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2020,</strong> <em>177 </em>
                                    (14)
                                     , 3309-3326. <a href="https://doi.org/10.1111/bph.15051" title="DOI URL">https://doi.org/10.1111/bph.15051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15051%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DDifferential%252Bhepatoprotective%252Brole%252Bof%252Bthe%252Bcannabinoid%252BCB%252B1%252Band%252BCB%252B2%252Breceptors%252Bin%252Bparacetamol%2525E2%252580%252590induced%252Bliver%252Binjury%26aulast%3DRivera%26aufirst%3DPatricia%26date%3D2020%26date%3D2020%26volume%3D177%26issue%3D14%26spage%3D3309%26epage%3D3326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sina  Matavos-Aramyan</span>, <span class="hlFld-ContribAuthor ">Sadaf  Soukhakian</span>, <span class="hlFld-ContribAuthor ">Mohammad Hossein  Jazebizadeh</span>. </span><span class="cited-content_cbyCitation_article-title">Selected methods for the synthesis of sulfoxides and sulfones with emphasis on oxidative protocols. </span><span class="cited-content_cbyCitation_journal-name">Phosphorus, Sulfur, and Silicon and the Related Elements</span><span> <strong>2020,</strong> <em>195 </em>
                                    (3)
                                     , 181-193. <a href="https://doi.org/10.1080/10426507.2019.1672691" title="DOI URL">https://doi.org/10.1080/10426507.2019.1672691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10426507.2019.1672691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10426507.2019.1672691%26sid%3Dliteratum%253Aachs%26jtitle%3DPhosphorus%252C%2520Sulfur%252C%2520and%2520Silicon%2520and%2520the%2520Related%2520Elements%26atitle%3DSelected%252Bmethods%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bsulfoxides%252Band%252Bsulfones%252Bwith%252Bemphasis%252Bon%252Boxidative%252Bprotocols%26aulast%3DMatavos-Aramyan%26aufirst%3DSina%26date%3D2020%26date%3D2019%26volume%3D195%26issue%3D3%26spage%3D181%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianjie  Han</span>, <span class="hlFld-ContribAuthor ">Rongyan  Zhou</span>, <span class="hlFld-ContribAuthor ">Chao  Huang</span>, <span class="hlFld-ContribAuthor ">Qingkai  Zeng</span>, <span class="hlFld-ContribAuthor ">Qiumeng  Long</span>, <span class="hlFld-ContribAuthor ">Qianjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Hang  Cong</span>, <span class="hlFld-ContribAuthor ">Qingdi  Zhou</span>, <span class="hlFld-ContribAuthor ">Gang  Wei</span>, <span class="hlFld-ContribAuthor ">Mao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient synthesis of sulfonylguanidines via reaction of tetra-substituted urine with ArSO2NCO. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2019,</strong> <em>60 </em>
                                    (48)
                                     , 151285. <a href="https://doi.org/10.1016/j.tetlet.2019.151285" title="DOI URL">https://doi.org/10.1016/j.tetlet.2019.151285</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2019.151285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2019.151285%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DEfficient%252Bsynthesis%252Bof%252Bsulfonylguanidines%252Bvia%252Breaction%252Bof%252Btetra-substituted%252Burine%252Bwith%252BArSO2NCO%26aulast%3DHan%26aufirst%3DJianjie%26date%3D2019%26volume%3D60%26issue%3D48%26spage%3D151285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexey O.  Chagarovskiy</span>, <span class="hlFld-ContribAuthor ">Vladimir V.  Kuznetsov</span>, <span class="hlFld-ContribAuthor ">Olga A.  Ivanova</span>, <span class="hlFld-ContribAuthor ">Alexander S.  Goloveshkin</span>, <span class="hlFld-ContribAuthor ">Irina I.  Levina</span>, <span class="hlFld-ContribAuthor ">Nina N.  Makhova</span>, <span class="hlFld-ContribAuthor ">Igor V.  Trushkov</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 1-Substituted Pyrazolines by Reaction of Donor-Acceptor Cyclopropanes with 1,5-Diazabicyclo[3.1.0]hexanes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (31-32)
                                     , 5475-5485. <a href="https://doi.org/10.1002/ejoc.201900579" title="DOI URL">https://doi.org/10.1002/ejoc.201900579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900579%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B1-Substituted%252BPyrazolines%252Bby%252BReaction%252Bof%252BDonor-Acceptor%252BCyclopropanes%252Bwith%252B1%25252C5-Diazabicyclo%25255B3.1.0%25255Dhexanes%26aulast%3DChagarovskiy%26aufirst%3DAlexey%2BO.%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D31-32%26spage%3D5475%26epage%3D5485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Malliga R.  Iyer</span>, <span class="hlFld-ContribAuthor ">Resat  Cinar</span>, <span class="hlFld-ContribAuthor ">Nathan J.  Coffey</span>, <span class="hlFld-ContribAuthor ">George  Kunos</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of
              13
              C
              6
              -labeled, dual-target inhibitor of cannabinoid-1 receptor (CB
              1
              R) and inducible nitric oxide synthase (iNOS). </span><span class="cited-content_cbyCitation_journal-name">Journal of Labelled Compounds and Radiopharmaceuticals</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 773-779. <a href="https://doi.org/10.1002/jlcr.3639" title="DOI URL">https://doi.org/10.1002/jlcr.3639</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jlcr.3639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjlcr.3639%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Labelled%2520Compounds%2520and%2520Radiopharmaceuticals%26atitle%3DSynthesis%252Bof%252B13%252BC%252B6%252B-labeled%25252C%252Bdual-target%252Binhibitor%252Bof%252Bcannabinoid-1%252Breceptor%252B%252528CB%252B1%252BR%252529%252Band%252Binducible%252Bnitric%252Boxide%252Bsynthase%252B%252528iNOS%252529%26aulast%3DIyer%26aufirst%3DMalliga%2BR.%26date%3D2018%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D773%26epage%3D779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nirajan  Shrestha</span>, <span class="hlFld-ContribAuthor ">James S.M.  Cuffe</span>, <span class="hlFld-ContribAuthor ">Dana S.  Hutchinson</span>, <span class="hlFld-ContribAuthor ">John P.  Headrick</span>, <span class="hlFld-ContribAuthor ">Anthony V.  Perkins</span>, <span class="hlFld-ContribAuthor ">Andrew J.  McAinch</span>, <span class="hlFld-ContribAuthor ">Deanne H.  Hryciw</span>. </span><span class="cited-content_cbyCitation_article-title">Peripheral modulation of the endocannabinoid system in metabolic disease. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2018,</strong> <em>23 </em>
                                    (3)
                                     , 592-604. <a href="https://doi.org/10.1016/j.drudis.2018.01.029" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.01.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.01.029%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DPeripheral%252Bmodulation%252Bof%252Bthe%252Bendocannabinoid%252Bsystem%252Bin%252Bmetabolic%252Bdisease%26aulast%3DShrestha%26aufirst%3DNirajan%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D592%26epage%3D604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cecilia J  Hillard</span>. </span><span class="cited-content_cbyCitation_article-title">Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?. </span><span class="cited-content_cbyCitation_journal-name">Neuropsychopharmacology</span><span> <strong>2018,</strong> <em>43 </em>
                                    (1)
                                     , 155-172. <a href="https://doi.org/10.1038/npp.2017.130" title="DOI URL">https://doi.org/10.1038/npp.2017.130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/npp.2017.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnpp.2017.130%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropsychopharmacology%26atitle%3DCirculating%252BEndocannabinoids%25253A%252BFrom%252BWhence%252BDo%252BThey%252BCome%252Band%252BWhere%252Bare%252BThey%252BGoing%25253F%26aulast%3DHillard%26aufirst%3DCecilia%2BJ%26date%3D2018%26date%3D2017%26volume%3D43%26issue%3D1%26spage%3D155%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Hongying  Liu</span>, <span class="hlFld-ContribAuthor ">Hua  Guan</span>, <span class="hlFld-ContribAuthor ">Nina  Xue</span>, <span class="hlFld-ContribAuthor ">Lili  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoid CB1 receptor inverse agonist MJ08 stimulates glucose production via hepatic sympathetic innervation in rats. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2017,</strong> <em>814 </em>, 232-239. <a href="https://doi.org/10.1016/j.ejphar.2017.08.030" title="DOI URL">https://doi.org/10.1016/j.ejphar.2017.08.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2017.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2017.08.030%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DCannabinoid%252BCB1%252Breceptor%252Binverse%252Bagonist%252BMJ08%252Bstimulates%252Bglucose%252Bproduction%252Bvia%252Bhepatic%252Bsympathetic%252Binnervation%252Bin%252Brats%26aulast%3DChen%26aufirst%3DWei%26date%3D2017%26volume%3D814%26spage%3D232%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Fengchun  Shui</span>, <span class="hlFld-ContribAuthor ">Cheng  Liu</span>, <span class="hlFld-ContribAuthor ">Xinbo  Zhou</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Zhibing  Zheng</span>, <span class="hlFld-ContribAuthor ">Wei  Fu</span>, <span class="hlFld-ContribAuthor ">Lili  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2017,</strong> <em>8 </em><a href="https://doi.org/10.3389/fphar.2017.00707" title="DOI URL">https://doi.org/10.3389/fphar.2017.00707</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2017.00707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2017.00707%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DNovel%252BPeripherally%252BRestricted%252BCannabinoid%252B1%252BReceptor%252BSelective%252BAntagonist%252BTXX-522%252Bwith%252BProminent%252BWeight-Loss%252BEfficacy%252Bin%252BDiet%252BInduced%252BObese%252BMice%26aulast%3DChen%26aufirst%3DWei%26date%3D2017%26date%3D2017%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Salman  Shojaei</span>, <span class="hlFld-ContribAuthor ">Zarrin  Ghasemi</span>, <span class="hlFld-ContribAuthor ">Aziz  Shahrisa</span>. </span><span class="cited-content_cbyCitation_article-title">Three-component synthesis of N -sulfonylformamidines in the presence of magnetic cellulose supported N -heterocyclic carbene-copper complex, as an efficient heterogeneous nanocatalyst. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (42)
                                     , 3957-3965. <a href="https://doi.org/10.1016/j.tetlet.2017.08.075" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.08.075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.08.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.08.075%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DThree-component%252Bsynthesis%252Bof%252BN%252B-sulfonylformamidines%252Bin%252Bthe%252Bpresence%252Bof%252Bmagnetic%252Bcellulose%252Bsupported%252BN%252B-heterocyclic%252Bcarbene-copper%252Bcomplex%25252C%252Bas%252Ban%252Befficient%252Bheterogeneous%252Bnanocatalyst%26aulast%3DShojaei%26aufirst%3DSalman%26date%3D2017%26volume%3D58%26issue%3D42%26spage%3D3957%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vincent  Simon</span>, <span class="hlFld-ContribAuthor ">Daniela  Cota</span>. </span><span class="cited-content_cbyCitation_article-title">MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Endocrinology</span><span> <strong>2017,</strong> <em>176 </em>
                                    (6)
                                     , R309-R324. <a href="https://doi.org/10.1530/EJE-16-1044" title="DOI URL">https://doi.org/10.1530/EJE-16-1044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1530/EJE-16-1044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1530%2FEJE-16-1044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Endocrinology%26atitle%3DMECHANISMS%252BIN%252BENDOCRINOLOGY%25253A%252BEndocannabinoids%252Band%252Bmetabolism%25253A%252Bpast%25252C%252Bpresent%252Band%252Bfuture%26aulast%3DSimon%26aufirst%3DVincent%26date%3D2017%26volume%3D176%26issue%3D6%26spage%3DR309%26epage%3DR324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. CB<sub>1</sub>R inverse agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Dual-target peripherally restricted CB<sub>1</sub>R strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0014.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Various Sulfonylurea Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) toluene, reflux.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0015.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Substituted Analogs of the Formula <b>A</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PCl<sub>5</sub>, chlorobenzene reflux; (b) QNH<sub>2</sub>, MeOH–DCM, Et<sub>3</sub>N, −78 °C to room temp.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Determining in vitro inverse agonism versus neutral antagonism. Inverse agonism and neutral antagonism were assessed for compounds by GTPγS binding assay using mouse crude brain membrane preparation. Compounds were incubated in the absence of any CB<sub>1</sub>R agonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of iNOS by selected CB<sub>1</sub>R/iNOS antagonists: V (vehicle), rimonabant (Rim), ibipinabant (SLV). Effects of compounds on iNOS activity were determined by using RAW 264.7 cells, which are incubated with LPS (50 ng/mL) and γ-interferon (10 ng/mL) for 24 h prior to treatment. Positive control in the assay system is provided by the iNOS inhibitor diphenylene iodonium (DPI).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0016.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Chiral Prep-HPLC Separation for Compound <b>6a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>R</i>,<i>R</i>-Whelk-O/ethanol (100%).</p></p></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. CB<sub>1</sub>R binding affinity of compound <b>7</b> and CB<sub>1</sub>R antagonism. (A) Binding affinity was determined from binding displacement isotherms using [<sup>3</sup>H]CP55940 as the labeled ligand. (B) Functional CB<sub>1</sub>R antagonism was determined using the agonist-stimulated [<sup>35</sup>S]GTPγS binding assay. The antagonists concentration-dependently antagonized the effect of CP55940 (1 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Single crystal X-ray of <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo peripheral CB<sub>1</sub>R blockade by compound <b>7</b>. Both rimonabant and compound <b>7</b> (1–10 mg/kg po) dose-dependently reversed the ACEA (CB<sub>1</sub>R agonist)-induced reduction in upper GI motility. Data represent the mean ± SEM from 4 to 5 mice per group. ∗ (<i>P</i> < 0.05) or # (<i>P</i> < 0.05) indicate significant difference from vehicle or ACEA + vehicle (V) group, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Tissue distribution of compound <b>7</b>. Tissue levels of compound <b>7</b> were measured 1 h after oral administration of acute (A) or 28-days chronic (B). Data represent the mean ± SEM from 3 mice per group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>7</b> is devoid of behavioral anxiogenic effect after 28 days of chronic oral administration. Rimonabant, but not <b>7</b> (10 mg kg<sup>–1</sup> day<sup>–1</sup> for 28 days), is anxiogenic in the elevated plus maze (EPM) test. EPM is performed 1 h after oral administration of last dosing following 28 days. Data represent the mean ± SEM from 6 mice per group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effect of compound <b>7</b> on metabolic parameters in DIO mice. (A) Body weight was measured daily during 2 weeks of treatment with oral dosing of 10 mg/kg of compound <b>7</b>. (B) Hepatic triglyceride content was determined from post-mortem liver tissue. (C) Glucose tolerance and (D) insulin sensitivity test were determined 14 days after the chronic oral dosing of compound <b>7</b>. Data represent the mean ± SEM from 5 to 6 mice/group. ∗ (<i>P</i> < 0.05) indicates significant difference from control. <i>#</i> indicates significant treatment effect (<i>P</i> < 0.05) relative to high fat diet (HFD) vehicle group. Standard diet (STD).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0011.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Antifibrotic effect of compound <b>7</b> in CCl<sub>4</sub>-induced liver fibrosis. CCl<sub>4</sub>-induced liver fibrosis was generated by intraperitoneal injection of CCl<sub>4</sub> (1 mL/kg, diluted 1:10 corn oil) twice weekly. Mice were also treated by either vehicle, rimonabant, compound <b>7</b>, or compound <b>7′</b> orally for 4 weeks. Liver fibrosis was assessed histologically by Sirius red staining (A). Fibrosis area was analyzed by computerized morphometry (C). CCl<sub>4</sub>-induced elevation of iNOS immunostaining was attenuated by the compound <b>7</b> and compound <b>7′</b> but not with rimonabant (B). Data represent the mean ± SEM from 7 to 8 mice per group. ∗ (<i>P</i> < 0.05) indicates significant difference from control. # indicates significant treatment effect (<i>P</i> < 0.05) relative to CCl<sub>4</sub>-treated vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0012.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Effects of compound <b>7</b> and rimonabant on progression of BDL-induced liver fibrosis. Wild-type and CB<sub>1</sub>R<sup>–/–</sup> mice were treated with daily oral doses of 3 mg/kg rimonabant or 10 mg/kg of compound <b>7</b>, starting on the day of BDL. Liver fibrosis was assessed histologically by Sirius red staining and the fibrosis area analyzed by computerized morphometry. Data represent the mean ± SEM from 7 to 8 mice per group. ∗ (<i>P</i> < 0.05) indicates significant difference from control. <i>#</i> indicates significant treatment effect (<i>P</i> < 0.05) relative to BDL vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/medium/jm-2016-01504a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0013.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Effect of compound <b>7</b> on regression of BDL-induced liver fibrosis. Wild type mice were sacrificed on day 6 to determine grade of fibrosis or were treated oral doses of 3 mg/kg of rimonabant or 10 mg/kg of compound <b>7</b> starting on day 6 after BDL to determine efficacy on fibrosis regression. Liver fibrosis was assessed histologically by Sirius red staining. Data represent the mean ± SEM from 6 mice per group. * (<i>P</i> < 0.05) indicates significant difference from control. # indicates significant treatment effect (<i>P</i> < 0.05) relative to BDL vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-3/acs.jmedchem.6b01504/20170203/images/large/jm-2016-01504a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01504&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57850" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57850" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Pacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bátkai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">The Endocannabinoid System as an Emerging Target of Pharmacotherapy</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span><span class="refDoi"> DOI: 10.1124/pr.58.3.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1124%2Fpr.58.3.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=16968947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=389-462&author=P.+Pacherauthor=S.+B%C3%A1tkaiauthor=G.+Kunos&title=The+Endocannabinoid+System+as+an+Emerging+Target+of+Pharmacotherapy&doi=10.1124%2Fpr.58.3.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as an emerging target of pharmacotherapy</span></div><div class="casAuthors">Pacher, Pal; Batkai, Sandor; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-462</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease.  Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metab. and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase.  In the past decade, the endocannabinoid system has been implicated in a growing no. of physiol. functions, both in the central and peripheral nervous systems and in peripheral organs.  More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathol. conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson's and Huntington's disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few.  An impediment to the development of cannabinoid medications has been the socially unacceptable psychoactive properties of plant-derived or synthetic agonists, mediated by CB1 receptors.  However, this problem does not arise when the therapeutic aim is achieved by treatment with a CB1 receptor antagonist, such as in obesity, and may also be absent when the action of endocannabinoids is enhanced indirectly through blocking their metab. or transport.  The use of selective CB2 receptor agonists, which lack psychoactive properties, could represent another promising avenue for certain conditions.  The abuse potential of plant-derived cannabinoids may also be limited through the use of prepns. with controlled compn. and the careful selection of does and route of administration.  The growing no. of preclin. studies and clin. trials with compds. that modulate the endocannabinoid system will probably result in novel therapeutic approaches in a no. of diseases for which current treatments do not fully address the patients' need.  Here, we provide a comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN_yobbKbuLbVg90H21EOLACvtfcHk0lhpHmVmNNdMbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfO&md5=f54e6d1303645a1c63809879ef2813f3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.2%26sid%3Dliteratum%253Aachs%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DB%25C3%25A1tkai%26aufirst%3DS.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DThe%2520Endocannabinoid%2520System%2520as%2520an%2520Emerging%2520Target%2520of%2520Pharmacotherapy%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D389%26epage%3D462%26doi%3D10.1124%2Fpr.58.3.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Howlett, A. C.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1124/pr.54.2.161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlett&title=International+Union+of+Pharmacology.+XXVII.+Classification+of+Cannabinoid+Receptors&doi=10.1124%2Fpr.54.2.161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0lhgcFvrS5M65Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXVII.%2520Classification%2520of%2520Cannabinoid%2520Receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202%26doi%3D10.1124%2Fpr.54.2.161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Rodríguez de Fonseca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Arco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bermudez-Silva, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilbao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cippitelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, M.</span><span> </span><span class="NLM_article-title">The Endocannabinoid System: Physiology and Pharmacology</span> <span class="citation_source-journal">Alcohol. Alcohol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1093/alcalc/agh110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1093%2Falcalc%2Fagh110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=15550444" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2004&pages=2-14&author=F.+Rodr%C3%ADguez+de+Fonsecaauthor=I.+Del+Arcoauthor=F.+J.+Bermudez-Silvaauthor=A.+Bilbaoauthor=A.+Cippitelliauthor=M.+Navarro&title=The+Endocannabinoid+System%3A+Physiology+and+Pharmacology&doi=10.1093%2Falcalc%2Fagh110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Falcalc%2Fagh110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Falcalc%252Fagh110%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez%2Bde%2BFonseca%26aufirst%3DF.%26aulast%3DDel%2BArco%26aufirst%3DI.%26aulast%3DBermudez-Silva%26aufirst%3DF.%2BJ.%26aulast%3DBilbao%26aufirst%3DA.%26aulast%3DCippitelli%26aufirst%3DA.%26aulast%3DNavarro%26aufirst%3DM.%26atitle%3DThe%2520Endocannabinoid%2520System%253A%2520Physiology%2520and%2520Pharmacology%26jtitle%3DAlcohol.%2520Alcohol.%26date%3D2004%26volume%3D40%26spage%3D2%26epage%3D14%26doi%3D10.1093%2Falcalc%2Fagh110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Zimmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmer, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herkenham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, T. I.</span><span> </span><span class="NLM_article-title">Increased Mortality, Hypoactivity, and Hypoalgesia in Cannabinoid CB1 Receptor Knockout Mice</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">5780</span><span class="NLM_x">–</span> <span class="NLM_lpage">5785</span><span class="refDoi"> DOI: 10.1073/pnas.96.10.5780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1073%2Fpnas.96.10.5780" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=5780-5785&author=A.+Zimmerauthor=A.+M.+Zimmerauthor=A.+G.+Hohmannauthor=M.+Herkenhamauthor=T.+I.+Bonner&title=Increased+Mortality%2C+Hypoactivity%2C+and+Hypoalgesia+in+Cannabinoid+CB1+Receptor+Knockout+Mice&doi=10.1073%2Fpnas.96.10.5780"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.10.5780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.10.5780%26sid%3Dliteratum%253Aachs%26aulast%3DZimmer%26aufirst%3DA.%26aulast%3DZimmer%26aufirst%3DA.%2BM.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26atitle%3DIncreased%2520Mortality%252C%2520Hypoactivity%252C%2520and%2520Hypoalgesia%2520in%2520Cannabinoid%2520CB1%2520Receptor%2520Knockout%2520Mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D5780%26epage%3D5785%26doi%3D10.1073%2Fpnas.96.10.5780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Galiègue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussossoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrière, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carayon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouaboula, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span> </span><span class="NLM_article-title">Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1111/j.1432-1033.1995.tb20780.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1111%2Fj.1432-1033.1995.tb20780.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=7556170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADyaK2MXnvVKksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=1995&pages=54-61&author=S.+Gali%C3%A8gueauthor=S.+Maryauthor=J.+Marchandauthor=D.+Dussossoyauthor=D.+Carri%C3%A8reauthor=P.+Carayonauthor=M.+Bouaboulaauthor=D.+Shireauthor=G.+Le+Furauthor=P.+Casellas&title=Expression+of+Central+and+Peripheral+Cannabinoid+Receptors+in+Human+Immune+Tissues+and+Leukocyte+Subpopulations&doi=10.1111%2Fj.1432-1033.1995.tb20780.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations</span></div><div class="casAuthors">Galiegue, Sylvaine; Mary, Sophie; Marchand, Jean; Dussossoy, Danielle; Carriere, Dominique; Carayon, Pierre; Bouaboula, Monsif; Shire, David; Le Fur, Gerard; Casellas, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Two proteins with 7 transmembrane-spanning domains typical of guanosine-nucleotide-binding-protein-coupled receptors have been identified as cannabinoid receptors; the central cannabinoid receptor, CB1, and the peripheral cannabinoid receptor, CB2, initially described in rat brain and spleen, resp.  The distribution patterns for both CB1 and CB2 transcripts in human immune cells and in several human tissues are reported, as analyzed by a PCR-based method.  CB1 was mainly expressed in the central nervous system and, to a lower extent, in several peripheral tissues such as adrenal gland, heart, lung, prostate, uterus, ovary, testis, bone marrow, thymus and tonsils.  The CB2 gene, which is not expressed in the brain, was particularly abundant in immune tissues, with an expression level 10-100-fold higher than that of CB1.  Although CB2 mRNA was also detected in some other peripheral tissues, its level remained very low.  In spleen and tonsils, the CB2 mRNA content was equiv. to that of CB1 mRNA in the central nervous system.  Among the main human blood cell subpopulations, the distribution pattern of the CB2 mRNA displayed important variations.  The rank order of CB2 mRNA levels in these cells was B-cells > natural killer cells » monocytes > polymorphonuclear neutrophil cells > T8 cells > T4 cells.  The same rank order was also established in human cell lines belonging to the myeloid, monocytic and lymphoid lineages.  The prevailing expression of the CB2 gene in immune tissues was confirmed by Northern-blot anal.  The expression of the CB2 protein was demonstrated by an immunohistol. anal. performed on tonsil sections by specific anti-(human CB2) IgG; this expt. showed that CB2 expression was restricted to B-lymphocyte-enriched areas of the mantle of secondary lymphoid follicles.  Thus, CB1 and CB2 can be considered as tissue-selective antigens of the central nervous system and immune system, resp., and cannabinoids may exert specific receptor-mediated actions on the immune system through the CB2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwC6x6XdvbW7Vg90H21EOLACvtfcHk0lhgcFvrS5M65Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvVKksL8%253D&md5=ff4c2f420824fdbef66c94ea9d129288</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1995.tb20780.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1995.tb20780.x%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8gue%26aufirst%3DS.%26aulast%3DMary%26aufirst%3DS.%26aulast%3DMarchand%26aufirst%3DJ.%26aulast%3DDussossoy%26aufirst%3DD.%26aulast%3DCarri%25C3%25A8re%26aufirst%3DD.%26aulast%3DCarayon%26aufirst%3DP.%26aulast%3DBouaboula%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DLe%2BFur%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26atitle%3DExpression%2520of%2520Central%2520and%2520Peripheral%2520Cannabinoid%2520Receptors%2520in%2520Human%2520Immune%2520Tissues%2520and%2520Leukocyte%2520Subpopulations%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1995%26volume%3D232%26spage%3D54%26epage%3D61%26doi%3D10.1111%2Fj.1432-1033.1995.tb20780.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Klein, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, H.</span><span> </span><span class="NLM_article-title">Cannabinoids and the Immune System</span> <span class="citation_source-journal">Pain. Res. Manag.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1155/2001/326867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1155%2F2001%2F326867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=11854771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A280%3ADC%252BD387itVWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=95-101&author=T.+W.+Kleinauthor=C.+A.+Newtonauthor=H.+Friedman&title=Cannabinoids+and+the+Immune+System&doi=10.1155%2F2001%2F326867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids and the immune system</span></div><div class="casAuthors">Klein T W; Newton C A; Friedman H</div><div class="citationInfo"><span class="NLM_cas:title">Pain research & management</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-101</span>
        ISSN:<span class="NLM_cas:issn">1203-6765</span>.
    </div><div class="casAbstract">The effect of cannabimimetic agents on the function of immune cells such as T and B lymphocytes, natural killer cells and macrophages has been extensively studied over the past several decades using human and animal paradigms involving whole animal models as well as tissue culture systems.  From this work, it can be concluded that these drugs have subtle yet complex effects on immune cell function and that some of the drug activity is mediated by cannabinoid receptors expressed on the various immune cell subtypes.  However, the overall role of the cannabinoid system of receptors and ligands in human health and disease is still unclear and requires extensive elucidation.  Further studies will define the precise structure and function of the putative immunocannabinoid system, the potential therapeutic usefulness of these drugs in chronic diseases such as acquired immune deficiency syndrome and multiple sclerosis, the effects of these agents on tumour growth and induction of apoptosis, and the potential anti-inflammatory and proinflammatory properties of cannabimimetic compounds.  It is likely that the cannabinoid system, along with other neuroimmune systems, has a subtle but significant role in the regulation of immunity and that this role can eventually be exploited in the management of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEM49hz1c8YWLFM_lbR1VmfW6udTcc2eYLxCPLM4kRB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387itVWguw%253D%253D&md5=168076ffbf5e6c305b687252d51939c3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1155%2F2001%2F326867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2001%252F326867%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DT.%2BW.%26aulast%3DNewton%26aufirst%3DC.%2BA.%26aulast%3DFriedman%26aufirst%3DH.%26atitle%3DCannabinoids%2520and%2520the%2520Immune%2520System%26jtitle%3DPain.%2520Res.%2520Manag.%26date%3D2001%26volume%3D6%26spage%3D95%26epage%3D101%26doi%3D10.1155%2F2001%2F326867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Mackie, K.</span><span> </span><span class="NLM_article-title">Cannabinoid Receptors: Where They Are and What They Do</span> <span class="citation_source-journal">J. Neuroendocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1111/j.1365-2826.2008.01671.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1111%2Fj.1365-2826.2008.01671.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=18426493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsl2itbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=10-14&issue=Suppl.+1&author=K.+Mackie&title=Cannabinoid+Receptors%3A+Where+They+Are+and+What+They+Do&doi=10.1111%2Fj.1365-2826.2008.01671.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors: where they are and what they do</span></div><div class="casAuthors">Mackie, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">10-14</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system consists of the endogenous cannabinoids (endocannabinoids), cannabinoid receptors and the enzymes that synthesize and degrade endocannabinoids.  Many of the effects of cannabinoids and endocannabinoids are mediated by two G protein-coupled receptors (GPCRs), CB1 and CB2, although addnl. receptors may be involved.  CB1 receptors are present in very high levels in several brain regions and in lower amts. in a more wide-spread fashion.  These receptors mediate many of the psychoactive effects of cannabinoids.  CB2 receptors have a more restricted distribution, being found in a no. of immune cells and in a few neurons.  Both CB1 and CB2 couple primarily to inhibitory G proteins and are subject to the same pharmacol. influences as other GPCRs.  Thus, partial agonism, functional selectivity and inverse agonism all play important roles in detg. the cellular response to specific cannabinoid receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE3tJevcn32LVg90H21EOLACvtfcHk0lhZpe_hemZtgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsl2itbs%253D&md5=e87a4821e2475ef50f57f26507c2dc7f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2008.01671.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2008.01671.x%26sid%3Dliteratum%253Aachs%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DCannabinoid%2520Receptors%253A%2520Where%2520They%2520Are%2520and%2520What%2520They%2520Do%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2008%26volume%3D20%26issue%3DSuppl.%25201%26spage%3D10%26epage%3D14%26doi%3D10.1111%2Fj.1365-2826.2008.01671.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hungund, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basavarajappa, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vadasz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez de Fonseca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koob, G. F.</span><span> </span><span class="NLM_article-title">Ethanol, Endocannabinoids, and the Cannabinoidergic Signaling System</span> <span class="citation_source-journal">Alcohol.: Clin. Exp. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">574</span><span class="refDoi"> DOI: 10.1111/j.1530-0277.2002.tb02575.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1111%2Fj.1530-0277.2002.tb02575.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=11981134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVSmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=565-574&author=B.+L.+Hungundauthor=B.+S.+Basavarajappaauthor=C.+Vadaszauthor=G.+Kunosauthor=F.+Rodriguez+de+Fonsecaauthor=G.+Colomboauthor=S.+Serraauthor=L.+Parsonsauthor=G.+F.+Koob&title=Ethanol%2C+Endocannabinoids%2C+and+the+Cannabinoidergic+Signaling+System&doi=10.1111%2Fj.1530-0277.2002.tb02575.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ethanol, endocannabinoids, and the cannabinoidergic signaling system</span></div><div class="casAuthors">Hungund, Basalingappa L.; Basavarajappa, Balapal S.; Vadasz, Csaba; Kunos, George; Rodriguez de Fonseca, Fernando; Colombo, Giancarlo; Serra, Salvatore; Parsons, Loren; Koob, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Alcoholism: Clinical and Experimental Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">ACRSDM</span>;
        ISSN:<span class="NLM_cas:issn">0145-6008</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  This article represents the proceedings of a symposium at the 2001 annual meeting of the Research Society on Alcoholism in Montreal, Canada.  The chairpersons were Appa Hungund and George Koob.  The presentations were (1) role of endocannabinoids in ethanol tolerance, by Appa Hungund; (2) modulation of cannabinoid receptor and its signal transduction in chronic alcoholism, by B. S. Basavarajappa; (3) endocannabinoid involvement in the control of appetitive behavior, by George Kunos; (4) regulation of voluntary ethanol intake by cannabinoid receptor agonists and antagonists in alc.-preferring sP rats, by Giancarlo Colombo; (5) role of endogenous cannabinoid system in alcoholism, by Fernado Rodriguez de Fonseca; and (6) Endocannabinoids and dopamine interactions in vivo, by Loren Parsons and George Koob.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL6exDvhzxF7Vg90H21EOLACvtfcHk0lhZpe_hemZtgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVSmsLY%253D&md5=a747925f1fbc11eac8b5158e46bfd5b4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1530-0277.2002.tb02575.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1530-0277.2002.tb02575.x%26sid%3Dliteratum%253Aachs%26aulast%3DHungund%26aufirst%3DB.%2BL.%26aulast%3DBasavarajappa%26aufirst%3DB.%2BS.%26aulast%3DVadasz%26aufirst%3DC.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DRodriguez%2Bde%2BFonseca%26aufirst%3DF.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DSerra%26aufirst%3DS.%26aulast%3DParsons%26aufirst%3DL.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26atitle%3DEthanol%252C%2520Endocannabinoids%252C%2520and%2520the%2520Cannabinoidergic%2520Signaling%2520System%26jtitle%3DAlcohol.%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2002%26volume%3D26%26spage%3D565%26epage%3D574%26doi%3D10.1111%2Fj.1530-0277.2002.tb02575.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Le Foll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, S. R.</span><span> </span><span class="NLM_article-title">Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">883</span><span class="refDoi"> DOI: 10.1124/jpet.104.077974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1124%2Fjpet.104.077974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=15525797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVOhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=875-883&author=B.+Le+Follauthor=S.+R.+Goldberg&title=Cannabinoid+CB1+Receptor+Antagonists+as+Promising+New+Medications+for+Drug+Dependence&doi=10.1124%2Fjpet.104.077974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence</span></div><div class="casAuthors">Le Foll, Bernard; Goldberg, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">875-883</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This review examines the development of cannabinoid CB1 receptor antagonists as a new class of therapeutic agents for drug addiction.  Abused drugs [alc., opiates, Δ9-tetrahydrocannabinol (Δ9-THC), and psychostimulants, including nicotine] elicit a variety of chronically relapsing disorders by interacting with endogenous neural pathways in the brain.  In particular, they share the common property of activating mesolimbic dopamine brain reward systems, and virtually all abused drugs elevate dopamine levels in the nucleus accumbens.  Cannabinoid CB1 receptors are expressed in this brain reward circuit and modulate the dopamine-releasing effects of Δ9-THC and nicotine.  Rimonabant (SR141716), a CB1 receptor antagonist, blocks both the dopamine-releasing and discriminative and rewarding effects of Δ9-THC in animals.  Blockade of CB1 receptor activity by genetic invalidation also decreases rewarding effects of opiates and alc. in animals.  Although CB1 receptor blockade is generally ineffective in reducing the self-administration of cocaine in rodents and primates, it reduces the reinstatement of extinguished cocaine-seeking behavior produced by cocaine-assocd. conditioned stimuli and cocaine-priming injections.  Likewise, CB1 receptor blockade is effective in reducing nicotine-seeking behavior induced by re-exposure to nicotine-assocd. stimuli.  Some of these findings have been recently validated in humans.  In clin. trials, Rimonabant blocks the subjective effects of Δ9-THC in humans and prevents relapse to smoking in ex-smokers.  Findings from both clin. and preclin. studies suggest that ligands blocking CB1 receptors offer a novel approach for patients suffering from drug dependence that may be efficacious across different classes of abused drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBmGfksQ6N0LVg90H21EOLACvtfcHk0lh6w4UjefoGhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVOhtbo%253D&md5=c147d69b248ce0da7078ac98f327e79b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.077974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.077974%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BFoll%26aufirst%3DB.%26aulast%3DGoldberg%26aufirst%3DS.%2BR.%26atitle%3DCannabinoid%2520CB1%2520Receptor%2520Antagonists%2520as%2520Promising%2520New%2520Medications%2520for%2520Drug%2520Dependence%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D875%26epage%3D883%26doi%3D10.1124%2Fjpet.104.077974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">Cannabinoids and the Gastrointestinal Tract</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">859</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span><span class="refDoi"> DOI: 10.1136/gut.48.6.859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1136%2Fgut.48.6.859" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2001&pages=859-867&author=R.+G.+Pertwee&title=Cannabinoids+and+the+Gastrointestinal+Tract&doi=10.1136%2Fgut.48.6.859"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1136%2Fgut.48.6.859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.48.6.859%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DCannabinoids%2520and%2520the%2520Gastrointestinal%2520Tract%26jtitle%3DGut%26date%3D2001%26volume%3D48%26spage%3D859%26epage%3D867%26doi%3D10.1136%2Fgut.48.6.859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1553</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span><span class="refDoi"> DOI: 10.1517/13543784.9.7.1553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1517%2F13543784.9.7.1553" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=1553-1571&author=R.+G.+Pertwee&title=Cannabinoid+Receptor+Ligands%3A+Clinical+and+Neuropharmacological+Considerations%2C+Relevant+to+Future+Drug+Discovery+and+Development&doi=10.1517%2F13543784.9.7.1553"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F13543784.9.7.1553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.9.7.1553%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DCannabinoid%2520Receptor%2520Ligands%253A%2520Clinical%2520and%2520Neuropharmacological%2520Considerations%252C%2520Relevant%2520to%2520Future%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2000%26volume%3D9%26spage%3D1553%26epage%3D1571%26doi%3D10.1517%2F13543784.9.7.1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Black, S. C.</span><span> </span><span class="NLM_article-title">Cannabinoid Receptor Antagonists and Obesity</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=389-394&author=S.+C.+Black&title=Cannabinoid+Receptor+Antagonists+and+Obesity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DS.%2BC.%26atitle%3DCannabinoid%2520Receptor%2520Antagonists%2520and%2520Obesity%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs.%26date%3D2004%26volume%3D5%26spage%3D389%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Giannone, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldassarre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domenicali, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaccherini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trevisani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caraceni, P.</span><span> </span><span class="NLM_article-title">Reversal of Liver Fibrosis by the Antagonism of Endocannabinoid CB1 Receptor in a Rat Model of CCl(4)-Induced Advanced Cirrhosis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">384</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span><span class="refDoi"> DOI: 10.1038/labinvest.2011.191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Flabinvest.2011.191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=22184091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=384-395&author=F.+A.+Giannoneauthor=M.+Baldassarreauthor=M.+Domenicaliauthor=G.+Zaccheriniauthor=F.+Trevisaniauthor=M.+Bernardiauthor=P.+Caraceni&title=Reversal+of+Liver+Fibrosis+by+the+Antagonism+of+Endocannabinoid+CB1+Receptor+in+a+Rat+Model+of+CCl%284%29-Induced+Advanced+Cirrhosis&doi=10.1038%2Flabinvest.2011.191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis</span></div><div class="casAuthors">Giannone, Ferdinando A.; Baldassarre, Maurizio; Domenicali, Marco; Zaccherini, Giacomo; Trevisani, Franco; Bernardi, Mauro; Caraceni, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-395</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The endocannabinoid system is involved in the pathogenesis of liver fibrosis.  Although many substances have been proved to reduce fibrosis in exptl. models of chronic liver injury, most of them appear to be effective only if given as a prophylactic or early treatment.  This study aimed to explore the effect of pharmacol. antagonism of the endocannabinoid cannabinoid type 1 (CB1) receptor started after the stage of full-blown cirrhosis had been reached.  Wistar-Han rats with carbon tetrachloride (CCl4)-induced cirrhosis were randomized to receive the CB1 receptor antagonist Rimonabant (10 mg/kg/day) or the vehicle for 2 wk.  Age-matched healthy rats served as controls.  Liver fibrosis was assessed using Sirius red staining, hydroxyproline concn. and α-smooth muscle actin expression.  Hepatic gene expression of mediators of fibrogenesis and inflammation were evaluated by real-time PCR.  We also assessed the hepatic expression of CB1 and CB2 receptors and that of the enzymes implicated in the endocannabinoid metab.  Fibrosis was significantly reduced in rats treated with Rimonabant compared with rats receiving the vehicle.  CB1 receptor antagonism limited the gene upregulation of fibrogenic and inflammatory mediators occurring in untreated cirrhotic rats.  CB1 and CB2 receptor expression was increased in cirrhotic animals.  Interestingly, pharmacol. CB1 receptor antagonism was assocd. with a further induction of the CB2 receptor expression.  Regression of fibrosis can be achieved by pharmacol. blockade of the CB1 receptor even when started in an advanced stage of the disease.  This effect is assocd. with the suppression of pro-fibrogenic and inflammatory mediators and may have been indirectly favored by the induction of CB2 receptor expression.  Lab. Investigation (2012) 92, 384-395; doi:10.1038/labinvest.2011.191; published online 19 Dec. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPmVZMX8omDbVg90H21EOLACvtfcHk0lh3pYzFriuu8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOjtbg%253D&md5=3e4d30f78fe6daa045b628e0c24b0d0e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2011.191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2011.191%26sid%3Dliteratum%253Aachs%26aulast%3DGiannone%26aufirst%3DF.%2BA.%26aulast%3DBaldassarre%26aufirst%3DM.%26aulast%3DDomenicali%26aufirst%3DM.%26aulast%3DZaccherini%26aufirst%3DG.%26aulast%3DTrevisani%26aufirst%3DF.%26aulast%3DBernardi%26aufirst%3DM.%26aulast%3DCaraceni%26aufirst%3DP.%26atitle%3DReversal%2520of%2520Liver%2520Fibrosis%2520by%2520the%2520Antagonism%2520of%2520Endocannabinoid%2520CB1%2520Receptor%2520in%2520a%2520Rat%2520Model%2520of%2520CCl%25284%2529-Induced%2520Advanced%2520Cirrhosis%26jtitle%3DLab.%2520Invest.%26date%3D2012%26volume%3D92%26spage%3D384%26epage%3D395%26doi%3D10.1038%2Flabinvest.2011.191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Teixeira-Clerc, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Julien, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran Van Nhieu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deveaux, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serriere-Lanneau, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ledent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotersztajn, S.</span><span> </span><span class="NLM_article-title">CB1 Cannabinoid Receptor Antagonism: A New Strategy for the Treatment of Liver Fibrosis</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span><span class="refDoi"> DOI: 10.1038/nm1421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Fnm1421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=16715087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlOjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=671-676&author=F.+Teixeira-Clercauthor=B.+Julienauthor=P.+Grenardauthor=J.+Tran+Van+Nhieuauthor=V.+Deveauxauthor=L.+Liauthor=V.+Serriere-Lanneauauthor=C.+Ledentauthor=A.+Mallatauthor=S.+Lotersztajn&title=CB1+Cannabinoid+Receptor+Antagonism%3A+A+New+Strategy+for+the+Treatment+of+Liver+Fibrosis&doi=10.1038%2Fnm1421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis</span></div><div class="casAuthors">Teixeira-Clerc, Fatima; Julien, Boris; Grenard, Pascale; Van Nhieu, Jeanne Tran; Deveaux, Vanessa; Li, Liying; Serriere-Lanneau, Valerie; Ledent, Catherine; Mallat, Ariane; Lotersztajn, Sophie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-676</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatic fibrosis, the common response assocd. with chronic liver diseases, ultimately leads to cirrhosis, a major public health problem worldwide.  We recently showed that activation of hepatic cannabinoid CB2 receptors limits progression of exptl. liver fibrosis.  We also found that during the course of chronic hepatitis C, daily cannabis use is an independent predictor of fibrosis progression.  Overall, these results suggest that endocannabinoids may drive both CB2-mediated antifibrogenic effects and CB2-independent profibrogenic effects.  Here we investigated whether activation of cannabinoid CB1 receptors (encoded by Cnr1) promotes progression of fibrosis.  CB1 receptors were highly induced in human cirrhotic samples and in liver fibrogenic cells.  Treatment with the CB1 receptor antagonist SR141716A decreased the wound-healing response to acute liver injury and inhibited progression of fibrosis in three models of chronic liver injury.  We saw similar changes in Cnr1-/- mice as compared to wild-type mice.  Genetic or pharmacol. inactivation of CB1 receptors decreased fibrogenesis by lowering hepatic transforming growth factor (TGF)-β1 and reducing accumulation of fibrogenic cells in the liver after apoptosis and growth inhibition of hepatic myofibroblasts.  In conclusion, our study shows that CB1 receptor antagonists hold promise for the treatment of liver fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaGl6D8ATtLLVg90H21EOLACvtfcHk0lh3pYzFriuu8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlOjtrw%253D&md5=c1e3eb1af474600c3d0d0a4fd9ae2013</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnm1421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1421%26sid%3Dliteratum%253Aachs%26aulast%3DTeixeira-Clerc%26aufirst%3DF.%26aulast%3DJulien%26aufirst%3DB.%26aulast%3DGrenard%26aufirst%3DP.%26aulast%3DTran%2BVan%2BNhieu%26aufirst%3DJ.%26aulast%3DDeveaux%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSerriere-Lanneau%26aufirst%3DV.%26aulast%3DLedent%26aufirst%3DC.%26aulast%3DMallat%26aufirst%3DA.%26aulast%3DLotersztajn%26aufirst%3DS.%26atitle%3DCB1%2520Cannabinoid%2520Receptor%2520Antagonism%253A%2520A%2520New%2520Strategy%2520for%2520the%2520Treatment%2520of%2520Liver%2520Fibrosis%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D671%26epage%3D676%26doi%3D10.1038%2Fnm1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Nanthakumar, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauldie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J.</span><span> </span><span class="NLM_article-title">Dissecting Fibrosis: Therapeutic Insights from the Small-Molecule Toolbox</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span><span class="refDoi"> DOI: 10.1038/nrd4592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Fnrd4592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=26338155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=693-720&author=C.+B.+Nanthakumarauthor=R.+J.+Hatleyauthor=S.+Lemmaauthor=J.+Gauldieauthor=R.+P.+Marshallauthor=S.+J.+Macdonald&title=Dissecting+Fibrosis%3A+Therapeutic+Insights+from+the+Small-Molecule+Toolbox&doi=10.1038%2Fnrd4592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span></div><div class="casAuthors">Nanthakumar, Carmel B.; Hatley, Richard J. D.; Lemma, Seble; Gauldie, Jack; Marshall, Richard P.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-720</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis, which leads to progressive loss of tissue function and eventual organ failure, has been estd. to contribute to ∼45% of deaths in the developed world, and so new therapeutics to modulate fibrosis are urgently needed.  Major advances in our understanding of the mechanisms underlying pathol. fibrosis are supporting the search for such therapeutics, and the recent approval of two anti-fibrotic drugs for idiopathic pulmonary fibrosis has demonstrated the tractability of this area for drug discovery.  This Review examines the pharmacol. and structural information for small mols. being evaluated for lung, liver, kidney and skin fibrosis.  In particular, we discuss the insights gained from the use of these pharmacol. tools, and how these entities can inform, and probe, emerging insights into disease mechanisms, including the potential for future drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk6pfSk3gsCrVg90H21EOLACvtfcHk0lh3pYzFriuu8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ&md5=b05a37db6ede2acc0f5c65826aa344f3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrd4592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4592%26sid%3Dliteratum%253Aachs%26aulast%3DNanthakumar%26aufirst%3DC.%2BB.%26aulast%3DHatley%26aufirst%3DR.%2BJ.%26aulast%3DLemma%26aufirst%3DS.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26atitle%3DDissecting%2520Fibrosis%253A%2520Therapeutic%2520Insights%2520from%2520the%2520Small-Molecule%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D693%26epage%3D720%26doi%3D10.1038%2Fnrd4592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Janero, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span> </span><span class="NLM_article-title">Cannabinoid Receptor Antagonists: Pharmacological Opportunities, Clinical Experience, and Translational Prognosis</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.1517/14728210902736568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1517%2F14728210902736568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=19249987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivFSmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=43-65&author=D.+R.+Janeroauthor=A.+Makriyannis&title=Cannabinoid+Receptor+Antagonists%3A+Pharmacological+Opportunities%2C+Clinical+Experience%2C+and+Translational+Prognosis&doi=10.1517%2F14728210902736568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis</span></div><div class="casAuthors">Janero, David R.; Makriyannis, Alexandros</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-65</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The endogenous cannabinoid (CB) (endocannabinoid) signaling system is involved in a variety of (patho)physiol. processes, primarily by virtue of natural, arachidonic acid-derived lipids (endocannabinoids) that activate G protein-coupled CB1 and CB2 receptors.  A hyperactive endocannabinoid system appears to contribute to the etiol. of several disease states that constitute significant global threats to human health.  Consequently, mounting interest surrounds the design and profiling of receptor-targeted CB antagonists as pharmacotherapeutics that attenuate endocannabinoid transmission for salutary gain.  Exptl. and clin. evidence supports the therapeutic potential of CB1 receptor antagonists to treat overweight/obesity, obesity-related cardiometabolic disorders, and substance abuse.  Lab. data suggest that CB2 receptor antagonists might be effective immunomodulatory and, perhaps, anti-inflammatory drugs.  One CB1 receptor antagonist/inverse agonist, rimon-abant, has emerged as the first-in-class drug approved outside the United States for wt. control.  Select follow-on agents (taranabant, otenabant, surinabant, rosonabant, SLV-319, AVE1625, V24343) have also been studied in the clinic.  However, rimonabant's market withdrawal in the European Union and suspension of rimonabant's, taranabant's, and otenabant's ongoing development programs have highlighted some adverse clin. side effects (esp. nausea and psychiatric disturbances) of CB1 receptor antagonists/inverse agonists.  Novel CB1 receptor ligands that are peripherally directed and/or exhibit neutral antagonism (the latter not affecting constitutive CB1 receptor signaling) may optimize the benefits of CB1 receptor antagonists while minimizing any risk.  Indeed, CB1 receptor-neutral antagonists appear from preclin. data to offer efficacy comparable to or better than that of prototype CB1 receptor antagonists/inverse agonists, with less propensity to induce nausea.  Continued pharmacol. profiling, as the prelude to first-in-man testing of CB1 receptor antagonists with unique modes of targeting/pharmacol. action, represents an exciting translational frontier in the crit. path to CB receptor blockers as medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCAfak12FUrVg90H21EOLACvtfcHk0lin4S1iwfiOfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivFSmtbc%253D&md5=7d862d2ded309124a4d753e568b275fa</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F14728210902736568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728210902736568%26sid%3Dliteratum%253Aachs%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DMakriyannis%26aufirst%3DA.%26atitle%3DCannabinoid%2520Receptor%2520Antagonists%253A%2520Pharmacological%2520Opportunities%252C%2520Clinical%2520Experience%252C%2520and%2520Translational%2520Prognosis%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2009%26volume%3D14%26spage%3D43%26epage%3D65%26doi%3D10.1517%2F14728210902736568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Patel, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, R.</span><span> </span><span class="NLM_article-title">Rimonabant: A Novel Selective Cannabinoid-1 Receptor Antagonist for Treatment of Obesity</span> <span class="citation_source-journal">Am. J. Health-Syst. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span><span class="refDoi"> DOI: 10.2146/060258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.2146%2F060258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=17322160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsF2nsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=481-489&author=P.+N.+Patelauthor=R.+Pathak&title=Rimonabant%3A+A+Novel+Selective+Cannabinoid-1+Receptor+Antagonist+for+Treatment+of+Obesity&doi=10.2146%2F060258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity</span></div><div class="casAuthors">Patel, Priti N.; Pathak, Rolee</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-489</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">A review.  Purpose: The pharmacol., pharmacokinetics, clin. efficacy, safety, drug interactions, and dosage and administration of rimonabant in the treatment of obesity and related metabolic factors are reviewed.  Summary: Discovery of the cannabinoid receptors has led to the development of rimonabant, a cannabinoid-1 (CB1) antagonist.  Selective blockade of this receptor has been shown to lead to decreased appetite and food intake in animal models.  Clin. studies have shown that rimonabant 20 mg once daily produces significant decreases in wt. and waist circumference in obese human subjects and improves the lipid profile and glucose control.  The frequency of metabolic syndrome also decreased significantly with rimonabant 20 mg daily.  Limited data are available regarding the pharmacokinetics and pharmacodynamics of rimonabant.  Preclin. data have demonstrated a long duration of action.  As of yet, no drug-drug, drug-food, or drug-disease interactions have been identified with rimonabant.  Adverse reactions occurred rarely, with nausea, dizziness, diarrhea, arthralgia, and back pain being the most common.  Psychiatric disorders, including depression and anxiety, were the most common reasons for subjects to withdraw from rimonabant studies.  Rimonabant has been shown to be safe for up to two years of treatment.  Further research will clarify currently unknown areas, including pharmacokinetics, drug interactions, and the drug's role in std. therapy.  Conclusion: Rimonabant, a selective CB1 antagonist, is a novel treatment option for obese and overweight individuals.  Significant wt. loss, decrease in waist circumference, and improvements in lipid profile and glucose control have been shown in clin. trials of rimonabant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgzvUSUcPsmLVg90H21EOLACvtfcHk0lin4S1iwfiOfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsF2nsbw%253D&md5=43fd1adda4b9d606cb761fe965b08b8d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2146%2F060258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252F060258%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BN.%26aulast%3DPathak%26aufirst%3DR.%26atitle%3DRimonabant%253A%2520A%2520Novel%2520Selective%2520Cannabinoid-1%2520Receptor%2520Antagonist%2520for%2520Treatment%2520of%2520Obesity%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2007%26volume%3D64%26spage%3D481%26epage%3D489%26doi%3D10.2146%2F060258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ward, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffa, R. B.</span><span> </span><span class="NLM_article-title">Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral-Antagonist/inverse-Agonist Therapies</span> <span class="citation_source-journal">Obesity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1325</span><span class="NLM_x">–</span> <span class="NLM_lpage">1334</span><span class="refDoi"> DOI: 10.1038/oby.2011.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Foby.2011.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=21475141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnjt1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1325-1334&author=S.+J.+Wardauthor=R.+B.+Raffa&title=Rimonabant+Redux+and+Strategies+to+Improve+the+Future+Outlook+of+CB1+Receptor+Neutral-Antagonist%2Finverse-Agonist+Therapies&doi=10.1038%2Foby.2011.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies</span></div><div class="casAuthors">Ward Sara Jane; Raffa Robert B</div><div class="citationInfo"><span class="NLM_cas:title">Obesity (Silver Spring, Md.)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1325-34</span>
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTq32LoUyLn5Ptos8R3JUhXfW6udTcc2eYDYpA_3p_Na7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnjt1OisQ%253D%253D&md5=17cafba99c5cc057e96c9bc3437f944a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Foby.2011.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foby.2011.69%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DS.%2BJ.%26aulast%3DRaffa%26aufirst%3DR.%2BB.%26atitle%3DRimonabant%2520Redux%2520and%2520Strategies%2520to%2520Improve%2520the%2520Future%2520Outlook%2520of%2520CB1%2520Receptor%2520Neutral-Antagonist%252Finverse-Agonist%2520Therapies%26jtitle%3DObesity%26date%3D2011%26volume%3D19%26spage%3D1325%26epage%3D1334%26doi%3D10.1038%2Foby.2011.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Chorvat, R. J.</span><span> </span><span class="NLM_article-title">Peripherally Restricted CB1 Receptor Blockers</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4751</span><span class="NLM_x">–</span> <span class="NLM_lpage">4760</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2Fj.bmcl.2013.06.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=23902803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Sjtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4751-4760&author=R.+J.+Chorvat&title=Peripherally+Restricted+CB1+Receptor+Blockers&doi=10.1016%2Fj.bmcl.2013.06.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Peripherally restricted CB1 receptor blockers</span></div><div class="casAuthors">Chorvat, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4751-4760</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antagonists (inverse agonists) of the cannabinoid-1 (CB1) receptor showed promise as new therapies for controlling obesity and related metabolic function/liver disease.  These agents, representing diverse chem. series, shared the property of brain penetration due to the initial belief that therapeutic benefit was mainly based on brain receptor interaction.  However, undesirable CNS-based side effects of the only marketed agent in this class, rimonabant, led to its removal, and termination of the development of other clin. candidates soon followed.  Re-evaluation of this approach has focused on neutral or peripherally restricted (PR) antagonists.  Supporting these strategies, pharmacol. evidence indicates most if not all of the properties of globally acting agents may be captured by mols. with little brain presence.  Methodol. that can be used to eliminate BBB penetration and the means (in vitro assays, tissue distribution and receptor occupancy detns., behavioral paradigms) to identify potential agents with little brain presence is discussed.  Focus will be on the pharmacol. supporting the contention that reported agents are truly peripherally restricted.  Notable examples of these types of compds. are: TM38837 (structure not disclosed); AM6545 (8); JD5037 (15b); RTI-12 (19).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVjNs61m-GtLVg90H21EOLACvtfcHk0lgK4cmlbl0hVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Sjtb3O&md5=b124aabace6d82a2fd23fa75681786d4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.066%26sid%3Dliteratum%253Aachs%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26atitle%3DPeripherally%2520Restricted%2520CB1%2520Receptor%2520Blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4751%26epage%3D4760%26doi%3D10.1016%2Fj.bmcl.2013.06.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Fulp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortoff, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marusich, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seltzman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitra, R.</span><span> </span><span class="NLM_article-title">Peripherally Selective Diphenyl Purine Antagonist of the CB1 Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8066</span><span class="NLM_x">–</span> <span class="NLM_lpage">8072</span><span class="refDoi"> DOI: 10.1021/jm401129n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401129n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8066-8072&author=A.+Fulpauthor=K.+Bortoffauthor=Y.+Zhangauthor=R.+Snyderauthor=T.+Fennellauthor=J.+A.+Marusichauthor=J.+L.+Wileyauthor=H.+Seltzmanauthor=R.+Maitra&title=Peripherally+Selective+Diphenyl+Purine+Antagonist+of+the+CB1+Receptor&doi=10.1021%2Fjm401129n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm401129n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401129n%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DT.%26aulast%3DMarusich%26aufirst%3DJ.%2BA.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DPeripherally%2520Selective%2520Diphenyl%2520Purine%2520Antagonist%2520of%2520the%2520CB1%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8066%26epage%3D8072%26doi%3D10.1021%2Fjm401129n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zhu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macielag, M. J.</span><span> </span><span class="NLM_article-title">Tetrahydropyrazolo[4,3-c]pyridine Derivatives as Potent and Peripherally Selective Cannabinoid-1 (CB1) Receptor Inverse Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5597</span><span class="NLM_x">–</span> <span class="NLM_lpage">5601</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2Fj.bmcl.2016.09.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5597-5601&author=B.+Zhuauthor=J.+M.+Matthewsauthor=M.+Xiaauthor=S.+Blackauthor=C.+Chenauthor=C.+Houauthor=Y.+Liangauthor=Y.+Tangauthor=M.+J.+Macielag&title=Tetrahydropyrazolo%5B4%2C3-c%5Dpyridine+Derivatives+as+Potent+and+Peripherally+Selective+Cannabinoid-1+%28CB1%29+Receptor+Inverse+Agonists&doi=10.1016%2Fj.bmcl.2016.09.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DB.%26aulast%3DMatthews%26aufirst%3DJ.%2BM.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DMacielag%26aufirst%3DM.%2BJ.%26atitle%3DTetrahydropyrazolo%255B4%252C3-c%255Dpyridine%2520Derivatives%2520as%2520Potent%2520and%2520Peripherally%2520Selective%2520Cannabinoid-1%2520%2528CB1%2529%2520Receptor%2520Inverse%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5597%26epage%3D5601%26doi%3D10.1016%2Fj.bmcl.2016.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Tam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szanda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chedester, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liow, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innis, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschamps, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorvat, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance</span> <span class="citation_source-journal">Cell Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.1016/j.cmet.2012.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2Fj.cmet.2012.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=22841573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFahsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=167-179&author=J.+Tamauthor=R.+Cinarauthor=J.+Liuauthor=G.+Godlewskiauthor=D.+Wesleyauthor=T.+Jourdanauthor=G.+Szandaauthor=B.+Mukhopadhyayauthor=L.+Chedesterauthor=J.+S.+Liowauthor=R.+B.+Innisauthor=K.+Chengauthor=K.+C.+Riceauthor=J.+R.+Deschampsauthor=R.+J.+Chorvatauthor=J.+F.+McElroyauthor=G.+Kunos&title=Peripheral+Cannabinoid-1+Receptor+Inverse+Agonism+Reduces+Obesity+by+Reversing+Leptin+Resistance&doi=10.1016%2Fj.cmet.2012.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance</span></div><div class="casAuthors">Tam, Joseph; Cinar, Resat; Liu, Jie; Godlewski, Grzegorz; Wesley, Daniel; Jourdan, Tony; Szanda, Gergo; Mukhopadhyay, Bani; Chedester, Lee; Liow, Jeih-San; Innis, Robert B.; Cheng, Kejun; Rice, Kenner C.; Deschamps, Jeffrey R.; Chorvat, Robert J.; McElroy, John F.; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-179</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Obesity-related leptin resistance manifests in loss of leptin's ability to reduce appetite and increase energy expenditure.  Obesity is also assocd. with increased activity of the endocannabinoid system, and CB1 receptor (CB1R) inverse agonists reduce body wt. and the assocd. metabolic complications, although adverse neuropsychiatric effects halted their therapeutic development.  In mice with diet-induced obesity (DIO), the peripherally restricted CB1R inverse agonist JD5037 is equieffective with its brain-penetrant parent compd. in reducing appetite, body wt., hepatic steatosis, and insulin resistance, even though it does not occupy central CB1R or induce related behaviors.  Appetite and wt. redn. by JD5037 are mediated by resensitizing DIO mice to endogenous leptin through reversing the hyperleptinemia by decreasing leptin expression and secretion by adipocytes and increasing leptin clearance via the kidney.  Thus, inverse agonism at peripheral CB1R not only improves cardiometabolic risk in obesity but has antiobesity effects by reversing leptin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXZCRIXdM8qLVg90H21EOLACvtfcHk0lgK4cmlbl0hVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFahsL%252FO&md5=412b24018a9a1620ebf533f5195b1659</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2012.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2012.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DWesley%26aufirst%3DD.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DChedester%26aufirst%3DL.%26aulast%3DLiow%26aufirst%3DJ.%2BS.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520Cannabinoid-1%2520Receptor%2520Inverse%2520Agonism%2520Reduces%2520Obesity%2520by%2520Reversing%2520Leptin%2520Resistance%26jtitle%3DCell%2520Metab.%26date%3D2012%26volume%3D16%26spage%3D167%26epage%3D179%26doi%3D10.1016%2Fj.cmet.2012.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Tam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vemuri, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bátkai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osei-Hyiaman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohnuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambudkar, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makriyannis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Peripheral CB1 Cannabinoid Receptor Blockade Improves Cardiometabolic Risk in Mouse Models of Obesity</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2953</span><span class="NLM_x">–</span> <span class="NLM_lpage">2966</span><span class="refDoi"> DOI: 10.1172/JCI42551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1172%2FJCI42551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=20664173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaiurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2010&pages=2953-2966&author=J.+Tamauthor=V.+K.+Vemuriauthor=J.+Liuauthor=S.+B%C3%A1tkaiauthor=B.+Mukhopadhyayauthor=G.+Godlewskiauthor=D.+Osei-Hyiamanauthor=S.+Ohnumaauthor=S.+V.+Ambudkarauthor=J.+Pickelauthor=A.+Makriyannisauthor=G.+Kunos&title=Peripheral+CB1+Cannabinoid+Receptor+Blockade+Improves+Cardiometabolic+Risk+in+Mouse+Models+of+Obesity&doi=10.1172%2FJCI42551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity</span></div><div class="casAuthors">Tam, Joseph; Vemuri, V. Kiran; Liu, Jie; Batkai, Sandor; Mukhopadhyay, Bani; Godlewski, Grzegorz; Osei-Hyiaman, Douglas; Ohnuma, Shinobu; Ambudkar, Suresh V.; Pickel, James; Makriyannis, Alexandros; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2953-2966</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Obesity and its metabolic consequences are a major public health concern worldwide.  Obesity is assocd. with overactivity of the endocannabinoid system, which is involved in the regulation of appetite, lipogenesis, and insulin resistance.  Cannabinoid-1 receptor (CB1R) antagonists reduce body wt. and improve cardiometabolic abnormalities in exptl. and human obesity, but their therapeutic potential is limited by neuropsychiatric side effects.  Here we have demonstrated that a CB1R neutral antagonist largely restricted to the periphery does not affect behavioral responses mediated by CB1R in the brains of mice with genetic or diet-induced obesity, but it does cause wt.-independent improvements in glucose homeostasis, fatty liver, and plasma lipid profile.  These effects were due to blockade of CB1R in peripheral tissues, including the liver, as verified through the use of CB1R-deficient mice with or without transgenic expression of CB1R in the liver.  These results suggest that targeting peripheral CB1R has therapeutic potential for alleviating cardiometabolic risk in obese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0VCuCx5tmorVg90H21EOLACvtfcHk0ljkq5GRDJyEUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaiurzM&md5=ba383f0abb4642df9843f6ee5784ecb4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1172%2FJCI42551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI42551%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DVemuri%26aufirst%3DV.%2BK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DB%25C3%25A1tkai%26aufirst%3DS.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DOsei-Hyiaman%26aufirst%3DD.%26aulast%3DOhnuma%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DPickel%26aufirst%3DJ.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DPeripheral%2520CB1%2520Cannabinoid%2520Receptor%2520Blockade%2520Improves%2520Cardiometabolic%2520Risk%2520in%2520Mouse%2520Models%2520of%2520Obesity%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2010%26volume%3D120%26spage%3D2953%26epage%3D2966%26doi%3D10.1172%2FJCI42551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Cinar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdelyi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szanda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, A. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenz, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innis, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Hybrid Inhibitor of Peripheral Cannabinoid-1 Receptors and Inducible Nitric Oxide Synthase Mitigates Liver Fibrosis</span> <span class="citation_source-journal">JCI. Insight</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e87336</span><span class="refDoi"> DOI: 10.1172/jci.insight.87336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1172%2Fjci.insight.87336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e87336&author=R.+Cinarauthor=M.+R.+Iyerauthor=Z.+Liuauthor=Z.+Caoauthor=T.+Jourdanauthor=K.+Erdelyiauthor=G.+Godlewskiauthor=G.+Szandaauthor=J.+Liuauthor=J.+K.+Parkauthor=B.+Mukhopadhyayauthor=A.+Z.+Rosenbergauthor=J.+Lieowauthor=R.+G.+Lorenzauthor=P.+Pacherauthor=R.+B.+Innisauthor=G.+Kunos&title=Hybrid+Inhibitor+of+Peripheral+Cannabinoid-1+Receptors+and+Inducible+Nitric+Oxide+Synthase+Mitigates+Liver+Fibrosis&doi=10.1172%2Fjci.insight.87336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.87336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.87336%26sid%3Dliteratum%253Aachs%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DErdelyi%26aufirst%3DK.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DRosenberg%26aufirst%3DA.%2BZ.%26aulast%3DLieow%26aufirst%3DJ.%26aulast%3DLorenz%26aufirst%3DR.%2BG.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DHybrid%2520Inhibitor%2520of%2520Peripheral%2520Cannabinoid-1%2520Receptors%2520and%2520Inducible%2520Nitric%2520Oxide%2520Synthase%2520Mitigates%2520Liver%2520Fibrosis%26jtitle%3DJCI.%2520Insight%26date%3D2016%26volume%3D1%26spage%3De87336%26doi%3D10.1172%2Fjci.insight.87336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Lange, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coolen, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Stuivenberg, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijksman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herremans, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronken, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keizer, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreary, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veerman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wals, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stork, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verveer, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">den Hartog, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jong, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolfs, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogendoorn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB(1) Cannabinoid Receptor Antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1021/jm031019q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031019q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=627-643&author=J.+H.+Langeauthor=H.+K.+Coolenauthor=H.+H.+van+Stuivenbergauthor=J.+A.+Dijksmanauthor=A.+H.+Herremansauthor=E.+Ronkenauthor=H.+G.+Keizerauthor=K.+Tipkerauthor=A.+C.+McCrearyauthor=W.+Veermanauthor=H.+C.+Walsauthor=B.+Storkauthor=P.+C.+Verveerauthor=A.+P.+den+Hartogauthor=N.+M.+de+Jongauthor=T.+J.+Adolfsauthor=J.+Hoogendoornauthor=C.+G.+Kruse&title=Synthesis%2C+Biological+Properties%2C+and+Molecular+Modeling+Investigations+of+Novel+3%2C4-Diarylpyrazolines+as+Potent+and+Selective+CB%281%29+Cannabinoid+Receptor+Antagonists&doi=10.1021%2Fjm031019q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm031019q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031019q%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%26aulast%3DCoolen%26aufirst%3DH.%2BK.%26aulast%3Dvan%2BStuivenberg%26aufirst%3DH.%2BH.%26aulast%3DDijksman%26aufirst%3DJ.%2BA.%26aulast%3DHerremans%26aufirst%3DA.%2BH.%26aulast%3DRonken%26aufirst%3DE.%26aulast%3DKeizer%26aufirst%3DH.%2BG.%26aulast%3DTipker%26aufirst%3DK.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DVeerman%26aufirst%3DW.%26aulast%3DWals%26aufirst%3DH.%2BC.%26aulast%3DStork%26aufirst%3DB.%26aulast%3DVerveer%26aufirst%3DP.%2BC.%26aulast%3Dden%2BHartog%26aufirst%3DA.%2BP.%26aulast%3Dde%2BJong%26aufirst%3DN.%2BM.%26aulast%3DAdolfs%26aufirst%3DT.%2BJ.%26aulast%3DHoogendoorn%26aufirst%3DJ.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DSynthesis%252C%2520Biological%2520Properties%252C%2520and%2520Molecular%2520Modeling%2520Investigations%2520of%2520Novel%25203%252C4-Diarylpyrazolines%2520as%2520Potent%2520and%2520Selective%2520CB%25281%2529%2520Cannabinoid%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D627%26epage%3D643%26doi%3D10.1021%2Fjm031019q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Dai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span> </span><span class="NLM_article-title">Rimonabant Inhibits Proliferation, Collagen Secretion and Induces Apoptosis in Hepatic Stellate Cells</span> <span class="citation_source-journal">Hepatogastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2052</span><span class="NLM_x">–</span> <span class="NLM_lpage">2061</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=25713910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A280%3ADC%252BC2MroslGhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=2052-2061&author=E.+Daiauthor=J.+Zhangauthor=D.+Zhangauthor=L.+Yangauthor=Y.+Wangauthor=X.+Jiangauthor=L.+Yeauthor=X.+Liauthor=H.+Liuauthor=J.+Maauthor=H.+Jiang&title=Rimonabant+Inhibits+Proliferation%2C+Collagen+Secretion+and+Induces+Apoptosis+in+Hepatic+Stellate+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in hepatic stellate cells</span></div><div class="casAuthors">Dai Erhei; Zhang Jian; Zhang Di; Yang Li; Wang Yan; Jiang Xiaoyu; Ye Lihong; Li Xiaojun; Liu Huimin; Ma Junji; Jiang Huiqing</div><div class="citationInfo"><span class="NLM_cas:title">Hepato-gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">135</span>),
    <span class="NLM_cas:pages">2052-61</span>
        ISSN:<span class="NLM_cas:issn">0172-6390</span>.
    </div><div class="casAbstract">BACKGROUND/AIMS:  Liver fibrosis represents a significant health problem worldwide.  Hepatic stellate cells (HSCs) play a critical role in the live fibrosis.  Rimonabant (SR141716) is cannabinoid receptor type 1 (CB1) antagonist.  The pharmacological effects of rimonabant on HSCs are not well characterized in HSCs.  METHODS:  CB1 receptor was detected by immunohistochemistry in human liver fibrosis specimens.  Cell proliferation was detected by MTT assay.  Cell apoptosis, caspase-3 protein expression and cell cycle were detected by TEM and flow cytometry, respectively.  Caspase-3 activity was measured using caspase-3 activity assay kit.  Collagen secretion was evaluated by radioimmunoassay.  CB1 receptor and signaling molecules were evaluated by qRTPCR and Western blot.  RESULTS:  Immunohistochemistry showed a discrete, punctuated CB1 immunoreactivity in human liver fibrosis specimens.  Rimonabant reduced HSC proliferation and increased HSC apoptosis.  Cell cycle analysis showed a decrease in G2/M phase cells and an increase in G0/G1 phase cells in HSC-T6 cells treated with rimonabant.  Caspase-3 protein expression and activity were increased by rimonabant.  Rimonabant decreased collagen secretion in HSC-T6 cells.  Moreover, rimonabant inhibited the expression of phosphorylated FAK and ERK and down-regulated CB1 mRNA expression.  CONCLUSION:  The study provides new insights toward the pharmacological effect of rimonabant on HSCs in vitro.  Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in HSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTa5dwEoYu4sz69zv1FsJFMfW6udTcc2eYmZFU7algRj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MroslGhsQ%253D%253D&md5=fff8cd2bfe46c26a9d43a76316ab76f9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26atitle%3DRimonabant%2520Inhibits%2520Proliferation%252C%2520Collagen%2520Secretion%2520and%2520Induces%2520Apoptosis%2520in%2520Hepatic%2520Stellate%2520Cells%26jtitle%3DHepatogastroenterology%26date%3D2014%26volume%3D61%26spage%3D2052%26epage%3D2061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Anavi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg-Bord, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn-Obercyger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirosh, O.</span><span> </span><span class="NLM_article-title">The Role of iNOS in Cholesterol-Induced Liver Fibrosis</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">914</span><span class="NLM_x">–</span> <span class="NLM_lpage">924</span><span class="refDoi"> DOI: 10.1038/labinvest.2015.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1038%2Flabinvest.2015.67" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=914-924&author=S.+Anaviauthor=M.+Eisenberg-Bordauthor=M.+Hahn-Obercygerauthor=O.+Geninauthor=M.+Pinesauthor=O.+Tirosh&title=The+Role+of+iNOS+in+Cholesterol-Induced+Liver+Fibrosis&doi=10.1038%2Flabinvest.2015.67"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2015.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2015.67%26sid%3Dliteratum%253Aachs%26aulast%3DAnavi%26aufirst%3DS.%26aulast%3DEisenberg-Bord%26aufirst%3DM.%26aulast%3DHahn-Obercyger%26aufirst%3DM.%26aulast%3DGenin%26aufirst%3DO.%26aulast%3DPines%26aufirst%3DM.%26aulast%3DTirosh%26aufirst%3DO.%26atitle%3DThe%2520Role%2520of%2520iNOS%2520in%2520Cholesterol-Induced%2520Liver%2520Fibrosis%26jtitle%3DLab.%2520Invest.%26date%3D2015%26volume%3D95%26spage%3D914%26epage%3D924%26doi%3D10.1038%2Flabinvest.2015.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Tipoe, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liong, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tom, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanji, A. A.</span><span> </span><span class="NLM_article-title">Inhibitors of Inducible Nitric Oxide (NO) Synthase Are More Effective than an NO Donor in Reducing Carbon-Tetrachloride Induced Acute Liver Injury</span> <span class="citation_source-journal">Histol. Histopathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=16874658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlant7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2006&pages=1157-1165&author=G.+L.+Tipoeauthor=T.+M.+Leungauthor=E.+Liongauthor=H.+Soauthor=K.+M.+Leungauthor=T.+Y.+Lauauthor=W.+M.+Tomauthor=M.+L.+Fungauthor=S.+T.+Fanauthor=A.+A.+Nanji&title=Inhibitors+of+Inducible+Nitric+Oxide+%28NO%29+Synthase+Are+More+Effective+than+an+NO+Donor+in+Reducing+Carbon-Tetrachloride+Induced+Acute+Liver+Injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of inducible nitric oxide (NO) synthase are more effective than an NO donor in reducing carbon-tetrachloride induced acute liver injury</span></div><div class="casAuthors">Tipoe, G. L.; Leung, T. M.; Liong, E.; So, H.; Leung, K. M.; Lau, T. Y. H.; Tom, W. M.; Fung, M. L.; Fan, S. T.; Nanji, A. A.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10,11 and 12</span>),
    <span class="NLM_cas:pages">1157-1165</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">The exact functional role of nitric oxide (NO) in liver injury is currently a source of controversy.  NO is enzymically synthesized by nitric oxide synthase (NOS).  In this study, we assessed the role of inducible NOS (iNOS) in carbon tetrachloride (CCl4)-induced acute liver injury using inhibitors of iNOS, and an NO donor.  Adult ICR mice were injected with CCl4 with or without the iNOS inhibitors (5-methylisothiourea hemisulfate [SMT] and 1-N6-(1-iminoethyl)-lysine [L-NIL]) and an NO donor (Sodium Nitroprusside [SNP]).  Blood and liver tissues were collected for anal.  Immunohistochem. (IHC), serum alanine aminotransferase (ALT), serum total 8-isoprostane anal., RT-PCR, Western Blotting (WB) and EMSA were done.  The results showed increased levels of ALT, necrosis, total 8-isoprostane and nitrotyrosine after CCl4 administration.  INOS inhibitors and SNP abrogated these effects but the effect was more pronounced with SMT and L-NIL.  RT-PCR, WB, and IHC in CCl4-treated mice demonstrated upregulation of TNF-α, iNOS, and COX-2.  The administration of iNOS inhibitors with CCl4 diminished the expression of these proinflammatory mediators.  NF-κB was also upregulated in CCl4-treated mice and was reversed in mice pretreated with iNOS inhibitors.  SNP pretreated mice also showed a lower expression of COX-2 when compared with CCl4 treated mice but TNF-α, iNOS and NF-κB activity were unaffected.  We propose that a high level of nitric oxide is assocd. with CCl4-induced acute liver injury and the liver injury can be ameliorated by decreasing the NO level with iNOS inhibitors and an NO donor with the former more effective in reducing CCl4-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXF80dL-7BabVg90H21EOLACvtfcHk0lgj6OLYJKPxHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlant7nM&md5=744fe40d5eb2b45681e0857ef7bfe9d0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTipoe%26aufirst%3DG.%2BL.%26aulast%3DLeung%26aufirst%3DT.%2BM.%26aulast%3DLiong%26aufirst%3DE.%26aulast%3DSo%26aufirst%3DH.%26aulast%3DLeung%26aufirst%3DK.%2BM.%26aulast%3DLau%26aufirst%3DT.%2BY.%26aulast%3DTom%26aufirst%3DW.%2BM.%26aulast%3DFung%26aufirst%3DM.%2BL.%26aulast%3DFan%26aufirst%3DS.%2BT.%26aulast%3DNanji%26aufirst%3DA.%2BA.%26atitle%3DInhibitors%2520of%2520Inducible%2520Nitric%2520Oxide%2520%2528NO%2529%2520Synthase%2520Are%2520More%2520Effective%2520than%2520an%2520NO%2520Donor%2520in%2520Reducing%2520Carbon-Tetrachloride%2520Induced%2520Acute%2520Liver%2520Injury%26jtitle%3DHistol.%2520Histopathol.%26date%3D2006%26volume%3D21%26spage%3D1157%26epage%3D1165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wilcock, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Nostrand, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Previti, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharkholonarehe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitek, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colton, C. A.</span><span> </span><span class="NLM_article-title">Progression of Amyloid Pathology to Alzheimer’s Disease Pathology in an Amyloid Precursor Protein Transgenic Mouse Model by Removal of Nitric Oxide Synthase 2</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1537</span><span class="NLM_x">–</span> <span class="NLM_lpage">1545</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.5066-07.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1523%2FJNEUROSCI.5066-07.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=18272675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvVSrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=1537-1545&author=D.+M.+Wilcockauthor=M.+R.+Lewisauthor=W.+E.+Van+Nostrandauthor=J.+Davisauthor=M.+L.+Previtiauthor=N.+Gharkholonareheauthor=M.+P.+Vitekauthor=C.+A.+Colton&title=Progression+of+Amyloid+Pathology+to+Alzheimer%E2%80%99s+Disease+Pathology+in+an+Amyloid+Precursor+Protein+Transgenic+Mouse+Model+by+Removal+of+Nitric+Oxide+Synthase+2&doi=10.1523%2FJNEUROSCI.5066-07.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2</span></div><div class="casAuthors">Wilcock, Donna M.; Lewis, Matthew R.; Van Nostrand, William E.; Davis, Judianne; Previti, Mary Lou; Gharkholonarehe, Nastaran; Vitek, Michael P.; Colton, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1537-1545</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by three primary pathologies in the brain: amyloid plaques, neurofibrillary tangles, and neuron loss.  Mouse models have been useful for studying components of AD but are limited in their ability to fully recapitulate all pathologies.  We crossed the APPSwDI transgenic mouse, which develops amyloid β (Aβ)-protein deposits only, with a nitric oxide synthase 2 (NOS2) knock-out mouse, which develops no AD-like pathol.  APPSwDI/NOS2-/- mice displayed impaired spatial memory compared with the APPSwDI mice, yet they have unaltered levels of Aβ.  APPSwDI mice do not show tau pathol., whereas APPSwDI/NOS2-/- mice displayed extensive tau pathol. assocd. with regions of dense microvascular amyloid deposition.  Also, APPSwDI mice do not have any neuron loss, whereas the APPSwDI/NOS2-/- mice have significant neuron loss in the hippocampus and subiculum.  Neuropeptide Y neurons have been shown to be particularly vulnerable in AD.  These neurons appear to be particularly vulnerable in the APPSwDI/NOS2-/- mice as we observe a dramatic redn. in the no. of NPY neurons in the hippocampus and subiculum.  These data show that removal of NOS2 from an APP transgenic mouse results in development of a much greater spectrum of AD-like pathol. and behavioral impairments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU_6m33MZwf7Vg90H21EOLACvtfcHk0lgj6OLYJKPxHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvVSrtrw%253D&md5=380f882e4ff5f7c84caeac589d2cdb5d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5066-07.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5066-07.2008%26sid%3Dliteratum%253Aachs%26aulast%3DWilcock%26aufirst%3DD.%2BM.%26aulast%3DLewis%26aufirst%3DM.%2BR.%26aulast%3DVan%2BNostrand%26aufirst%3DW.%2BE.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DPreviti%26aufirst%3DM.%2BL.%26aulast%3DGharkholonarehe%26aufirst%3DN.%26aulast%3DVitek%26aufirst%3DM.%2BP.%26aulast%3DColton%26aufirst%3DC.%2BA.%26atitle%3DProgression%2520of%2520Amyloid%2520Pathology%2520to%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Pathology%2520in%2520an%2520Amyloid%2520Precursor%2520Protein%2520Transgenic%2520Mouse%2520Model%2520by%2520Removal%2520of%2520Nitric%2520Oxide%2520Synthase%25202%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D1537%26epage%3D1545%26doi%3D10.1523%2FJNEUROSCI.5066-07.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Chorvat, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berbaum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seriacki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElroy, J. F.</span><span> </span><span class="NLM_article-title">JD-5006 and JD-5037: Peripherally Restricted (PR) Cannabinoid-1 Receptor Blockers Related to SLV-319 (Ibipinabant) as Metabolic Disorder Therapeutics Devoid of CNS Liabilities</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6173</span><span class="NLM_x">–</span> <span class="NLM_lpage">6180</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2Fj.bmcl.2012.08.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6173-6180&author=R.+J.+Chorvatauthor=J.+Berbaumauthor=K.+Seriackiauthor=J.+F.+McElroy&title=JD-5006+and+JD-5037%3A+Peripherally+Restricted+%28PR%29+Cannabinoid-1+Receptor+Blockers+Related+to+SLV-319+%28Ibipinabant%29+as+Metabolic+Disorder+Therapeutics+Devoid+of+CNS+Liabilities&doi=10.1016%2Fj.bmcl.2012.08.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DChorvat%26aufirst%3DR.%2BJ.%26aulast%3DBerbaum%26aufirst%3DJ.%26aulast%3DSeriacki%26aufirst%3DK.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26atitle%3DJD-5006%2520and%2520JD-5037%253A%2520Peripherally%2520Restricted%2520%2528PR%2529%2520Cannabinoid-1%2520Receptor%2520Blockers%2520Related%2520to%2520SLV-319%2520%2528Ibipinabant%2529%2520as%2520Metabolic%2520Disorder%2520Therapeutics%2520Devoid%2520of%2520CNS%2520Liabilities%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6173%26epage%3D6180%26doi%3D10.1016%2Fj.bmcl.2012.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Grosscurt, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellinga, K.</span><span> </span><span class="NLM_article-title">1-Phenylcarbamoyl-2-Pyrazolines, a New Class of Insecticides. 3. Synthesis and Insecticidal Properties of 3,4-Diphenyl-1-Phenylcarbamoyl-2-Pyrazolines</span> <span class="citation_source-journal">J. Agric. Food Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span><span class="refDoi"> DOI: 10.1021/jf60222a061</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf60222a061" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1979&pages=406-409&author=A.+C.+Grosscurtauthor=R.+Van+Hesauthor=K.+Wellinga&title=1-Phenylcarbamoyl-2-Pyrazolines%2C+a+New+Class+of+Insecticides.+3.+Synthesis+and+Insecticidal+Properties+of+3%2C4-Diphenyl-1-Phenylcarbamoyl-2-Pyrazolines&doi=10.1021%2Fjf60222a061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjf60222a061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf60222a061%26sid%3Dliteratum%253Aachs%26aulast%3DGrosscurt%26aufirst%3DA.%2BC.%26aulast%3DVan%2BHes%26aufirst%3DR.%26aulast%3DWellinga%26aufirst%3DK.%26atitle%3D1-Phenylcarbamoyl-2-Pyrazolines%252C%2520a%2520New%2520Class%2520of%2520Insecticides.%25203.%2520Synthesis%2520and%2520Insecticidal%2520Properties%2520of%25203%252C4-Diphenyl-1-Phenylcarbamoyl-2-Pyrazolines%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D1979%26volume%3D27%26spage%3D406%26epage%3D409%26doi%3D10.1021%2Fjf60222a061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabó, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiemermann, C.</span><span> </span><span class="NLM_article-title">Isothioureas: Potent Inhibitors of Nitric Oxide Synthases with Variable Isoform Selectivity</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">510</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.1995.tb13256.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1111%2Fj.1476-5381.1995.tb13256.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=7533622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADyaK2MXjt12ltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1995&pages=510-516&author=G.+J.+Southanauthor=C.+Szab%C3%B3author=C.+Thiemermann&title=Isothioureas%3A+Potent+Inhibitors+of+Nitric+Oxide+Synthases+with+Variable+Isoform+Selectivity&doi=10.1111%2Fj.1476-5381.1995.tb13256.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity</span></div><div class="casAuthors">Southan, Garry J.; Szabo, Csaba; Thiemermann, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">510-16</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">The induction of a calcium-independent isoform of nitric oxide (NO) synthase (iNOS) and a subsequent enhanced formation of NO has been implicated in the pathophysiol. of a variety of diseases including inflammation and circulatory shock.  Here the authors demonstrate that the S-substituted isothioureas, S-methylisothiourea (SMT), S-(2-aminoethyl)isothiourea (aminoethyl-TU), S-ethylisothiourea (ethyl-TU) and S-isopropylisothiourea (isopropyl-TU) potently inhibit iNOS activity in J774.2 macrophages activated with bacterial endotoxin with EC50 values 8-24 times lower than that of NG-methyl-L-arginine (MeArg) and 200-times lower than that of NG-nitro-L-arginine (L-NO2Arg).  The inhibition of iNOS activity by these S-substituted isothioureas is dose-dependently prevented by excess of L-arginine, suggesting that these isothioureas are competitive inhibitors of iNOS at the L-arginine binding site.  Ethyl-TU and isopropyl-TU are 4-6 times more potent than MeArg in inhibiting the constitutive NOS activity in homogenates of bovine aortic endothelial cells (eNOS) and are more potent pressor agents than MeArg in the anesthetized rat.  SMT is equipotent with MeArg, whereas aminoethyl-TU is 6-times less potent in inhibiting eNOS activity in vitro.  Both SMT and aminoethyl-TU, however, elicit only weak pressor responses (approx. 15 mmHg at 10 mg kg-1, i.v.) in vivo.  A comparison of the potencies of ethyl-, isopropyl-, n-propyl-, t-butyl- and n-butyl-isothioureas on iNOS activity shows that the inhibitory activity of S-substituted isothioureas declines sharply if the side chain exceeds 2 carbon atoms in length.  Similarly, substitution of the ethylene side chain of ethyl-TU also results in a diminished potency.  Substitution of either one or both nitrogens of SMT with either amino or alkyl groups also substantially reduce its NOS inhibitory potency.  In conclusion, isothioureas represent a new class of NOS inhibitors which includes the most potent inhibitors of iNOS activity reported to date.  Some members of this class (ethyl-TU and isopropyl-TU) are potent inhibitors of eNOS and iNOS with little selectivity towards either isoform, while others (SMT and aminoethyl-TU) are relatively selective inhibitors of iNOS activity.  These latter agents may become useful tools for studying the role of iNOS in various disease models and may be useful in the therapy of diseases that are assocd. with an enhanced formation of NO due to iNOS induction, such as inflammation, circulatory shock or cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4rARv43bRL7Vg90H21EOLACvtfcHk0lhYvXiMogIJRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjt12ltLc%253D&md5=bb597041836fc523fdabfe4fc0a1beca</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1995.tb13256.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1995.tb13256.x%26sid%3Dliteratum%253Aachs%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DSzab%25C3%25B3%26aufirst%3DC.%26aulast%3DThiemermann%26aufirst%3DC.%26atitle%3DIsothioureas%253A%2520Potent%2520Inhibitors%2520of%2520Nitric%2520Oxide%2520Synthases%2520with%2520Variable%2520Isoform%2520Selectivity%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D114%26spage%3D510%26epage%3D516%26doi%3D10.1111%2Fj.1476-5381.1995.tb13256.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Liedtke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luedde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauerbruch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streetz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tacke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolba, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trautwein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trebicka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiskirchen, R.</span><span> </span><span class="NLM_article-title">Experimental Liver Fibrosis Research: Update on Animal Models, Legal Issues and Translational Aspects</span> <span class="citation_source-journal">Fibrog. Tissue Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="refDoi"> DOI: 10.1186/1755-1536-6-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1186%2F1755-1536-6-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=24274743" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=19&author=C.+Liedtkeauthor=T.+Lueddeauthor=T.+Sauerbruchauthor=D.+Scholtenauthor=K.+Streetzauthor=F.+Tackeauthor=R.+Tolbaauthor=C.+Trautweinauthor=J.+Trebickaauthor=R.+Weiskirchen&title=Experimental+Liver+Fibrosis+Research%3A+Update+on+Animal+Models%2C+Legal+Issues+and+Translational+Aspects&doi=10.1186%2F1755-1536-6-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-6-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-6-19%26sid%3Dliteratum%253Aachs%26aulast%3DLiedtke%26aufirst%3DC.%26aulast%3DLuedde%26aufirst%3DT.%26aulast%3DSauerbruch%26aufirst%3DT.%26aulast%3DScholten%26aufirst%3DD.%26aulast%3DStreetz%26aufirst%3DK.%26aulast%3DTacke%26aufirst%3DF.%26aulast%3DTolba%26aufirst%3DR.%26aulast%3DTrautwein%26aufirst%3DC.%26aulast%3DTrebicka%26aufirst%3DJ.%26aulast%3DWeiskirchen%26aufirst%3DR.%26atitle%3DExperimental%2520Liver%2520Fibrosis%2520Research%253A%2520Update%2520on%2520Animal%2520Models%252C%2520Legal%2520Issues%2520and%2520Translational%2520Aspects%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2013%26volume%3D6%26spage%3D19%26doi%3D10.1186%2F1755-1536-6-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Reddy, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span> </span><span class="NLM_article-title">Polypharmacology: Drug Discovery for the Future</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1586/ecp.12.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1586%2Fecp.12.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=23272792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlei" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=41-47&author=A.+S.+Reddyauthor=S.+Zhang&title=Polypharmacology%3A+Drug+Discovery+for+the+Future&doi=10.1586%2Fecp.12.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: drug discovery for the future</span></div><div class="casAuthors">Reddy, A. Srinivas; Zhang, Shuxing</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-47</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets.  This is primarily due to their side effects or toxicities.  Drug mols. often interact with multiple targets, coined as polypharmacol., and the unintended drug-target interactions could cause side effects.  Polypharmacol. remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents.  This review outlines the latest progress and challenges in polypharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh9arBzCHL27Vg90H21EOLACvtfcHk0lhYvXiMogIJRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlei&md5=651b742d7e8254d8f4ef00f225dfa39e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.74%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DPolypharmacology%253A%2520Drug%2520Discovery%2520for%2520the%2520Future%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D6%26spage%3D41%26epage%3D47%26doi%3D10.1586%2Fecp.12.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Tal, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlish, S. J. D.</span><span> </span><span class="NLM_article-title">Synthesis of a Novel Series of Arylmethylisothiouronium Derivatives</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3823</span><span class="NLM_x">–</span> <span class="NLM_lpage">3830</span><span class="refDoi"> DOI: 10.1016/0040-4020(95)00105-H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1016%2F0040-4020%2895%2900105-H" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1995&pages=3823-3830&author=D.+M.+Talauthor=S.+J.+D.+Karlish&title=Synthesis+of+a+Novel+Series+of+Arylmethylisothiouronium+Derivatives&doi=10.1016%2F0040-4020%2895%2900105-H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2895%2900105-H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252895%252900105-H%26sid%3Dliteratum%253Aachs%26aulast%3DTal%26aufirst%3DD.%2BM.%26aulast%3DKarlish%26aufirst%3DS.%2BJ.%2BD.%26atitle%3DSynthesis%2520of%2520a%2520Novel%2520Series%2520of%2520Arylmethylisothiouronium%2520Derivatives%26jtitle%3DTetrahedron%26date%3D1995%26volume%3D51%26spage%3D3823%26epage%3D3830%26doi%3D10.1016%2F0040-4020%2895%2900105-H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Iyer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cinar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szanda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puhl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschamps, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbach, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">244</span><span class="refDoi"> DOI: 10.1124/mol.115.098541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1124%2Fmol.115.098541" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=238-244&author=M.+R.+Iyerauthor=R.+Cinarauthor=J.+Liuauthor=G.+Godlewskiauthor=G.+Szandaauthor=H.+Puhlauthor=S.+R.+Ikedaauthor=J.+Deschampsauthor=Y.+S.+Leeauthor=P.+J.+Steinbachauthor=G.+Kunos&title=Structural+Basis+of+Species-Dependent+Differential+Affinity+of+6-Alkoxy-5-Aryl-3-Pyridinecarboxamide+Cannabinoid-1+Receptor+Antagonists&doi=10.1124%2Fmol.115.098541"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.098541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.098541%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DSzanda%26aufirst%3DG.%26aulast%3DPuhl%26aufirst%3DH.%26aulast%3DIkeda%26aufirst%3DS.%2BR.%26aulast%3DDeschamps%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BS.%26aulast%3DSteinbach%26aufirst%3DP.%2BJ.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DStructural%2520Basis%2520of%2520Species-Dependent%2520Differential%2520Affinity%2520of%25206-Alkoxy-5-Aryl-3-Pyridinecarboxamide%2520Cannabinoid-1%2520Receptor%2520Antagonists%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D88%26spage%3D238%26epage%3D244%26doi%3D10.1124%2Fmol.115.098541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Mukhopadhyay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajesh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horváth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdelyi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holovac, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaudet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamdaoui, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafdil, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haskó, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulares, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacher, P.</span><span> </span><span class="NLM_article-title">Poly (ADP-Ribose) Polymerase-1 Is a Key Mediator of Liver Inflammation and Fibrosis</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1998</span><span class="NLM_x">–</span> <span class="NLM_lpage">2009</span><span class="refDoi"> DOI: 10.1002/hep.26763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1002%2Fhep.26763" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=1998-2009&author=P.+Mukhopadhyayauthor=M.+Rajeshauthor=Z.+Caoauthor=B.+Horv%C3%A1thauthor=O.+Parkauthor=H.+Wangauthor=K.+Erdelyiauthor=E.+Holovacauthor=Y.+Wangauthor=L.+Liaudetauthor=N.+Hamdaouiauthor=F.+Lafdilauthor=G.+Hask%C3%B3author=C.+Szaboauthor=A.+H.+Boularesauthor=B.+Gaoauthor=P.+Pacher&title=Poly+%28ADP-Ribose%29+Polymerase-1+Is+a+Key+Mediator+of+Liver+Inflammation+and+Fibrosis&doi=10.1002%2Fhep.26763"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fhep.26763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26763%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DP.%26aulast%3DRajesh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DHorv%25C3%25A1th%26aufirst%3DB.%26aulast%3DPark%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DErdelyi%26aufirst%3DK.%26aulast%3DHolovac%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiaudet%26aufirst%3DL.%26aulast%3DHamdaoui%26aufirst%3DN.%26aulast%3DLafdil%26aufirst%3DF.%26aulast%3DHask%25C3%25B3%26aufirst%3DG.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3DBoulares%26aufirst%3DA.%2BH.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DPacher%26aufirst%3DP.%26atitle%3DPoly%2520%2528ADP-Ribose%2529%2520Polymerase-1%2520Is%2520a%2520Key%2520Mediator%2520of%2520Liver%2520Inflammation%2520and%2520Fibrosis%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D1998%26epage%3D2009%26doi%3D10.1002%2Fhep.26763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Cinar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godlewski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jourdan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey-White, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunos, G.</span><span> </span><span class="NLM_article-title">Hepatic Cannabinoid-1 Receptors Mediate Diet-Induced Insulin Resistance by Increasing de Novo Synthesis of Long-Chain Ceramides</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1002/hep.26606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;key=10.1002%2Fhep.26606" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=143-153&author=R.+Cinarauthor=G.+Godlewskiauthor=J.+Liuauthor=J.+Tamauthor=T.+Jourdanauthor=B.+Mukhopadhyayauthor=J.+Harvey-Whiteauthor=G.+Kunos&title=Hepatic+Cannabinoid-1+Receptors+Mediate+Diet-Induced+Insulin+Resistance+by+Increasing+de+Novo+Synthesis+of+Long-Chain+Ceramides&doi=10.1002%2Fhep.26606"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fhep.26606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26606%26sid%3Dliteratum%253Aachs%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DGodlewski%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTam%26aufirst%3DJ.%26aulast%3DJourdan%26aufirst%3DT.%26aulast%3DMukhopadhyay%26aufirst%3DB.%26aulast%3DHarvey-White%26aufirst%3DJ.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DHepatic%2520Cannabinoid-1%2520Receptors%2520Mediate%2520Diet-Induced%2520Insulin%2520Resistance%2520by%2520Increasing%2520de%2520Novo%2520Synthesis%2520of%2520Long-Chain%2520Ceramides%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D143%26epage%3D153%26doi%3D10.1002%2Fhep.26606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i97"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01504">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_04628"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01504">10.1021/acs.jmedchem.6b01504</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">NMR spectra, HPLC chromatogram, crystallographic data, and effects of <b>7</b> on mutagenicity test and hERG potassium channels (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01504/suppl_file/jm6b01504_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01504/suppl_file/jm6b01504_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01504/suppl_file/jm6b01504_si_001.pdf">jm6b01504_si_001.pdf (746.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01504/suppl_file/jm6b01504_si_002.csv">jm6b01504_si_002.csv (3.87 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01504&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01504%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-3%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01504" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67990e758f5a23e0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
